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“ In science it often happens that scientists say, ‘You know that’s 
a really good argument; my position is mistaken,’ and then they 
would actually change their minds and you never hear that old 
view from them again. They really do it. It doesn’t happen as 
often as it should, because scientists are human and change is 
sometimes painful. But it happens every day. I cannot recall the 
last time something like that happened in politics or religion.”
 Carl Sagan
Coen BW1.indd   5 15-Aug-13   11:36:29 AM
Coen BW1.indd   6 15-Aug-13   11:36:29 AM
CONTENTS
Chapter 1 General Introduction 11
1.1    T cell therapy to treat melanoma: impressive first clinical 
successes
13
1.2    Gene-engineering of T cells: therapeutic potential and new 
challenges
16
   1.2.1   Therapy related toxicities 18
      1.2.1.1   How to prevent or limit on-target toxicities 18
      1.2.1.1   How to prevent or limit off-target toxicities 21
   1.2.2   Efficacy of TCR gene therapy 22
      1.2.2.1   T cell co-stimulation 22
      1.2.2.2   TCR affinity 23
      1.2.2.3   TCR expression levels 23
1.3   Scope of this thesis 25
Chapter 2 T cell receptor gene therapy: strategies for optimizing transgenic 
TCR pairing
Trends in Molecular Medicine 2010; 16(2):77-87
29
Chapter 3 T cell receptor fused to CD3ζ: transmembrane domain of CD3ζ 
prevents TCR mis-pairing, whereas complete CD3ζ directs 
functional TCR expression
The Open Gene Therapy Journal 2011; 4(1):11-22
49
Chapter 4 T cell receptors genetically linked to CD28 and CD3ε do not 
mis-pair with endogenous TCR chains and mediate enhanced and 
antigen-specific T cell activation
Manuscript submitted
73
Chapter 5 CDR3α mutations in gp100/HLA-A2 TCR causing minor affinity-
enhancement demonstrate improved T cell function without gain 
in self-reactivity
Manuscript under revision
99
Chapter 6 Magnetic-activated cell sorting of TCR-engineered T cells, using 
tCD34 as a gene marker, but not peptide-MHC multimers, results in 
significant numbers of functional CD4+ and CD8+ T cells
Human Gene Therapy Methods 2012; 23(3): 213-224
121
Coen BW1.indd   7 15-Aug-13   11:36:29 AM
Chapter 7 General Discussion 143
7.1   Equipment of TCR transgenes with signaling cassettes 145
7.2   Enhancement of TCR affinity 148
7.3   Enrichment of TCR T cells using MACS technology 150
7.4   What have findings learned us for future clinical trials? 152
   7.4.1   Immune-suppressive tumor environments 153
   7.4.2   Treatment related toxicities 154
References 159
Summary 187
Samenvatting 191
Curriculum vitae 199
List of publications 201
PhD portfolio 203
Dankwoord 205
Coen BW1.indd   8 15-Aug-13   11:36:29 AM
Coen BW1.indd   9 15-Aug-13   11:36:29 AM
Coen BW1.indd   10 15-Aug-13   11:36:30 AM
1
General introduction
Coen BW1.indd   11 15-Aug-13   11:36:31 AM
Coen BW1.indd   12 15-Aug-13   11:36:31 AM
General introduction 13
1
1.1 T CELL THERAPY TO TREAT MELANOMA: IMPRESSIVE FIRST CLINICAL 
SUCCESSES
The incidence of cutaneous melanoma has increased dramatically over the past 40 
years. The yearly increase in incidence rates in the Netherlands is on average 4.1%. 
Although the 10-year survival rates improved over the last fifteen years, the yearly 
mortality rates are further increasing with 2.3%, mainly in elderly patients (1). In case 
cutaneous melanoma metastasizes, the 10-year survival rate drops dramatically to less 
than 10%. Table 1.1 lists the U.S. Food and Drug Administration (FDA)-approved treat-
ments for melanoma. The current standard cares of treatment for melanoma are either 
administration of the alkylating agent Dacarbazine (2), which induces DNA damage, or 
administration of high-dose IL-2 (3), which serves as a T cell growth factor. However, both 
treatments demonstrate fairly low response rates and significant adverse effects. More 
recent FDA-approved treatments for melanoma include: Ipilimumab, an antibody that 
blocks the T cell inhibitory molecule CTLA-4 to lower the threshold of T cell activation (4, 
5); Vemurafenib, a drug that inhibits the serine-threonine protein kinase B-RAF (BRAF), 
a kinase that is constitutively active in 36 to 54% of melanoma patients due to a V600E 
mutation (6); and pegylated interferon α2b, used as an adjuvant that demonstrates 
anti-proliferative effects on melanoma cells and modulates immune responses (7). In 
Table 1.1. FDA-approved therapeutic drugs to treat metastatic melanoma
Treatment Year of FDA
approval
Mechanism of action OR in % (#pts) CR in % Toxicities 
in %a
Reference
Dacarbazine 1975 Alkylates DNA 12 (149) 3 36 (2)
High-dose IL-2 1992 Induces T cell growth 16 (270) 6 45 (3)
Ipilimumab 2011 Blocks T cell CTLA-4 28 (137) 2b 23 (4)
Vemurafenib 2011 Inhibits BRAF kinase 
activity
48 (219) 1 38c (6)
PEG-IFN 2011 Reduces tumor cell 
proliferation
6.2d (627) N.A. 33 (7)
Nivolumab Applied Blocks T cell PD-1 28 (94) 14 14 (8)
Ipilimumab and 
Nivolumab
N.A. Blocks T cell CTLA-4 
and PD-1
40 (53) 10 53 (9)
Lambrolizumab 2013 Blocks T cell PD-1 38 (135) 4 0 (10)
a Grade 3 and 4 according to National Cancer Institute’s (NCI) Common Toxicity Criteria (CTC)
b Long-term follow up revealed an unexpected CR of 17%, which is likely explained by continued tumor 
eradication months or years after treatment (5)
c Adverse events, including grade 2, leading to modification of dosage or interruption of treatment
d Percentage of patients with treatment-mediated relapse-free survival following surgical resection
Abbreviations used in this table: CTLA-4, Cytotoxic T-lymphocyte Antigen-4; CR, complete responses; N.A., 
not applicable; OR, objective responses; PD-1, Programmed Death-1; Pegylated Interferon α2b (PEG-IFN); 
and pts, patients.
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addition, Nivolumab, an antibody that blocks the T cell inhibiting PD1 receptor (CD279), 
is currently under consideration for FDA approval (8). Interestingly, the combined use of 
Ipilimumab and Nivolumab, with the intent to lower the T cell activation threshold and 
prevent T cell exhaustion, demonstrated an objective response rate of 40% and a com-
plete response rate of 10% (9). The response rate of the combined antibodies was higher 
when compared to single use of either Ipilimumab or Nivolumab, underscoring the po-
tency of combining immune-therapies when considering the mechanistic background. 
Another PD-1 blocking antibody (Lambrolizumab) has recently been developed, which 
in a first clinical study demonstrated a competitive objective response rate (38%) and no 
grade 3/4 toxicities when compared to Nivolumab (10).
In addition to the above-mentioned drugs, there is also a large array of new treatments 
under development and/or tested in clinical trials with the intent to provide anti-tumor 
T cell immunity (11, 12). Treatments include the use of vaccines, such as peptides (13) 
or antigen-loaded autologous dendritic cells (14-16) to actively induce a T cell mediated 
anti-tumor response. Also, the adoptive transfer of tumor infiltrating lymphocytes (TILs) 
has been tested clinically and has demonstrated impressive results in patients suffering 
from metastatic melanoma (17). Advantages of T cells when compared to more standard 
drugs in the treatment of melanoma and tumors in general are listed in figure 1.1.
The T cell population can broadly be divided into CD4 and CD8 T cells. CD4 T cells are 
commonly described as ‘helper’ T cells, whereas CD8 T cells are described as ‘cytotoxic’ 
T cells. Helper T cells facilitate immune responses and can be subdivided in various 
subsets, depending on production of signature cytokines, of which Th1 and Th17 may 
have the most pronounced anti-tumor activities (18, 19). Cytotoxic T cells are optimally 
equipped to kill tumor cells and constitute the T cell subset of interest for this thesis. 
CD8 T cells are able to survey individual cells for expression of intracellular proteins, as 
explained in box 1.1. Besides tumor reactive CD8 T cells, other cells have a part in the 
net anti-tumor response such as T cell activating B-cells, dendritic cells or CD4-helper 
T cells but also inhibiting regulatory T cells, tumor associated macrophages, myeloid-
derived suppressor cells or other T cell inhibiting factors as more elaborately described 
in chapter 7 and reviewed in Malyguine et. al. (20).
Adoptive T cell therapy is based on the isolation of tumor-specific T cells from tumor 
tissue or peripheral blood, expansion to clinical numbers (generally 108 or more per in-
jection) and re-infusion in patients (21). This therapy extends the early successes of bone 
marrow transplantation after it became evident that T cells present in transplants were 
of critical importance in the treatment of leukemia (22, 23). Adoptive T cell therapy using 
autologous TILs, often supported by stringent patient pre-conditioning and IL-2 injec-
tions to enhance the clinical effect of T cell administration (24), has shown significant ob-
jective clinical response rates that ranged from 49 to 72% (based on Response Evaluation 
Criteria In Solid Tumors (RECIST)). Notably, ongoing complete responses are observed in 
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20% of the patients (25) (see also chapter 2). More recently, a modified ex vivo culture 
protocol was initiated (so-called ‘young TIL protocol’) (26), which shortened culture time 
and omitted selection for recognition of antigen-positive cells. Using this protocol, the 
success rate of obtaining TILs increased, TILs were younger, and functionally more active 
than non-young TILs, and clinical activities of young TILs resulted in objective responses 
of 48% and 40% and complete responses of 9% and 10%, respectively (27, 28). So far, 
tumor-reactive TILs were only successfully isolated from melanoma. Other tumor types 
have demonstrated T cell infiltration, but appear to lack tumor-specific T cells (17).
T cells can
1. specifically recognize tumor cells
2. serially kill tumor cells
3. self-replicate
4. form immunological memory to provide future protection
5. switch mechanisms of killing
  - in example, exocytosis of lytic molecules, such as perforins
  and granzymes, and activation of the FAS pathway
Figure 1.1. Advantages of T cells when compared to drugs in the treatment of tumors. A schematic 
representation of primary characteristics of T cells that are considered advantages when comparing T cell 
therapy with standard drug treatment of metastatic melanoma. Abbreviations used in this figure: CD.., clus-
ter of differentiation ..; ERK, extracellular-signal-regulated kinases; FAS, tumor necrosis factor superfamily, 
member 6; FASL, FAS ligand; LAT, linker for activation of T cells; LCK, lymphocyte-specific protein tyrosine 
kinase; MHC, major histocompatibility complex; TCR, T cell receptor; and ZAP70, zeta-chain associated pro-
tein kinase 70; (see also box 1.1 for details). Figure was adapted from: Appelbaum, Nature, 17; 411:385.
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1.2. GENE-ENGINEERING OF T CELLS: THERAPEUTIC POTENTIAL AND NEw 
CHALLENGES
T cells can be re-directed towards tumor antigens through genetic introduction of 
tumor-specific TCRα and TCRβ genes, after which TCR-engineered T cells can be adminis-
tered to patients (TCR gene therapy). The therapeutic use of TCR transgenes is explained 
in figure 1.2.
To obtain TCR genes, one generally acquires tumor-reactive T cells as a source for 
TCR genes. To this end, several methods can be employed. (I) Tumor-reactive T cells can 
Box 1.1. T cell receptor expression and target cell recognition
The T cell’s specificity is governed by its T cell receptor (TCR). A TCR consists of an α- and β-chain (leav-
ing γ and δ-chains out of the scope of this thesis) which are the products of recombining of various 
segments encoded by TCR-Variable (α: ~70, and β: 52 genes), Diversity (β: 2 genes) and Joining genes 
(α: 61, and β: 13 genes). Recombination and other processes that tweak the genetic sequence re-
sult in ~1018 potentially different TCR specificities. A TCR binds to major histocompatibility complexes 
(MHCs) class I or II, which present peptide fragments of intra- and extracellular proteins, respectively, 
and are termed T cell antigens. Antigen binding by T cells induces the formation of immune-synapses 
and recruitment of various co-receptors (29). CD8αα or CD8αβ and CD4 co-receptors also bind MHC 
class I or II molecules, respectively, but at sites distant from the sites bound by TCR and independently 
of presented peptides. These co-receptors increase the stability of the TCR:peptide-MHC complex and 
are of critical importance during T cell selection in the thymus and T cell homeostasis in the periphery. 
T cell selection in the thymus will remove T cells with TCRs that have a too low or too high affinity 
for self-peptide-MHC (these T cells will die by neglect or negative selection, respectively) and yield a 
functional T cell repertoire of ~2.5x108 different TCRs.
 TCR are expressed on the cell surface in a complex with invariant CD3 proteins (see also chapter 2 
for details on assembly and expression of TCR/CD3 complex). CD3 proteins contain immune receptor 
tyrosine-based activation motifs (ITAMs) that provide means for intracellular signaling upon antigen 
binding. Antigen presenting cells (APCs) can efficiently present pathogen-derived peptide-fragments 
in MHC molecules and activate T cells through engaging the TCR/CD3 complex and, by exposing co-
stimulatory ligands, engaging co-stimulatory receptors expressed by T cells. Co-stimulatory receptors 
expressed by T cells generally belong to the CD28 co-stimulatory family of molecules, such as CD28, 
CD134, and CD137 (30). T cell co-stimulation is required to optimally induce T cell proliferation and 
differentiation into effector T cells. In addition, T cell co-stimulatory signals prevent T cell anergy and 
apoptosis, rearrange the cytoskeleton, activate transcription factors and boost the secretion of cyto-
kines or chemokines. Lack of T cell co-stimulation, which often occurs in tumors that present antigen 
but have down-regulated the expression of co-stimulatory ligands, may lead to impaired T cell persis-
tence and T cell exhaustion.
 TCR-mediated antigen binding is reported to induce conformational changes in CD3-proteins 
which may initiate the first steps in downstream signaling (31). TCR signaling involves activation of 
LCK, often recruited to the TCR/CD3 complex by CD8/CD4 and CD28 molecules, ZAP70, recruited by 
phosphorylated CD3ζ, and subsequent activation of LAT and the RAS/MAPK/ERK pathway. T cell sig-
naling results in cytoskeletal changes and release of cytotoxic effector molecules, such as perforins 
and granzymes, enhanced gene transcription of cytokines, such as IFNγ, IL-2, and TNFα, and enhanced 
expression of apoptosis-inducing ligands, such as FasL. See figure 1.1 for a schematic illustration of T 
cell antigen binding and the first steps in downstream signaling and tumor cell killing.
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be isolated from patients’ TILs (32), tumor draining lymph nodes or peripheral blood 
(33). In some cases, where frequencies of patient-derived TILs are low, vaccination with 
tumor-specific peptides or tumor antigen-loaded DCs prior to isolation of T cells may 
boost the numbers of specific T cells (34-36). Combinatorial coding with peptide-MHC 
has recently been developed and may facilitate the detection and isolation of multiple 
T cells specific for various antigens, significantly shortening the process to acquire pure 
T cell populations of desired specificities (37). (II) Tumor-reactive T cells can be isolated 
from allo-reactive settings that circumvent self-tolerance and generally yield T cells with 
a higher avidity than those derived from patients. Examples of such settings include 
peptide-vaccination of MHC-mismatched healthy donors (38), immunization of mice 
transgenic for human-MHC or human TCR loci (39, 40), in vitro T cell stimulation using T2 
cells pulsed with peptide, B cells loaded with allogeneic peptide-MHC monomers (41) or 
TCR gene-engineering of T cells allows
1. targeting tumor antigens of interest
2. timely and cost-effective production of therapeutic T cells
at clinical scale
3. genetic engineering to address TCR mis-pairing and
enhance TCR affinity and/or functional expression
4. ‘off-the-shelf’ treatment
Figure 1.2. The therapeutic use of TCR transgenes. A schematic representation of reasons to therapeuti-
cally use TCR transgenes. Stars indicate amino acid substitutions in complementarity determining regions 
(CDR) to enhance TCR affinity (see box 1.2 for details). Signaling cassettes are described below and con-
sist of transmembrane and/or intracellular accessory and/or co-stimulatory domains genetically fused to 
TCRαβ. Abbreviations used in this figure (in addition to the ones explained in the legend of figure 1.1): A2, 
human leukocyte antigen A*0201; MAGE, melanoma antigen gene; MART-1, melanoma-associated antigen 
recognized by T cells 1; and NY-ESO-1, New York esophageal squamous cell carcinoma 1.
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autologous dendritic cells gene-transferred with RNA encoding peptide and MHC (42). 
Once the desired tumor-reactive T cells have been obtained, then the corresponding 
TCR genes can be aquired by molecular methods such as rapid amplification of cDNA 
ends (RACE) (43). To introduce TCR genes into patient T cells, one of the most commonly 
utilized gene delivering systems, also for the generation of clinical batches of T cells, 
makes use of retro- or lentiviruses. In addition, several other vehicles and methods can 
be used for TCR gene introduction, such as DNA plasmid transfer, transposons-mediated 
transfer, and RNA electroporation, techniques that do show differences with respect 
to gene-transfer efficiency and stability of transgene expression (briefly reviewed in 
Gilham et. al. (44)).
The first clinical trials have clearly demonstrated feasibility and anti-tumor activity of 
TCR gene therapy, but at the same time revealed treatment-related toxicity. A summary 
of these findings is presented in table 1.2. Objective clinical responses, although variable 
and tested in a limited number of patients, ranged from 12 to 67%. Treatment-related 
toxicities varied from severe, but transient and/or treatable inflammation of organs, to 
neuro- and cardiological which resulted, in some cases, in death of patients. Current 
challenges of TCR gene therapy aim at preventing toxicity and further increasing thera-
peutic efficacy. These challenges are discussed in more detail below, including strategies 
to address these challenges with an emphasis on those strategies that use genetically 
modified TCR transgenes (main topic of this thesis).
1.2.1 Therapy-related toxicities
As mentioned above, TCR gene therapy in patients bears the risk to induce on- and 
off-target toxicities. On-target toxicities are toxicities that occur in healthy organs that 
express the T cell target antigen, whereas off-target toxicities occur in healthy organs 
that do not express the target antigen. Both types of toxicities are likely to be halted by 
the use of so-called ‘suicide genes’ which are not the topic of the current chapter, but are 
described in more detail in chapters 2 and 7.
1.2.1.1 How to prevent or limit on-target toxicities
Several TCR gene therapy studies reported the onset of on-target toxicities as described 
in table 1.2. Targeting melanoma-associated antigen recognized by T cells 1 (MART-1) 
(AAG epitope), glycoprotein 100 (gp100) (KTW epitope), or carcinoma embryonic an-
tigen (IMI epitope) with affinity-enhanced TCRs resulted in severe, although treatable, 
toxicities (40, 45). More recently, a study using a TCR specific for an alternative MART-1 
epitope (ELA) demonstrated lethal cardiotoxicity. On-target toxicities can be addressed 
by targeting antigens that show a highly specific or even exclusive expression on tumor 
cells when compared to healthy cells. Indeed, when targeting an alternative antigen, 
Coen BW1.indd   18 15-Aug-13   11:36:45 AM
General introduction 19
1
NY-ESO-1 (SLL), no toxicities and a strong anti-tumor response were observed (46). 
Metastatic melanoma is an immunogenic tumor and expresses several tumor-associated 
antigens (TAA). Such TAA can generally be divided into four groups (47, 48):
v Differentiation antigens: cell surface proteins that are selectively expressed at dif-
ferent stages of development or cell activation. Expression of these antigens may 
discriminate tumor cells from surrounding healthy cells, but expression is not absent 
on healthy cells. Examples include MART-1, gp100, tyrosinase related protein 1 (TRP-
1) and TRP-2.
v Over-expressed antigens: cell surface proteins that are highly, but not selectively, 
expressed on tumor cells when compared to healthy cells. Examples include CEA and 
ERBB2.
v Cancer Testis Antigen (CTA): a large group of immunogenic proteins that are ex-
pressed by tumors of different histology and, depending on the specific CTA, not or 
Table 1.2. Current overview of clinical TCR gene therapy trials
TCR specificity (epitope) Tumor type Toxicities OR in % (#pts) Reference
MART-1 / HLA-A2 (AAG) Metastatic 
melanoma
None reported 12 (15) (32)
MART-1 / HLA-A2 (AAG)
(high affinity TCR)
Metastatic 
melanoma
Severe inflammation of skin, 
eye or ear in 8 out of 20 pts
30 (20) (45)
gp100 / HLA-A2 (KTW)
(murine TCR)
Metastatic 
melanoma
Severe inflammation of skin, 
eye or ear in 1 out of 16 pts
19 (16) (45)
CEA / HLA-A2 (IMI)
(murine TCR)
Metastatic 
colorectal 
carcinoma
Severe inflammation of 
colon in 3 pts
33 (3) (40)
NY-ESO-1 / HLA-A2 (SLL)
(affinity enhanced TCR)
Metastatic synovial 
carcinoma
None reported 67 (6) (46)
NY-ESO-1 / HLA-A2 (SLL)
(affinity enhanced TCR)
Metastatic 
melanoma
None reported 45 (11) (46)
MAGE-A3 / HLA-A2 (KVA)
(affinity enhanced and 
murine TCR)
Metastatic 
melanoma
Mental changes in 3 pts and 
comas and death in 2 pts
57 (9) (62)
MART-1 / HLA-A2 (ELA)
(affinity enhanced cysteine-
modified and murine TCR)
Metastatic 
melanoma
Lethal cardiotoxicity in 1 pt 0 (1) note a
MAGE-A3 / HLA-A1 (EVD)
(affinity enhanced TCR)
Metastatic 
melanoma
Lethal cardiotoxicity in 2 pt 0 (2) note b
a Prof.dr. John Haanen and b Dr. Bent Jakobsen, Cellular Therapy against Cancer Symposium, London, Febr. 
27th - March 2nd, 2013.
Abbreviations used in this table (in addition to the ones explained in the legends of table 1.1 and figure 1.1 
and 1.2): CEA, carcinoembryonic antigen; and gp100, glycoprotein 100. 
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only a limited number of healthy and adult cell types. Examples include melanoma 
antigen gene A1 (MAGE-A1), MAGE-C2 and NY-ESO-1.
v Neo-antigens: new proteins as a result from gene mutations or aberrations that are 
present in tumor cells. These proteins are uniquely expressed by tumor and not by 
healthy cells. Examples include protein 53 (p53), Ras and cyclin-dependent kinase 4 
(CDK4).
With respect to tumor-restricted expression, neo-antigens and CTA may represent the 
preferred groups of target antigens. In an elaborate study that ranked known tumor 
antigens according to multiple characteristics that are considered important for T cell 
targeting, several neo-antigens and CTA were identified as high-priority antigens (49). 
Neo-antigens are unique to tumor tissues, not present in healthy tissues, but their 
expression may be restricted to a single or a limited number of patient(s). Current 
developments of second-generation sequencing techniques may make it feasible to 
identify tumor-specific mutations (50, 51). Although up to 100,000 mutations can be 
encountered in tumor genomes (52), 85% of these are considered ‘passenger’ mutations, 
whereas the remaining 15% may be ‘driver’ mutations (53). Passenger mutations are not 
related to oncogenic development, making them less suitable as T cell target antigens. 
Driver mutations are related to oncogenesis, may be linked to known genes (~400), and 
may provide tumors with a selective growth advantage (52, 54). However, not all driver 
mutations result in new immunogenic antigens. Thus, although new techniques allow 
fast analysis of mutations, additional techniques or screening methods may be neces-
sary to determine whether a tumor expresses an immunogenic epitope that is suitable 
as a target for T cell therapy (55).
CTAs represent an expanding class of tumor-associated proteins. Currently, over 250 
CTA genes have been identified of which more than 50% are located on the X-chromo-
some, including CTA families such as MAGE, GAGE, BAGE, SSX and NY-ESO-1 (see for a full 
description of CTAs: http://www.cta.lncc.br). CTA can serve as potential T cell target an-
tigens for several reasons. First, using extensive RT-PCR of various tissues, 39 CTA genes, 
of which 35 CTA genes are located on the X-chromosome, demonstrated expression 
that was limited to testes and placentas, which do not express MHC-molecules and are 
therefore not targeted by T cells (56). In tumor tissues, aberrant epigenetic regulation, 
such as promotor demethylation, appears to drive the expression of CTAs (57). Second, 
CTAs are expressed in tumor tissues of various histological origins. In fact, expression 
in tumor tissues has been associated with advanced stages of disease and unfavorable 
patient prognosis (58). Third, both humoral and cell-mediated immune responses to CTA 
proteins have occurred in tumor-bearing patients and pointed to the immunogenic na-
ture of these antigens (35, 36, 59). Fourth, X-chromosome linked CTAs are coordinately 
expressed in tumor tissues, which allows the simultaneous targeting of multiple CTAs 
thereby potentially decreasing the risk of tumor recurrence following T cell therapy (60). 
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Fifth, expression of some CTAs may be restricted to tumor stem cells and these CTAs may 
provide unique targets to treat tumor recurrence and metastasis (61). Unexpectedly, in 
a recent clinical study using TCR-engineered T cells directed against MAGE-A3/HLA-A2 
(KVA epitope; see table 1.2), 2 patients with metastatic melanoma lapsed into comas and 
died, most likely because of T cell recognition of rare neurons positive for MAGE-A12 and 
possibly MAGE-A9 and expressing the shared KVA epitope (62).
Taken this observation into account, we consider neo-antigens and those CTA epi-
topes that are not expressed by healthy adult tissues and not shared among multiple 
CTAs as potentially safe and effective T cell target antigens. However, whatever the 
choice of antigen, it should be recommended to perform stringent preclinical testing to 
confirm that healthy cells do not express the target antigen prior to proceeding with the 
clinical testing of TCR-engineered T cells.
1.2.1.2 How to prevent or limit off-target toxicities
TCR mis-pairing, a phenomenon that is inherent to the generation of TCR-engineered T 
cells, is considered a potential cause of off-target toxicities. Introduced TCRα and TCRβ 
chains can form TCR heterodimers with endogenously expressed TCRβ and TCRα chains, 
respectively (63, 64), and these newly formed heterodimers are of unknown specificity 
and can yield self-reactive T cells (65, 66). Although in clinical TCR gene therapy trials 
performed so far, no formal observations of toxicities mediated by TCR mis-pairing have 
been made, preclinical studies have clearly demonstrated that TCR mis-pairing can 
induce new and harmful recognition of self-antigens under conditions that significantly 
enhance in vivo T cell proliferation (65). TCR mis-pairing can be prevented or limited 
by the genetic modification of TCR transgenes or by the silencing of endogenous TCRs. 
Strategies that prevent or reduce TCR mis-pairing through genetically modifying the 
TCR transgene are reviewed in chapter 2. These strategies include the murinization of 
the TCR, addition of cysteine amino acids to the TCR, and equipping the TCR with a sig-
naling cassette that consists of the CD3ζ accessory molecule (i.e., TCR:ζ; see figure. 1.2). A 
signaling cassette introduced into TCRs, designed in analogy to signaling cassettes used 
in Chimeric Antigen Receptors (CARs) (44), typically replaces TCR transmembrane and 
intracellular domains with accessory and/or co-stimulatory molecules to enhance the 
functional expression of the TCR transgene. In addition, RNA interference technologies 
have been shown to specifically interrupt the expression of endogenous but not trans-
genic TCR chains (67, 68). Another method to abolish the expression of endogenous 
TCR chains encompasses the use of zinc finger nucleases and a sequential knock-out 
of endogenous TCRα and β chains and introduction of TCRα and β transgenes, com-
bined with cell sorting for CD3-negative and CD3-positive T cells (69). The latter two 
techniques are relatively new and not yet widely or clinically applied, but without doubt 
appear promising to address TCR mis-pairing-related toxicities.
Coen BW1.indd   21 15-Aug-13   11:36:45 AM
22 Chapter 1
A second cause of off-target toxicities became evident in a recent study in which 
MAGE-A3/HLA-A1 (EVD epitope; see table 1.2) was targeted in metastatic melanoma 
and multiple myeloma patients. In this study, 2 patients suffered from cardiotoxicity and 
died, most likely because of T cell recognition of a similar but not identical peptide from 
the muscle protein Titin (Dr. Bent Jakobsen, Cellular Therapy against Cancer Symposium, 
London, Febr. 27th - March 2nd, 2013).
Collectively, the studies referred to in the above paragraphs on toxicities clearly war-
rant for the inclusion of a strategy to address TCR mis-pairing as well as stringent safety 
screening to exclude recognition of healthy cells by TCR-engineered T cells to reduce the 
risk of toxicities in future trials.
1.2.2 Efficacy of TCR gene therapy
Here, I introduce how to potentially further improve the efficacy of TCR gene therapy by 
enhancing T cell co-stimulation, TCR affinity and level of TCR surface expression.
1.2.2.1 T cell co-stimulation
T cells are routinely stimulated with anti-CD3 antibodies and high concentrations of IL-2 
to allow for extensive ex vivo proliferation of T cells and significant efficiency of retroviral 
transduction to acquire clinical-scale numbers of therapeutic T cells (70, 71). This procedure, 
however, induces insufficient T cell co-stimulation and accelerates T cell differentiation, 
which may result in hampered T cell persistence and anti-tumor T cell responses in vivo (72) 
(see also box 1.1). One way to enhance T cell co-stimulation is to equip the TCR with a sig-
naling cassette that consists of a co-stimulatory molecule, such as CD28. Preclinical studies 
have shown that the addition of CD28 to the signaling cassette of a CAR potentiates T cell 
cytokine secretion, including IL-2, prevents apoptosis and sustains CD8 T cell proliferation 
(73, 74). In addition, clinical testing of a CD19-specific CAR bearing a CD28-containing 
signaling cassette, in a manner that allowed intra-patient and side-by-side comparison 
with the same CAR containing a non-CD28 signaling cassette, revealed enhanced T cell 
persistence (75). In fact, several clinical trials have reported prolonged in vivo persistence 
as well as enhanced anti-tumor reactivity of CARs that contained co-stimulatory molecules 
such as CD28 and CD137 (between 6 and 26 weeks (76-78)) when compared to trials with 
CARs that did not contain a co-stimulatory molecule (between 3 and 9 weeks (79-83)). The 
observed enhanced persistence of T cells is most likely explained by a substantial pres-
ence of less-differentiated central memory T cells, and may allow for a clinical protocol that 
depends less on supportive treatment to aid proliferation of administered T cells. A study 
by Kalos and colleagues confirms this notion, as in this study CAR-expressing T cells with 
a central memory phenotype persisted, potentially at the expense of more differentiated 
effector memory T cells, using a protocol without IL-2 administrations (77).
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Another way to enhance T cell co-stimulation is to stimulate T cells ex vivo with human 
artificial antigen presenting cells (aAPCs) that express both HLA-A*0201 loaded with the 
peptide of interest and co-stimulatory ligands, with stimulations often taking place in 
the presence of common-γ cytokines other than IL-2 (84, 85). This approach educates T 
cells with a certain HLA-A2-restricted specificity, a young phenotype (CD45RA+ CD62L+) 
and superior T cell functions (84). In a clinical study, T cells educated with aAPC present-
ing MART-1 peptide and the co-stimulatory receptor ligands CD80 and CD83, and stimu-
lated in the presence of IL-2 and IL-15, resulted in objective responses and in peripheral 
persistence of therapeutic T cells of up to 12 months (85). Notably, in the latter study, 
the clinical protocol did neither include patient preconditioning with chemotherapy nor 
administration of IL-2.
1.2.2.2 TCR affinity
Functional T cell avidity can be enhanced via increasing the TCR’s affinity for peptide-
MHC (this paragraph) or via increasing its level of TCR surface expression (the next para-
graph) (see box 1.2 for a description of TCR affinity and T cell avidity). In case of T cells 
specific for pathogens, KD values are generally between 0.18 and 25 µM (mean = 8.2 
µM). In contrast, T cells specific for tumor antigens, most often self-antigens, revealed 
KD values between 11 and 387 µM (mean = 96.6 µM), the likely consequence of thymic 
selection of TCRs with a low affinity for self-peptide MHC ligands (86). Since TCR affinity 
is a strong determinant for functional T cell avidity (87), one could argue that there 
is a window for affinity-enhancement of tumor specific TCRs to enhance anti-tumor 
responses. In support of this argument, clinical TCR gene therapy studies have revealed 
improved objective response rates when using affinity-enhanced TCRs (see table 1.2). 
One example is the high-affinity MART-1/HLA-A2 specific TCR that mediated an objec-
tive response rate of 30%, whereas the lower affinity variant resulted in an objective 
response rate of 12% (32, 45). Other examples include the affinity-enhanced NY-ESO-1/
HLA-A2 specific TCR and affinity-enhanced MAGE-A3/HLA-A2 specific TCR that demon-
strate significant objective response rates (46, 62). Affinity-enhanced TCRs for use in TCR 
gene therapy can be obtained from allo-reactive settings to circumvent self-tolerance, 
as described above, and phage, yeast, or T cell display selections to acquire TCR vari-
ants harboring amino acid substitutions in their complementarity-determining regions 
(CDRs).
1.2.2.3 TCR expression levels
To enhance the level of TCR surface expression one can use strategies to enhance the ex-
pression in individual T cells or in the T cell population as a whole. The expression of TCR 
transgenes at a cellular level can be enhanced by optimizing various aspects of the TCR 
gene transfer methodology, such as: choice of gene delivery method (shortly described 
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above); use of optimal vector elements (i.e., splice signals, constitutive RNA transport 
elements, posttranscriptional regulatory elements (93, 94); use of multi-cystronic vec-
tors (95); and codon optimization of TCR transgene (96) (for an overview see Coccoris 
et. al. (97)). As referred to earlier, genetically introduced TCRs need to compete with 
endogenous TCRs for the limited availability of CD3ζ (98) (see also box 1.1 and chapter 
2). The following genetic strategies have been reported to provide transgenic TCRs with 
a competitive advantage (see chapter 2 for a more complete overview of these strate-
gies): (I) replacement of positively charged residues in the TCRα transmembrane region 
with hydrophobic residues to enhance the stability of surface expressed TCRs (99); (II) 
removal of intracellular TCRαβ glycosylation sites to prevent degradation and enhance 
the TCR’s ability to move within the plasma membrane (100); (III) co-transduction of the 
TCR transgene with CD3γ, δ, ε, and ζ genes to decrease the competitive pressure for 
endogenous CD3 chains (101); (IV) RNA interference or zinc finger nuclease technolo-
gies to ablate the expression of endogenous TCR chains (67-69); and (V) genetic incor-
poration of a CD3ζ signaling cassette into TCR (i.e., TCR:ζ) to create a TCR that expresses 
independently of CD3 and demonstrates a level of surface expression that goes beyond 
those of endogenous TCR (63, 64).
The expression of TCR transgenes at a T cell population level, i.e., the frequency of 
TCR-transduced T cells, can be increased by selectively enriching T cells that highly 
express the TCR transgene. Patients treated with TCR gene therapy have received T cell 
populations with fractions of TCR-transduced T cells being as low as 3% (32). There are 
several methods to improve percentages of TCR-engineered T cells in a T cell population, 
including fluorescent- and magnetic-activated cell sorting (FACS and MACS, respec-
tively). MACS is well suited for rapid isolation of single cells and has already been ap-
Box 1.2. TCR affinity and T cell avidity
A measure of TCR affinity for peptide-MHC is the dissociation constant (KD), the rate by which a 
TCR:peptide-MHC complex dissociates into single TCR and peptide-MHC molecules. The KD itself is 
defined as the ratio between the off-rate (Koff) and on-rate constant (Kon). Typically, as a result of nega-
tive selection in the thymus, T cells bear TCR with KD values in the range of 1-100 µM (88-90). TCRs 
interact with peptide-MHC via loops of the three complementarity determining regions (CDRs) in 
each of the TCRα and TCRβ chains. CDR1α/β and CDR2α/β, which are germline encoded genes, bind 
the MHC molecule and position the highly variable CDR3α/β to interact with the peptide present in 
the MHC groove (88, 89). TCR affinity can be increased by amino acid substitutions in CDRs to reduce 
Koff or increase Kon rates and hence lower the KD.
 T cell avidity is the T cell’s ability to interact with a target cell, and is defined as the sum of affinities 
of all cellular interactions, such as TCR:peptide-MHC, CD28:B7, CD4/8:MHC, PD-1:PD-L1 and so on. 
Functional T cell avidity is the T cell’s ability to respond to antigen-positive tumor cells and can be 
enhanced via increasing the TCR’s affinity for peptide-MHC or via increasing its level of cell surface 
expression. Notably, functional T cell avidity does not fully correlate with T cell affinity (chapter 5 and 
(91, 92)).
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plied under General Medical Practice conditions and tested clinically. In example, MACS 
allowed for the isolation and increase in frequencies of CMV-specific CD8 T cells (>95%), 
which resulted in the control of CMV re-activation in 9 patients who received a stem cell 
transplantation and the MACS-prepared CMV-specific T cells (102).
1.3. SCOPE OF THIS THESIS
In this thesis, I have worked along the following lines of research (see figure 1.3):
1. Equipment of TCR transgenes with signaling cassettes
2. Enhancement of TCR affinity
3. Enrichment of TCR-engineered T cells using MACS technology
First, in chapter 2 an overview is provided of strategies to prevent or limit TCR mis-
pairing by genetically modifying TCR transgenes.
In chapter 3 we compared various TCRs for their ability to prevent TCR mis-pairing, 
become functionally expressed and mediate antigen-specific functions. We focused 
on TCR:ζ variants with minimized CD3ζ content, which we generated by applying two 
different strategies, i.e., domain exchange and 3D modeling strategies. In our studies, 
we also included a TCR that was modified via murinization and cysteine-modification 
and compared all TCRs with a previously characterized TCR:ζ., which has demonstrated 
strong functional properties.
In chapter 4 we designed and tested multiple signaling cassettes consisting of various 
accessory molecules with or without the co-stimulatory CD28 molecule. These were 
compared and selected for optimal functional expression by T cells. Next, we evaluated 
the most optimal cassette, i.e., a CD28-CD3ε signaling cassette, for its ability to prevent 
TCR mis-pairing, provide functional T cell avidity, and form antigen-specific immune 
synapses.
In chapter 5 we investigated whether the extent of TCR affinity enhancement that leads 
to improved T cell function differs from the extent of TCR affinity enhancement that 
leads to self-reactivity. Using phage-display, we generated a set of TCRs that covered 
an almost 3-log range of affinities and analyzed whether these TCRs result in gain of 
antigen sensitivity and/or loss of antigen specificity when compared to wt TCR.
In chapter 6 we compared different types of peptide-MHC multimers and CD34 mAb to 
MACSort TCR and/or CD34 engineered T cells. T cell sorts were compared with respect to 
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T cell yield, enrichment for engineered T cells, stability of TCR transgene expression and 
functional avidity.
Finally, in chapter 7, I have discussed experimental results in the context of recent 
developments in the field of T cell therapy, and I have proposed a combination of the 
presented strategies to advance TCR gene therapy.
1. Enhance correct pairing and functional TCR expression
via the incorporation of signaling cassettes
 - chapters 3 and 4
2. TCR affinity-enhancement via amino acid substitutions in
CDR
 - chapter 5
3. MACS enrichment of TCR-engineered T cells
 - chapter 6
Figure 1.3: Strategies designed and tested in current thesis to advance TCR gene therapy. A schematic 
representation of a T cell expressing a therapeutic TCR, containing a signaling cassette and amino acid sub-
stitutions in CDR, and a truncated CD34 surrogate marker that can both be targeted for magnetic activated 
cell sorting (MACS). Abbreviations used in this figure (in addition to the ones explained in the legends of 
table 1.1 and 1.2 and figure 1.1 and 1.2): tCD34, truncated CD34.
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ABSTRACT
T cell receptor (TCR) gene therapy provides patients with autologous T cells that are 
genetically engineered with TCRαβ chains, and constitutes a promising approach for 
the treatment of tumors and virus infections. Among the current challenges of TCR gene 
therapy is the optimization of TCRα and β transgene pairing to enhance the functional 
avidity of therapeutic T cells. Recently, various genetically modified TCRs have been 
developed that enhance TCR pairing and minimize mis-pairing – i.e., pairing between 
transgenic and endogenous TCR chains. Here, we classify such receptors according 
to their CD3-dependence for surface expression and review their abilities to address 
functional T cell avidity. In addition, we discuss the anticipated clinical value of these 
and other strategies to generate high-avidity T cells.
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INTRODUCTION
Adoptive transfer of autologous tumor-infiltrating or peripheral blood T cells results in 
clinical responses when treating melanoma (103, 104) as well as virus infections and 
virus-associated tumors (105-110). Notably, objective response rates were as high as 
51% when melanoma patients were treated with non-myeloablative chemotherapy 
prior to transfer of autologous tumor-infiltrating lymphocytes (TIL) (111). Recently, 
myeloablative irradiation as a more stringent patient preconditioning regimen resulted 
in response rates of up to 72% (112). In comparison, patients with metastatic melanoma, 
of which the incidence has increased dramatically over the last few decades, face a 10 
year survival rate of less than 10% after standard systemic treatment with either chemo-
therapy, such as dacarbazine, or high-dose interleukin-2 (IL-2) (113).
T cell receptor (TCR) gene therapy has extended the principle of therapy with T cells 
that are non-modified to T cells that have been retrovirally transduced with genes en-
coding TCRαβ. TCR gene therapy does not depend on the isolation and expansion of TILs 
for patient treatment, often laborious and having a limited success rate, and constitutes 
a more universal variant of T cell therapy. The genetic introduction of a single set of 
TCRα and β genes enables the generation of large numbers of T cells with a defined 
specificity that is generally not present in the endogenous T cell repertoire due to toler-
ance towards self-antigens, such as many tumor-antigens. Clinical TCR gene therapy, 
using TCRs directed at the HLA-A2-restricted MART-127-35 antigen (epitope: amino acids 
27-35) (termed MART-1/A2), resulted in an objective response rate of 12% in patients 
with metastatic melanoma (32). Recently, the clinical use of a highly reactive murine 
TCR specific for human gp100154-162/HLA-A2 (gp100/A2) and a high-affinity TCR specific 
for MART-1/A2 revealed objective response rates of 19% and 30%, respectively, which 
coincided with toxicities such as melanocyte destruction and severe inflammation of 
target tissues in ears and eyes (45). Reasons that might explain the observed drop in 
therapeutic effectiveness of TCR-transduced T cells compared to TIL include suboptimal 
surface expression and/or function of TCR transgenes when compared to natural TCRs, 
resulting in therapeutic T cells with suboptimal avidity.
Recently, various genetic strategies have been developed to optimize the functional 
avidity of TCR-engineered T cells, which are presented in table 2.1. Here we focus on 
genetic modifications of receptor transgenes that are designed to enhance the ability of 
TCRα and β transgenic chains to correctly pair and, consequently, enhance the functional 
expression of transgenic TCRαβ. This review first describes the TCRαβ/CD3 complex, after 
which it describes and discusses genetically modified receptors, with special emphasis 
on TCR pairing and mis-pairing. Lastly, we discuss the value of these receptors and other 
strategies to generate high-avidity T cells for clinical TCR gene therapy.
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Box 2.1. Glossary
Autoreactive T cells: T cells that recognize self-antigens and are capable of destroying patient’s healthy 
cells and tissues.
Clinical adoptive T cell transfer: therapy that is based on re-infusion of mostly autologous tumor infil-
trating lymphocytes or peripheral lymphocytes that have been activated, selected in vitro for tumor-
reactivity, and expanded to clinically relevant numbers.
Functional T cell avidity: in general, the combined strength of multiple protein-protein interactions 
between a T cell and a pMHC ligand or an antigen-positive target cell (strength of single protein-
protein interactions determine affinity). In particular, T cell avidity is determined by the strength of T 
cell-pMHC interactions. Functional T cell avidity defines the sensitivity of T cells to respond to pMHC 
ligands or antigen-positive target cells.
Objective clinical response rate: according to the ‘RECIST’ criteria all responses that fall in the follow-
ing categories are considered an objective response: complete response, partial response, and stable 
disease (http://imaging.cancer.gov/clinicaltrials/imaging/).
Peptide-MHC: major histocompatibility complex (MHC) glycoproteins are divided into 2 classes (i.e. 
MHC I and II) and expressed on the cell surface displaying short peptides. Complexes of peptide and 
MHC (pMHC) are considered antigens to T cells and constitute ligands for TCRαβ.
TCR heterodimerization: pairing of a TCR α-chain and a corresponding TCR β-chain that are both re-
quired to recognize an antigen.
T cell cytokines: proteins that are generally produced by antigen-activated T cells to aid an immune 
response. Cytokines may have different effects on recipient cells, such as cellular activation or migra-
tion. Some cytokines, such as IFNγ, have clear anti-tumor effects.
T cell cytotoxicity: killing of target cells (i.e. tumor cells) by T cells upon antigen recognition often 
through the release of lytic granules containing perforin (forms pores in target cell) and granzymes 
(activates caspase cascade that leads to apoptosis).
TCR gene transfer: transfer of genes encoding TCR into target cells. In general, retrovirusses are used 
that allow stable integration of TCR transgenes in the genome of T cells (i.e. T cell transduction).
Table 2.1. Genetic strategies to improve the functional avidity of TCR-engineered T cells
Receptor modifications that address TCR pairing
CD3 dependent receptors • Murinized TCR
• Cysteine-modified TCR
• Exclusive TCR heterodimer
CD3- independent receptors • TCR:ζ
• scTCR
• TCR-like antibody
Other strategies to enhance the functional avidity of gene-engineered T cells
Vectors and transgene cassette to increase 
transduction efficiency
•  Optimized gammaretroviral vectors combined with 2A 
transgene cassette
TCR modifications aimed at improving TCR 
surface expression and function
• Codon optimization
• Affinity maturation
• Incorporation of stimulatory T cell molecules
Defined T cell populations to enhance T cell  
responsiveness
• TCRαβ gene transfer in monoclonal cytotoxic T cells
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TCR/CD3: STRUCTURE AND INITIAL SIGNALING
TCRαβ is a heterodimer that consists of a TCRα and TCRβ chain, which both contain a 
variable (V) and a constant (C) domain. TCR V gene segments encode two out of three 
complementarity determining regions (CDR) that comprise the peptide/Major Histo-
compatibility Complex (pMHC) binding site. The V, Diversity (D, only in case of TCRβ) 
and Joining (J) domains of both TCR chains form the third CDR. TCR chains each have 
a single membrane-spanning domain, a very short cytoplasmic tail, and are covalently 
linked through disulphide bonds. Surface expression and proper function of the vari-
able TCRαβ requires intracellular assembly with invariant CD3 components (see also box 
1.1). There are 4 different CD3 proteins that form two heterodimers (CD3δε and CD3γε) 
and one homodimer (CD3ζζ) before their association and surface expression with TCRαβ 
subunits (the structure of a surface expressed TCR/CD3 complex is schematically illus-
trated in figure 2.1A).
The assembly of CD3 dimers with TCRαβ occurs in a strict temporal and spatial fashion. 
First, three transmembranal tri-polar interactions are formed between CD3δε and TCRα, 
CD3γε and TCRβ, and CD3ζζ and TCRα (CD3 molecules provide an acidic amino acid and 
TCRα or β chains provide a basic amino acid to form polar interactions (114)). Notably, 
CD3ζ is considered a limiting factor for the total number of TCR/CD3 complexes ex-
pressed on a T cell’s surface (98). Second, tetracysteine motifs in the membrane-proximal 
stalk regions of CD3γε and CD3δε dimers interact with TCR connecting peptide motifs 
(115, 116). Third, extracellular interactions between CD3δε and a loop in TCR-Cα help to 
stabilize CD3γε within the complex (which itself interacts with a TCR-Cβ loop) (117).
CD3 components contain immune receptor tyrosine-based activation motifs (ITAMs) 
that endow the TCR/CD3 complex with means for intracellular signaling. CD3δ, CD3ε, 
and CD3γ each contain 1 ITAM, whereas CD3ζ contains 3 ITAMs, supplying each TCR/
CD3 complex with a total of 10 ITAMs. Following pMHC binding, the TCR/CD3 complex 
initiates synapse formation and T cell activation, possibly through conformational 
changes of TCRαβ and CD3ε (117, 118). These conformational changes might establish a 
molecular platform that allows recruitment of NCK, phosphorylation of CD3 ITAMs and 
subsequent docking and activation of a large number of signaling components (119-
121).
TCR GENE THERAPY: TRANSGENE MODIFICATIONS THAT ADDRESS TCR 
PAIRING
TCRα and β chains that are genetically modified to enhance their ability to correctly 
pair are expected to yield improved surface expression levels of the transgenic TCRαβ 
Coen BW1.indd   33 15-Aug-13   11:36:51 AM
34 Chapter 2
heterodimer. An expected consequence of enhanced TCR pairing is a concomitantly 
decreased TCR mis-pairing. TCR mis-pairing is a recognized phenomenon in the field of 
TCR gene therapy, which defines the incorrect pairing between a TCRα or β transgene 
and an endogenous TCRβ or α chain, respectively, and results in diluted surface expres-
sion of the therapeutic TCRαβ. Although there is currently no clinical evidence for TCR 
mis-pairing induced autoreactivity, the generation of autoreactive TCRs upon TCR mis-
pairing cannot be excluded. In fact, T cells expressing mis-paired TCRs and expanded 
under high IL-2 conditions (similar to the current clinical setting) were demonstrated 
to induce Graft-versus-Host Disease (GvHD) in a preclinical model (122). Strategies that 
increase preferential TCR pairing and counteract TCR mis-pairing are anticipated to yield 
T cells with higher avidity for the antigen of interest and at the same time avoid the 
generation of unknown TCR specificities and the development of potential off-target 
autoimmune reactivity. Here we divide genetically modified receptors into two classes, 
termed CD3-dependent and independent receptors, with examples of both classes 
listed in table 2.1. Receptor modifications, described in more detail below, affect TCR 
pairing and mis-pairing as well as surface expression and redirected T cell function to 
different extents. An inventory of observed and anticipated effects of modifications on 
various receptor characteristics is given in table 2.2.
CD3-DEPENDENT RECEPTORS
CD3-dependent receptors are designed to have a competitive advantage towards 
endogenous TCR chains for surface expression and to improve the avidity of T cells by 
functional allelic exclusion of endogenous TCR chains. Examples of CD3-dependent 
receptors are depicted in figure 2.1.
Murinized TCR
Murinization of human TCRs is defined by replacement of human TCR-Cα and Cβ by the 
corresponding murine TCR-Cα and Cβ domains (fig. 2.1B). Although human and murine 
TCR-C domains show a high degree of homology, it is anticipated that small differences 
affect the stability of TCR/CD3 interactions and hence TCR surface expression levels.
Evidence for a competitive advantage of murinized TCR for interacting with hu-
man CD3 molecules comes from the observation that murine, and not human, TCR-C 
domains bind more strongly to human CD3ζ (123). TCR murinization as a mean to 
enhance preferential TCR pairing was investigated using the MDM281-88/HLA-A2 (MDM2/
A2) and Wilms Tumor antigen 1126-134/HLA-A2 (WT1/A2) specificities (124, 125) and more 
extensively using the p53264-272 HLA-A2 (p53/A2) and MART-1/A2 specificities (123). Gene 
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transfer of murinized TCRs in human T cells resulted in enhanced and more sustained 
levels of surface expression when compared to fully human TCRs as determined by flow 
cytometry (123-125). With regard to TCR function, murinized MART-1/A2, p53/A2 and 
WT1/A2 TCR demonstrated increased T cell activity relative regarding cytotoxicity as 
well as interferon-γ (IFNγ) and granulocyte macrophage-colony stimulating factor (GM-
CSF) production in response to antigen-positive tumor cell lines (123). Interestingly, 
this increase in T cell activity was lost in T cell populations following various rounds 
of antigen-specific stimulation and having high and equal frequencies of T cells trans-
duced with either modified or non-modified TCRs, which suggested that enhanced T 
cell reactivity is related to an increased frequency of TCR-positive T cells rather than an 
increased potency of murinized (or cysteine-modified, see below) TCRs.
In another study, however, murinized MDM2/A2 TCR did not mediate a change in 
cytotoxicity and cytokine production upon antigenic stimulation (124, 125). Notably, 
MART-1/A2 binding by human or murinized TCR in Jurkat T cells was reduced by 80 and 
20%, respectively, upon introduction of a second non-related human TCR. The reduced 
expression of a murinized MART-1/A2 TCR suggests that TCR murinization addresses TCR 
mis-pairing, yet not to a full extent. In addition, murinized WT1/A2 TCR did not reveal re-
duced TCR mis-pairing compared to non-modified TCR when tested in TCR-engineered 
Jurkat as well as primary human T cells. Instead the level of TCR mis-pairing appeared 
to be determined by sequences of the TCR-V domains (125), in part providing a possible 
explanation for the discrepancy between the above-mentioned findings with different 
TCRs.
Cysteine-modified TCR
Introduction of cysteine amino acids at a structurally favourable position allows forma-
tion of an additional disulphide bridge and promotes correct pairing between the two 
TCR chains (126) (fig. 2.1C). Site-directed mutations of TCR-Cα Threonine-48-Cysteine 
and TCR-Cβ Serine-57-Cysteine resulted in a TCRαβ heterodimer linked by 2 interchain 
bonds (i.e., an introduced plus an endogenous transmembrane disulphide bridge 
(Cα-95 and Cβ-131) (127, 128)). It is noteworthy that the endogenous cysteines are not 
dispensable for surface expression of this modified TCR (125). Introduction of cysteine-
modified WT1/A2 TCR in human T cells resulted in increased TCR expression and pMHC 
multimer binding compared to non-modified TCR, which corresponded to enhanced 
peptide-specific T cell cytotoxicity and IFNγ production (127).
Interestingly, increased pMHC binding was also noted when T cell populations were 
standardized for equal TCR expression levels, which suggested enhanced preferential 
pairing of cysteine-modified TCRs. Indeed, experiments measuring TCRβ that remains 
surface expressed following antigen-specific TCR down-regulation demonstrated that 
Coen BW1.indd   35 15-Aug-13   11:36:51 AM
36 Chapter 2
A
C
B
D
Figure 2.1. Genetic strategies that address TCR pairing (1): receptor transgenes that are dependent 
on endogenous CD3 for expression and function. Genetic modifications that result in CD3-dependent 
receptors, using the non-modified TCR as a reference (depicted in A), are the following: murinized TCR in 
which human constant domains are exchanged for their murine counterparts (B); cysteine-modified TCR in 
which additional cysteine residues provide a second interchain disulfide bond (i.e., TCR-Cα T48C and TCR-
Cβ S57C) (C); and exclusive TCR heterodimers (based on the mutations TCR-Cα S85R and TCR-Cβ A88G) (D). 
TCRα and TCRβ variable and constant domains are indicated by Vα, Vβ, Cα and Cβ, respectively. The amino 
acids cysteine, arginine and glycine are abbreviated as ‘C’., ‘R’, and ‘G’.
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cysteine-modified, but not non-modified TCRβ, correctly pairs with corresponding TCRα 
chains (127). In contrast, the ability of cysteine-modified TCR to mis-pair was at best 
modestly decreased when compared to non-modified TCRs (125, 127). Surface expres-
sion levels of cysteine-modified TCRs were clearly detectable following gene transfer of 
single TCRα or β chains, or corresponding combinations of cysteine-modified and non-
modified TCRα and β chains (125, 127). As might be expected, giving the single amino 
acid change, cysteine-modified and non-modified TCRs associate to CD3ε and CD3ζ to 
similar extents as determined by flow cytometry and immune precipitation (125).
When combining TCR murinization and cysteine-modification, human primary T cells 
revealed enhanced levels of p53/A2 TCR surface expression as well as p53-specific IFNγ 
release when compared to TCR that were either murinized or cysteine-modified (128). In 
these comparative analyses, TCR murinization revealed higher levels of surface expres-
sion and IFNγ release than cysteine-modification. Although expression and functional 
data are promising, no characterization regarding TCR pairing or CD3 complex forma-
tion of this dual-modified TCR has yet been performed.
Exclusive TCR heterodimer
To generate an exclusive TCR heterodimer, sterical and electrostatic forces were ex-
ploited to facilitate correct pairing between TCRα and β transgenes and at the same 
time inhibit pairing between exogenous and endogenous TCRα and β chains. The crystal 
structures of murine 2C/H-2Kb and human Tax11-19/HLA-A2 specific TCRs identified Ser-
ine-85-Arginine for TCR-Cα and Arginine-88-Glycine for TCR-Cβ as mutations that would 
yield the required changes in electrostatic charges. These mutations were expected to 
generate a reciprocal ‘knob-into-hole’ configuration, and to minimally distort second-
ary and tertiary structures (schematically illustrated in figure 2.1D) (129). Initial tests 
were performed using primary human T cells transduced with a single non-modified 
or mutated MDM2/A2 TCRβ chain. Voss and colleagues observed that the expression 
of mutated TCRβ was reduced two-fold compared to non-mutated TCRβ, implying that 
mutated TCRβ chains have a reduced ability to mis-pair with endogenous TCRα chains. 
Further experiments using a TCR-negative thymoma cell line demonstrated that mu-
tated TCRα has an even ten-fold lower ability to mis-pair than mutated TCRβ. Authors 
suggested that the large Arginine side chain in TCRα-S85R may result in enhanced steric 
interference when compared to the small Glycine side chain in TCRβ-R88G upon pairing 
with corresponding non-mutated TCR chains. In contrast to their ability to decrease TCR 
mis-pairing, mutated TCR chains also showed decreased expression of correctly paired 
TCRαβ resulting in compromised tetramer binding and antigen-specific cytolysis, but 
not IFNγ secretion, when transduced in primary human T cells.
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CD3-INDEPENDENT RECEPTORS
CD3-independent receptors are comprised of TCR or TCR-like receptors that, in contrast 
to wild-type TCR, are expressed independently of endogenous CD3 molecules, and as 
such do not compete with endogenous TCR for surface expression. Examples of CD3-
independent receptors are depicted in figure 2.2.
TCR:ζ
TCRα and β chains can be endowed with CD3ζ-driven dimerization by fusing each chain 
to a complete human CD3ζ molecule (abbreviated as TCR:ζ, see figure 2.2A). Already 
in 2000 it was reported that transduction of primary human T cells with either TCRα:ζ 
or TCRβ:ζ does not result in cell surface expression, pointing out that these TCR chains 
lack the ability to mis-pair with endogenous TCR chains (64). TCR pairing properties of 
TCR:ζ were more extensively studied in dual TCR Jurkat T cells expressing MelanA26-35/
HLA-A2 (MelanA/A2) specific TCR and either MAGE-A1161-169/A1 (M1/A1) specific TCRαβ 
or TCR:ζ. In this study flow cytometric measurement of Fluorescent Resonance Energy 
Transfer (FRET) indicated high preferential pairing for TCRα:ζ and β:ζ and absence of TCR 
mis-pairing (63). TCR:ζ’s surface expression is characterized by high mean fluorescence 
intensity levels and by being independent of the expression levels of endogenous TCR. 
Immune precipitation revealed that TCR:ζ did not associate with CD3ε, CD3γ, or CD3δ, 
and only marginally with CD3ζ. Studies into pMHC binding and T cell signaling and 
function, such as activation of nuclear factor of activated T-cells (NFAT), cytotoxicity and 
cytokine production, demonstrated that TCR:ζ performs equally well as non-modified 
TCR (63, 64, 130). So far, the TCR:ζ format has been applied to TCRs specific for several tu-
mor and virus antigens, including M1/A1, gp100154-162/HLA-A2 (gp100/A2), BMFL-1280-288/
HLA-A2 (BMFL-1/A2), JC100-108/HLA-A2 (JC/A2) and EBNA-4416-424/HLA-A11 (EBNA4/A11) by 
various laboratories (64, 131-133).
Single-chain TCR
Single-chain TCRs combine the V domains of TCRα and TCRβ into one chain. Generally, a 
TCR-Vα domain is attached to a TCR-Vβ domain, interspersed by a linker sequence, and 
followed by a TCR-Cβ domain which is fused to the complete human CD3ζ to provide 
downstream signaling and T cell activation (64, 134) (abbreviated as scTCR:ζ, see figure 
2.2B). Reformatting a parental M1/A1 specific TCR, derived from the cytotoxic T lympho-
cyte (CTL) 82/30 (135), to generate a scTCR:ζ led to increased surface expression but 
reduced pMHC binding when compared to two-chain TCR:ζ (64). Lowered pMHC bind-
ing by scTCR:ζ was reflected by compromised T cell cytotoxicity and production of IFNγ 
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and TNFα, but not GM-CSF, in response to antigen-positive melanoma cells. Single-chain 
TCRs can express independently of CD3 (136), but in analogy to scFv (described below), 
these receptors are expected to weakly heterodimerize with endogenous CD3ζ/η, which 
may negatively affect antigen-specific T cell activation (137, 138).
CD3ζ
Cκ
Fc(ε)RIγ
Cκ
Fc(ε)RIγ
A
C
B
D
Figure 2.2. Genetic strategies that address TCR pairing (2): receptor transgenes that are independent 
of endogenous CD3 for expression and function. Genetic modifications that result in CD3-independent 
receptors are the following: TCR coupled to complete human CD3ζ (i.e., TCR:ζ) (A); single chain (sc)TCR, 
comprising TCR-Vα and Vβ (interspersed by a flexible linker) followed by TCR-Cβ and coupled to complete 
human CD3ζ (i.e., scTCR:ζ) (B); pMHC-specific Fab or scFv modified to allow surface expression and antigen-
specific signaling (i.e., pMHC Fab:γ or scFv:γ) (C and D). TCRα and TCRβ variable and constant domains are 
indicated by Vα, Vβ, Cα and Cβ, respectively. Antibody heavy and light chains and their variable and con-
stant domains are indicated by VH, CH, VL and CL, respectively. The Cκ linker-, CD4 transmembrane-, and Fc(ε)
RIγ intracellular domain are abbreviated as Cκ, CD4 and Fc(ε)RIγ, respectively.
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TCR-like antibodies
Antibodies that recognize pMHC ligands represent a novel generation of receptors for 
immunogene therapy. Since antibody-based receptors, whether be it non-MHC or MHC-
restricted antibodies, lack TCR-V and C domains, they are not expected to mis-pair with 
endogenous TCRα and β chains. General reviews on conventional non-MHC-restricted 
antibody-based receptors and their use to redirect T cell responses are provided by Gross 
and colleagues (139), Abken and colleagues (140) and Sadelain and colleagues (141).
TCR-like antibodies are derived in vitro from phage-displayed antibody fragments 
following selection with pMHC multimers. They are subsequently engineered for gene 
transfer after which T cells are able to bind and functionally respond to MHC-restricted 
tumor antigens (reviewed in (142, 143)). For example, selections from a large non-
immune phage antibody repertoire yielded a fully human Fab fragment, termed G8 
Fab, which specifically recognized M1/A1 complexes (144). The G8 Fab heavy (VHCH) and 
light chains (VLCL) were fused to the human CD4 transmembrane region and the Fc(ε)RIγ 
intracellular domain (general abbreviation: pMHC Fab:γ, see figure 2.2C) and upon gene 
transfer enabled T cells to bind tetramers (145, 146). Stimulating T cells engineered with 
G8 Fab:γ or its single chain variant, in which VH and VL were combined into one chain 
(general abbreviation: pMHC scFv:γ, see figure 2.2D), with M1/A1 antigen-positive mela-
noma cells leads to T cell cytotoxicity and production of cytokines (145, 146).
Interestingly, when compared to natural TCRs, TCR-like antibodies may use different 
contact residues but bind pMHC with a diagonal docking mode that is similar to that of 
natural TCRs (147, 148).
Thus far, phage-display and pMHC multimer selections yielded more than a dozen 
MHC-restricted Fab molecules, particularly true for HLA-A2-restricted antigens, and 
constitute a formally validated method to obtain TCR-like molecules (143). In contrast 
to full-length or modified TCR, the generation of these reagents is an entirely in vitro 
procedure and does not depend on the availability of T cells making these receptors 
promising candidates for gene therapy.
OTHER STRATEGIES TO ENHANCE THE FUNCTIONAL AVIDITY OF GENE-
ENGINEERED T CELLS
The functional avidity of TCR-engineered T cells can also be improved via strategies other 
than those modifying receptors to address TCR pairing, such as the use of (I) optimal vec-
tors and transgene cassettes to increase transduction efficiency, (II) genetically modified 
TCR formats aimed at improving TCR surface expression and function, or (III) defined 
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T cell populations to enhance T cell responsiveness. An overview of these strategies is 
included in table 2.1.
Vectors and transgene cassette to increase transduction efficiency
Generally, TCR gene transfer studies have made use of gammaretroviral vectors 
for transgene delivery, and clinically there is experience with gammaretroviral MFG 
Table 2.2 – Comparison of modified receptors that address TCR pairinga
Receptor format
Assembly 
with 
endogenous 
CD3εb
Reduction 
of TCR mis-
pairingc
Preferential 
TCR pairingd
Cell surface 
expressione
T cell 
functionf
Reference(s)
Non-modified 
TCR
0 0 0 0 0
Murinized 
TCR
+ ++/0g ++ + ++/0g (123, 124)
Cysteine-modified 
TCR
0 + + 0 + (127)
Murinized and 
cysteine-modified TCR
N.D. N.D. N.D. ++ ++ (128)
Exclusive TCR 
heterodimer
N.D. ++ - -- - (129)
TCR:ζ -- ++ ++ ++ 0 (63, 64)
scTCR:ζ N.D. N.A. N.A. ++h --h (64, 136)
Fab:γ / scFv:γ -- N.A. N.A. -h --h (137, 145, 
146)
a Modified receptors (schematically depicted in figures 2.1 and 2.2) were scored for several characteristics. 
Performances of the modified receptors were monitored in receptor-transduced human T cells and are 
scored ‘0’ for equal performance; ‘+’ or ‘-‘ for ≥ 1,5-fold and ‘++’ or ‘--‘ for ≥ 2-fold increased or decreased per-
formance, respectively, when compared to non-modified TCR. N.D. is not determined. N.A. is not applicable. 
Results reflect intra-study comparisons between modified and non-modified receptors.
b Assembly with endogenous CD3ε has been measured by flow cytometry, immunoprecipitation or FRET.
c Reduction of TCR mis-pairing has been measured by FRET between non-corresponding TCR chains fol-
lowing transduction with two TCR chains (i.e., TCRα + β) and/or flow cytometry of surface expressed TCR 
transgenes following transduction with single TCR chains (i.e., TCRα or β).
d Preferential TCR pairing has been measured indirectly using flow cytometry to determine the fraction of 
TCRβ positive T cells that bind pMHC or directly using FRET between corresponding TCR chains (i.e., TCR:ζ).
e Cell surface expression has been measured by flow cytometry following staining with pMHC ligands and 
using MFI as a readout.
f T cell function has been measured by cytolytic activity or IFNγ production.
g Conflicting findings between studies: See main text for details.
h Head-to-head comparisons to non-modified TCR are lacking, but performances of receptors are compared 
to either TCR:ζ (for scTCR:ζ) or CTL clone with identical specificity (for TCR-like antibodies).
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vectors or MFG-derived vectors. Notably, mature T cells in contrast to hematopoietic 
progenitor cells are resistant to oncogenic transformation (149), and have shown no 
evidence of adverse effects of retroviral gene transfer when transferred in high num-
bers to patients.
There is accumulated evidence that transduction efficiencies differ substantially 
between different vectors, with a major role for the viral origin of the Long Terminal 
Repeats (LTRs) and splice and start sequences. In this context, it of interest to mention 
that the pMP71 gammaretroviral vector, which has a Myeloproliferative Sarcoma Virus 
(MPSV) LTR and optimal 5’ sequences, demonstrated highly improved TCR transduction 
efficiencies (93, 94). An additional optimization of TCR expression is accomplished by 
introducing TCRα and TCRβ genes into one vector downstream of a single promotor and 
separated by an internal ribosomal entry site (IRES) or a 2A peptide sequence. In clinical 
studies, both IRES and 2A sequences have been used to separate TCRα and β genes (45). 
Recent work suggests that placing the TCRβ chain in front of the TCRα chain, especially 
when separated by a 2A sequence, renders optimal functional TCR expression levels for 
most TCRs tested (95).
TCR modifications aimed at improving TCR surface expression and function
Examples of genetic strategies that augment the expression and function of TCR trans-
genes include: (I) codon optimization; (II) affinity maturation; and (III) incorporation of 
stimulatory T cell molecules.
First, the functional expression of TCR transgenes can be enhanced by the use of 
codon optimized synthetic genes. The genetic code is redundant in that many of the 
20 amino acids are encoded by multiple codons. Highly expressed mammalian genes 
share a similar codon usage, suggesting that codon usage can affect protein production. 
Recent data show that codon optimization of TCR genes, which also takes into account 
structural factors (150), has a beneficial effect on surface expression and in vitro and in 
vivo function of TCR-engineered T cells (96, 151, 152).
Second, the functional expression of TCR transgenes can be increased through in 
vitro affinity evolution of CDR-mutated TCRs via phage-display methodology. For ex-
ample, HIV-1-specific TCRs have recently been selected with ligand-binding affinities 
that improved from the nM range to a high affinity pM interaction and provided T cells 
with HIV-1-specific and highly-avid responsiveness (153). In addition, the phage-display 
methodology has also been applied to TCR-like antibodies. The M1/A1 specific Hyb3 
Fab:γ, the affinity-matured variant of G8 Fab:γ, was obtained by combining light-chain 
shuffling, heavy-chain targeted mutagenesis and more stringent in vitro selections, and 
displayed an increased ligand-binding affinity (KD of 14 nM) yet an identical peptide-
specificity (154). Following expression by human T cell transductants, Hyb3 Fab resulted 
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in improved ligand-specific T cell responses (154). Interestingly, amino acid changes to 
the TCR–C domains, resulting in a decreased N-glycosylation, have also been reported 
to enhance TCR-pMHC interactions and to result in enhanced functional T cell avidity as 
measured by cytokine release and lytic activity (100).
Third, the TCR’s functional expression can be improved by genetic incorporation of 
transmembrane and/or intracellular domains of accessory, co-stimulatory and kinase 
molecules. In extension to the genetic introduction of CD3ζ or Fc(e)RIγ into receptors, 
as discussed for TCR:ζ, scTCR:ζ and TCR-like antibodies, other ‘building blocks’ have been 
analyzed for their effect on surface expression and function of various receptors. For 
example, the Ovalbumin257-264/H-2K
b specific scTCRs coupled to the transmembrane 
domain of CD3ζ followed by the intracellular domain of CD28 and the co-receptor 
molecule LCK (i.e., TCR-ζ-28-LCK) constituted a promising format with respect to T cell 
activation and peptide-specific T cell functions (136), which confirmed an earlier study 
performed by Geiger and colleagues (155). Despite constructive efforts to optimize 
scTCRs, it has generally been observed that these receptors are less responsive than 
non-modified TCR to low concentrations of antigen (64, 136). The coupling of the co-
stimulatory molecule CD28 to EBNA-4/A11 specific TCR:ζ (i.e., TCR:28ζ) (131, 156) and 
MA1/A1 specific G8 Fab:γ (157) resulted in increased antigen-specific T cell responses. In 
addition, the incorporation of other TNF receptor super family members, such as CD134 
and CD137, into TCR molecules may further optimize T cell functions as suggested by 
studies with scFv receptors that incorporate co-stimulatory molecules (158).
Defined T cell populations to enhance T cell responsiveness
A strategy that makes use of monoclonal T cells as recipient cells for gene transfer results 
in enhanced peripheral T cell persistence and sustained immune responses against tu-
mors (159). The generation of dual-specific T cells is expected to result in ongoing T cell 
stimulation via the endogenous TCR and prevention of tumor-induced T cell anergy (82, 
159). Treatment of neuroblastoma patients with EBV-specific CTL expressing a receptor 
directed against diasialoganglioside GD2 showed enhanced T cell survival and tumor 
regression in half of the patients treated (82, 160) (clinical findings are also presented in 
table 2.3). TCR gene transfer into restricted T cell populations is anticipated not only to 
enhance T cell responsiveness but also to reduce the risks of auto-immune reactivities 
for two reasons: recipient T cells are non-self reactive and chances that new TCR reactivi-
ties are generated as a consequence of TCR mis-pairing is reduced or even absent (161). 
Defined T cell populations may be transduced with genetically modified receptors that 
address TCR pairing to further reduce the chances of generating self-reactive T cells. A 
note of concern, the choice of defined T cell populations might affect the anti-tumor 
efficacy of TCR-engineered T cells. For example, TCRαβ-engineered γδT cells showed no 
Coen BW1.indd   43 15-Aug-13   11:36:53 AM
44 Chapter 2
evidence of TCR mis-pairing, yet demonstrated compromised anti-tumor efficacy in an 
OVA mouse model when compared to TCRαβ-engineered αβT cells (162).
THERAPEUTIC IMPLICATIONS
Clinical application of receptor gene therapy with either TCRs to treat melanoma, or 
antibody-based receptors (so-called Chimeric Antigen Receptors, CARs) to treat renal 
cell cancer, ovarian cancer, neuroblastoma or lymphoma have shown some successes, 
Table 2.3. Clinical TCR and CAR gene therapy trialsa
Antigen-
specific TCR 
or CAR
Disease Treatment 
response
On-target toxicity Institute/ 
company
Reference
MART-1/A2 
(DMF4) TCR
Metastatic 
melanoma
17 pts. treated: 
2PR, 1MR
None National Cancer 
institute, Bethesda, 
USA
(32)
MART-1/A2 
(DMF5) TCR
Metastatic 
melanoma
20 pts. treated: 
6PR
Melanocyte destruction 
and inflammation in 
ears and eyes
National Cancer 
institute, Bethesda, 
USA
(45)
gp100/A2 
TCR
Metastatic 
melanoma
16 pts. treated: 
1CR, 2PR
Melanocyte destruction 
and inflammation in 
ears and eyes
National Cancer 
institute, Bethesda, 
USA
(45)
CAIX CAR Renal cell 
carcinoma
No response Liver toxicity Erasmus University 
Medical Center, 
Rotterdam, 
Netherlands
(163)
FR CAR Ovarian 
carcinoma
No response None National Cancer 
institute, Bethesda, 
USA
(79)
GD2 CARb Neuroblastoma 8 pts. treated: 
1CR, 1SD, 2 
tumor necrosis
None Baylor College of 
Medicine, Houston, 
USA
(82)
CD20 CARc Indolent B-cell 
lymphoma or 
mantle cell 
lymphoma
7 pts. treated: 
2CR, 1PR, 4SD
None University of 
Washington, 
Seattle, USA
(83)
a Evaluation of clinical trials performed with T cells retrovirally transduced with either TCR or CAR with re-
spect to treatment response and on-target toxicity.
b In this study virus-specific T cells were used in contrast to the other receptor gene therapy studies which 
use polyclonal peripheral T cells.
c In this study peripheral T cells were electroporated in contrast to the other receptor gene therapy studies 
in which T cells were retrovirally transduced.
Abbreviations: TCR is T cell receptor; CAR is chimeric antigen receptor; CAIX is carbonic anhydrase IX; FR 
is folate receptor; GD2 is diasialoganglioside; CR is complete response; PR is partial response; MR is minor 
response; and SD is stable disease.
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summarized in table 2.3, but generally not in a substantial number of patients (32, 45, 
79, 82, 83, 163). Strategies that enhance the functional avidity of TCR-engineered T cells, 
such as the ones described in the present review, are expected to improve anti-tumor 
responses in clinical studies.
A TCR transgene can be genetically modified in various ways to enhance its functional 
expression, including optimization of preferential TCR pairing, codon usage, ligand-
binding affinity and/or signaling potency. We consider it of critical importance that the 
TCR format of choice is modified to improve functional surface expression, and at the 
same time minimizes the risk of mis-pairing with endogenous TCR chains. Although 
based on in vitro data the murinized TCRαβ and TCR:ζ might represent good candidate 
TCR formats (see table 2.2), there is a need for in vivo data with respect to anti-tumor 
efficacy as well as off-target toxicity to justify their use in clinical studies.
Additional challenges of the clinical use of TCR-engineered T cells include: (I) toxici-
ties (see table 2.3), (II) limited antigen specificity, (III) decreased peripheral persistence 
and (IV) potential immunogenicity of receptor-engineered T cells. First, and with respect 
to toxicities, two clinical studies, one with CAR-engineered T cells to treat renal cell carci-
noma (RCC) patients and one with TCR-engineered T cells to treat metastatic melanoma, 
show ‘on-target’ toxicities that are related to the expression of the target antigen on 
healthy tissue (45, 163). These results argue for the use of TCR recognizing non-self an-
tigens or cancer testis antigens. This latter group of antigens represents a small number 
of gene families that are expressed in many tumors, but not in healthy tissues except 
immune-privileged male germline and thymic medullary epithelial cells (164, 165), and 
may encode candidate target antigens for T cell therapy. One should note that in an 
event toxicities do occur, auto-reactive T cells might be removed via drug-induced T cell 
suicide (166, 167) or tag-mediated T cell killing (168, 169).
Second, TCR gene transfer results in T cells that are specific for a single (therapeutic) 
antigen, which is in contrast to TILs that may cover a few antigen specificities (111). 
To enhance antigen-reactivity and consequently reduce the risk of immune escape, 
one could opt to use two instead of one set of TCRαβ genes to engineer T cells. Third, 
peripheral persistence of TCR-engineered T cells is decreased when compared to TILs 
following adoptive transfer (32, 45, 111). T cell persistence is reported to be inversely 
associated with differentiation state and replicative history of transferred T cells (170). 
One way to obtain less differentiated T cells might be to expose T cells to common-γ 
cytokines other than IL-2 prior to adoptive T cell transfer. For example, treatments with 
either IL-15+IL-21 or IL-7+IL-15 have been shown to generate gene-engineered T cells 
with a less differentiated CD8 T cell phenotype (i.e., central memory phenotype) and 
potent antigen reactivity and prolonged peripheral persistence (171, 172). Alternatively, 
one can also use less differentiated T cell populations as recipient cells for gene transfer 
(173, 174).
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Finally, TCR-engineered T cells may evoke an immune response in patients. Studies 
with CAR-engineered T cells to treat RCC patients revealed humoral and cellular re-
sponses directed at the CAR’s murine CDR domains (163, 284). With respect to genetically 
modified TCRs, the TCR-V domains remain unchanged, but the extent of modifications to 
the TCR-C domains varies between the different receptor formats. Although severity of 
potential immunogenicity might be estimated based on the extent of genetic modifica-
tions, for all described receptors this needs to be verified in in vivo studies. Another way 
to address the potential immunogenicity of receptor-transduced T cells might be by 
immune suppressive preconditioning of patients in order to limit or delay the patient’s 
immune response towards transduced T cells. This latter option, combining chemo-
therapy with T cell therapy, potentiates the responses of the adoptively transferred T 
cells (175). Combining T cell therapy with other therapies, such as those stimulating the 
innate immune system, also appear promising and await clinical testing (176).
For future clinical trials, we propose to combine strategies that on the one hand 
genetically modify TCR transgenes to enhance preferential TCR pairing and minimize 
TCR mis-pairing and on the other hand further enhance the efficacy and safety of TCR-
engineered T cells, such as the use of T cells with an optimal T cell differentiation state 
and a TCR specific for a tumor-specific antigen.
CONCLUDING REMARkS
There are numerous ways to increase the functional avidity of TCR-engineered T cells 
(presented in table 2.1), but those that address TCR pairing recently got special atten-
tion in the field of TCR gene therapy since they are expected to enhance the functional 
avidity as well as the potential safety of T cells (see table 2.2).
Genetically modified receptors that address TCR pairing can be classified according to 
the CD3-dependence for surface expression. Classification into CD3-dependent and CD3-
independent receptors represents not only a convenient way of listing genetic modifica-
tions, but points to fundamental differences in cell surface expression and downstream 
signaling. The abilities of CD3-dependent receptors to address TCR mis-pairing are not 
absolute. On the one hand, the murinized and cysteine-modified TCRs, and especially 
the combination of these formats, do show enhanced preferential pairing, but are less 
potent at addressing TCR mis-pairing. On the other hand, the exclusive TCR heterodimer 
addresses TCR mis-pairing to a fair extent, but unfortunately shows limited preferential 
TCR pairing, pMHC binding and redirected T cell function. In contrast, CD3-independent 
receptors (with most data available for TCR:ζ) combine high preferential pairing with 
none or clearly less TCR mis-pairing. Murinized TCR, cysteine-modified TCR and TCR:ζ, 
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but not scTCR and MHC-restricted scFv, show good pMHC binding and TCR-mediated T 
cell functions.
Receptor modifications to enhance functional T cell avidity other than those that 
specifically address TCR pairing include codon optimization, affinity maturation, and 
incorporation of stimulatory T cell molecules. A combined effort of such strategies to-
wards improved T cell avidity is expected to potently enhance the anti-tumor efficacy of 
clinical TCR gene therapy. Importantly, various receptor modifications, especially those 
that address TCR pairing, as well as combinations of receptor modifications need valida-
tion in in vivo studies prior to their translation to clinical trials (see box 2.2. Outstanding 
questions). In addition to the design of an optimal TCR transgene, key parameters that 
may affect the clinical impact of TCR gene therapy include the choice of vector and 
transgene cassette, definition of T cell population, and combination therapies. In our 
view of critical importance to the safety of TCR gene therapy is the choice of T cell target 
antigen.
Taken together, we consider CD3-independent receptors valuable transgenes to 
optimally address TCR pairing and functional T cell avidity. Combining such receptors 
with strategies to further enhance anti-tumor activity and safety of TCR-engineered T 
cells holds great promise to the development of clinical TCR gene therapy.
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Box 2.2. Outstanding questions
•  How do the various modified receptors perform in vivo with respect to anti-tumor efficacy as well 
as safety? Is there a winner?
•  What combination of strategies performs best in vivo without showing toxicities: modified recep-
tors, T cell phenotype, antigen choice?
•  Would TCR mis-pairing lead to off-target toxicities in clinical TCR gene therapy when conditions 
would promote expansion of adoptively transferred T cells more strongly? And if so, would the 
modified receptors prevent or decrease the extent of such toxicities?
•  Would it be feasible to identify and remove T cells with mis-paired TCRs prior to adoptive transfer?
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ABSTRACT
TCR gene therapy represents a feasible and promising treatment for patients with cancer 
and virus infections. Currently, this treatment rationale is hampered by diluted surface 
expression of the TCR transgene and generation of potentially self reactive T-cells, both 
a direct consequence of mis-pairing with endogenous TCR chains. As we reported 
previously (63, 64), TCR mis-pairing can be successfully addressed by a TCR:CD3ζ fusion 
protein (i.e., TCR:ζ). Here, we set out to minimize the content of CD3ζ in TCR:ζ, specific for 
MAGE-A1/HLA-A1, without compromising TCR pairing and function. Domain-exchange 
and 3D-modeling strategies defined a set of minimal TCR:ζ variants, which, together 
with a murinized and cysteine-modified TCR (TCR:mu+cys), were tested for functional 
TCR expression and TCR pairing. Our data with Jurkat T cells show that the CD3ζ trans-
membrane domain is important for cell-surface expression, whereas the CD3ζ intracel-
lular domain is crucial for T-cell activation. Notably, the inability of TCR:ζ to mis-pair was 
not observed for TCR:mu+cys, depended exclusively on the transmembrane domain of 
CD3ζ and could not be recapitulated by a limited number of structurally defined CD3ζ 
transmembrane amino acids. The extracellular CD3ζ domain was dispensable for TCR:ζ’s 
ability to prevent TCR mis-pairing, bind pMHC and mediate NFAT activation. In primary 
human T cells, however, minimal TCR:ζ without CD3ζ’s extracellular domain but not 
TCR:ζ nor TCR:mu+cys revealed compromised cell surface expression and T cell function. 
Taken together, our study demonstrates that CD3ζ’s transmembrane domain dictates 
TCR:ζ’s inability to TCR mis-pair, but only TCR coupled to complete CD3ζ and not its 
minimal variants were functionally expressed in primary T cells.
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INTRODUCTION
T cell receptor (TCR) gene therapy is based on retroviral transduction of T cells with tu-
mor or virus-specific TCRαβ transgenes. Clinical TCR gene therapy trials proved feasible 
and applicable towards multiple tumor types, such as metastatic melanoma, colorectal 
carcinoma and synovial sarcoma (32, 40, 45, 46). This first series of studies with TCR-
engineered T cells, although showing variable clinical responses in limited numbers of 
patients, demonstrate that responses generally lag behind those observed with non 
gene-engineered T cells (27, 28, 103, 104, 111). In addition, in case of TCRs directed 
against MART-1, gp100 or CEA, but not the cancer testis antigen NY-ESO-1, treatment 
resulted in on-target toxicity, i.e., severe inflammation of healthy tissue expressing the 
target antigen (40, 45, 46).
The efficacy and safety of clinical TCR gene transfer may be further enhanced by 
strategies that address TCR mis-pairing. TCR mis-pairing is a recognized phenomenon of 
TCR gene transfer, and defined by the incorrect pairing of TCRα or TCRβ transgenes with 
endogenous TCRβ or TCRα chains, respectively. TCR mis-pairing leads to the formation of 
unknown TCR specificities, which dilute the surface-expression of the therapeutic TCRαβ 
heterodimer and can potentially result in off-target toxicity. Although, there is no clini-
cal evidence for TCR mis-pairing-induced autoreactivity, preclinical data derived from a 
mouse model, demonstrate that TCR mis-pairing can lead to graft-versus-host disease 
(65). Strategies that prevent TCR mis-pairing are therefore expected to improve T cell 
avidity by increasing the level of cell surface expression of therapeutic TCRαβ heterodi-
mer and at the same time reduce potential off-target toxicity, as described in chapter 
2. These strategies include the murinization of TCRα and –β constant domains (123), 
introduction of additional cysteine residues in TCRα and –β to form an extra disulfide 
bridge (127), the exchange of structurally important amino acids between TCRα and –β 
(129), or the replacement of parts of TCRα and –β constant domains by complete human 
CD3ζ (TCR:ζ) (64).
In previous studies, TCR:ζ has been extensively characterized regarding its ability 
to address TCR mis-pairing and functionally retarget T cells towards several tumor and 
virus antigens, such as MAGE-1/HLA-A1, gp100/HLA-A2, BMFL-1/HLA-A2, JC/HLA-A2 
and EBNA-4/HLA-A11 (63, 64, 131-133, 177). Notably, TCR:ζ’s surface expression, which 
is enhanced when compared to wt TCR, and its ability to form immune synapses are 
independent of endogenous CD3 proteins. This receptor, possibly as a consequence of 
conformational changes, results in enlarged synapse sizes in TCR-transduced T cells (63, 
177). Despite these unique properties, TCR:ζ and wt TCR do not differ with respect to the 
molecular ‘make-up’ of immune synapses and their ability to mediate antigen-specific T 
cell functions.
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In the current study, we set out to minimize the content of CD3ζ present in TCR:ζ, 
specific for MAGE-A1/HLA-A1, without compromising the pairing and functional proper-
ties of TCR:ζ, and with the intent to potentially decrease the immunogenicity of this 
receptor. In analogy to a study by Sommermeyer and colleagues, who defined a limited 
number of amino acids that preserved the benefits of murinized TCRs (178), the present 
effort would define those domains or amino acids of CD3ζ responsible for improved TCR 
pairing and function. To generate minimal TCR:ζ variants we applied a domain-exchange 
as well as a 3-dimensional (3D) modeling strategy, and tested variants for TCR pairing 
and functional expression. We observed that the CD3ζ transmembrane domain, but 
not a limited number of structurally defined amino acids, is critical for TCR:ζ’s surface 
expression and its inability to mis-pair with endogenous TCR chains, whereas the intra-
cellular CD3ζ domain is critical for T cell activation. A minimal TCR:ζ variant that lacked 
the extracellular CD3ζ domain was best at preserving both TCR pairing and function in 
Jurkat T cells, but was not functionally expressed in primary T cells.
MATERIALS AND METHODS
Cells and reagents
Jurkat T cell clone 19 (63), which expresses MelA/HLA-A2 (MelA) TCR, and EBV-transformed 
B cell blasts (APD) were cultured in RPMI 1640 medium (BioWhittaker, Verviers, Belgium) 
containing 10% Fetal Bovine Serum (FBS, Stonehouse, Gloucestershire, UK), streptomy-
cin (100 μg/ml) and penicillin (100 U/ml). The human embryonic kidney cell line 293T, 
the packaging cell line Phoenix-A, and melanoma cell line Mel2A were cultured in DMEM 
medium (BioWhittaker) supplemented with 10% FBS, 2 mM L-glutamine, non-essential 
amino acids and antibiotics. T lymphocytes derived from healthy donors were isolated 
and expanded as described elsewhere (179) and cultured in HEPES buffered RPMI 1640 
medium supplemented with 10% Human Serum, 2 mM L-glutamine, streptomycin and 
penicillin. Monoclonal Abs included: FITC- and non-conjugated anti-TCR-Vα19 mAb 
(Pierce Biotechnology, Inc., Rockford, IL); PE- and non-conjugated anti-TCR Vβ27 mAb (BD 
Biosciences, San Jose, USA); PE- and non-conjugated anti-TCR-Vβ9 mAb (BD Biosciences 
and Coulter-Immunotech, Marseille, France, respectively); PE-conjugated anti-CD107a 
mAb (BD biosciences); APC-and non-conjugated anti-CD3ε mAb (OKT3) (BD Biosciences 
and Coulter-Immunotech, respectively); Cy5- and non-conjugated Rabbit-anti-Mouse 
(RαM) IgG Fab (Jackson ImmunoResearch, Suffolk, UK). Peptide/MHC (pMHC) monomers 
included: MAGE-1 (M1: EADPTGHSY)/HLA-A*0101; and Melan-A (MelA: ELAGIGILTV)/
HLA-A*0201 biotinylated peptide/MHC monomers (Sanquin, Amsterdam, Netherlands), 
and these pMHC monomers were tetramerized as described previously (180). Other 
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reagents included: Retronectin (human fibronectin fragments CH-296, Takara Shuzo Co. 
Ltd., Otsu, Japan); PMA (Sigma-Aldrich, St. Louis, USA); PHA (Remel Europe, Dartford, 
England); golgistop (BD biosciences) and streptavidin-PE (BD biosciences).
Cloning of minimal TCR:ζ variants
We have generated a panel of 11 TCRs, as schematically represented in figure 3.1, that 
are specific for MAGE-A1/HLA-A1 (M1/A1) and have the TCR-V gene usage TRAV19/
J39/C and TRBV9/D2/J2-3/C2 (with TCR-V(D)J gene nomenclature according to http://
imgt.cines.fr), originally derived from CTL clone MZ2-82/30 as described previously (64). 
Control TCRs (n=3) included wt TCR (63), TCR:ζ (63, 64) and a murinized plus cysteine-
modified TCR (i.e., TCR:mu+cys), the latter designed according to Cohen and colleagues 
(128). TCR:mu+cys was generated via overlap PCR to fuse together M1/A1 TCR-V and 
murine TCR-C domains (Vα-mCα and Vβ-mCβ2), which were ligated in pBullet vectors 
(64) via SalI-XhoI (TCRα) and NcoI-XhoI (TCRβ). Cysteine mutations (TCRα T189, and TCRα 
S191) were generated using QuickChange Site-Directed Mutagenesis Kit (Fynnzymes, 
Espoo, Finland) according to the manufacturer’s instructions. The minimal TCR:ζ variants 
(n=8) were generated via either one of two approaches. First, six variants were made 
using a domain-exchange strategy in which extracellular (ec), transmembrane (tm) or 
intracellular (ic) domains of CD3ζ, and combinations of these domains, were exchanged 
for corresponding TCR domains. These six variants were named as follows: TCR:ζ ∆ec; 
TCR:ζ ∆tm; TCR:ζ ∆ic; TCR:ζ ∆ec+ic; TCR:ζ ∆tm+ic; and TCR:ζ ∆ec+tm (∆ indicates lack of 
CD3ζ domain(s), and replacement by corresponding TCR domain(s)). The exact boundar-
ies of ec, tm and ic domains of CD3ζ, TCRα and TCRβ are provided in the legend to figure 
3.1. These variants were generally constructed by overlap PCR and gene synthesis, as de-
scribed in detail in supplementary methods. Second, two additional TCR:ζ variants were 
made using a 3D-modelling strategy in which a limited number of amino acids of TCR tm 
were exchanged for CD3ζ tm amino acids at structurally favorable positions. These two 
variants were named as follows: TCR tmζ1 and 2, with the exact tm sequences provided 
by figure 3.1. The modeling software to design these variants, and their construction, 
generally by gene synthesis, is described in detail in supplementary methods. All TCR 
constructs made (n=11) were sequence verified (Service XS, Leiden, Netherlands).
Retroviral TCR gene transfer into T cells
TCR cDNAs were used to transduce Jurkat T cell clone 19 as well as human PBMC. To this 
end, Moloney Murine Leukemia retroviruses were produced by a co-culture of the pack-
aging cells 293T and Phoenix-A following calcium-phosphate transfections (63, 131). 
Packaging cells were transfected with TCR cDNAs, pHIT60 MLV GAG/POL, and VSV-G 
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envelope plasmids for Jurkat T cell transductions, or with TCR cDNAs, pHIT60 MLV GAG/
POL, and pCOLT-GALV-envelope encoding plasmids for human PBMC transductions. The 
transduction procedure used was optimized for human T cells and described previously 
(71).
wt TCR
TCR: 
mu+cys TCR:ζ ∆ec ∆tm ∆ic ∆ec+ic ∆tm+ic ∆ec+tm tmζ 1 tmζ 2
Minimal TCR:ζ variants
= TCR sequence = Murine sequence = CD3ζ sequence = CD3ζ amino acids = disulfide bridge
A
B
Figure 3.1. Scheme of minimal TCR:ζ variants. (A) Minimal TCR:ζ constructs were modified via replace-
ment of either extracellular (∆ec), transmembrane (∆tm), intracellular (∆ic), extra and intracellular (∆ec+ic), 
transmembrane and intracellular (∆tm+ic) or extracellular and transmembrane CD3ζ domains (∆ec+tm) 
(black) by corresponding TCRα and TCRβ domains (white). Boundaries for the CD3ζ/TCRαβ ec, tm and ic 
domains were defined as follows. CD3ζ (genbank accession number: CAI21380.1) ec, tm and ic: nucleotide 
(nt) 73-90 (aa 25-30); nt 91-153 (aa 31-51); and nt 154-489 (aa 52-163). TCRα ec, tm and ic: nt 703-765 (aa 
235-255); nt 766-825 (aa 256-275); and nt 826-840 (aa 276-280). TCRβ ec, tm and ic: nt 790-846 (aa 264-
282); nt 847-912 (aa 283-304); and nt 913-933 (aa 305-311). In addition, two minimal TCR:ζ constructs were 
designed in which defined amino acids of tm CD3ζ were transplanted onto structurally favorable positions 
in TCRα and TCRβ tm domains, and were termed minimal TCR:tmζ1 and 2 (see figure 3.1B). Control TCRs in-
clude: wt TCR, TCR:ζ and a TCR containing murine constant domains and additional cysteines (TCR:mu+cys, 
as described in (128). (B) Transmembrane amino acids of CD3ζ and minimal TCR:ζ variants TCRα:tmζ1, 
TCRα:tmζ2, and TCRβ:tmζ (CD3ζ amino acids underlined).
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Flow cytometry and FACSort
TCR-transduced T cells (1x104 cells) were monitored by flow cytometry for surface 
expression of transgenic TCR using FITC-conjugated anti-TCR-Vα19, PE-conjugated 
anti-TCR-Vβ9 mAbs and/or R-PE-conjugated M1/A1 tetramer; endogenous TCR (in case 
of Jurkat T cells) using PE-conjugated anti-TCR-Vβ27 mAb and/or R-PE-conjugated 
MelanA/A2 tetramer; and endogenous CD3 using APC-conjugated anti-CD3ε mAb. After 
T cells were washed, they were incubated with mAbs for 30 min on ice, or 15 min at 
RT for pMHC tetramers. Next, T cells were washed and fixed with 1% PFA (Brunschwig, 
Amsterdam, the Netherlands) before measurements on a FACSCalibur dual-laser flow cy-
tometer (Beckton Dickinson, Alphen a/d Rijn, the Netherlands). Samples were analyzed 
using BD Cellquest software and displayed as dotplots or histograms. Enrichment of 
M1/A1 TCR-expressing Jurkat Clone 19 T cells was performed by two-color Fluorescent 
Activated Cell Sorting (FACS) following staining with FITC conjugated anti-TCR-Vα19 and 
PE conjugated anti-TCR-Vβ9 mAbs.
Flow cytometry-based FRET
PE-labeled mAbs were used as donor and Cy5-labeled RαM antibody as acceptor and 
used in the following donor/acceptor combinations (as described in (63)): anti-TCR-
Vb27PE + anti-TCR-Vα19/ GαMCy5 and anti-TCR-Vb9PE + anti-CD3ε (OKT3)/GαMCy5. Stain-
ing was performed sequentially, with extensive washing steps in between, using the 
following order of staining steps: first non-conjugated mAbs, second Cy5-labeled Abs, 
and last PE-labeled donor Abs. Fluorescence intensities of emissions at 570 nm (donor 
channel, excitation at 488nm), 670 nm (acceptor channel, excitation at 635), and over 
670 (FRET channel, excitation at 488 nm) were measured and collected on a FACSCalibur. 
Data were analyzed with the FLEX software on a per-cell basis (181).
NFAT reporter gene assay
Gaussia-Luciferase reporter gene under the control of 6 NFAT response elements, a 
minimal IL-2 promotor, and a TATA box (in short: GLuc-NFAT(RE)6) was used to quan-
tify TCR-mediated stimulation. Gluc-NFAT(RE)6 was generated by digesting a plasmid 
containing NFAT-6-luc (182) with NcoI-HinDIII and ligating this fragment (containing 
the 6 NFAT response elements, minimal IL-2 promotor and TATA box), together with a 
EcoRI-NcoI linker, in EcoRI-HinDIII digested pGluc-basic vector (New England Biolabs, 
Ipswich, USA). 5x106 Jurkat TCR-transduced T cells were transiently nucleofected with 
an Amaxa nucleofector (AmaxaBiosystems, Cologne, Germany) according to previous 
optimizations (130, 183). Briefly, T cells were resuspended in 100 μl supplemented buf-
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fer V to which 5 μg GLuc-NFAT(RE)6 was added and pulsed with the Nucleofector set at 
program C-16. Next, T cells were immediately transferred to 2.5 ml warm Jurkat T-cell 
medium in T25 flasks for O/N recovery at 37°C and 5% CO2. Non-tissue culture-treated 
96-well plates were coated with non-conjugated mIg Ab, anti-TCR-Vβ9 mAb (100 ng) 
or biotinylated M1/A1 or JC/A2 monomers (titrated from 126 nM down to 4 nM). The 
latter added to streptavidin-coated plates O/N at 4°C. Twenty hours post-transfection, 
0.2x106 T cells at a concentration of 1x106/ml were transferred to each well in the 
96-well plates and stimulated for 6 hours at 37°C and 5% CO2. Subsequently, 25 μl 
supernatant was transferred to 96 wellplate read-out plates (Corning incorporated, 
Costar assay plate, Lowell, USA) and placed in a luminometer. Next, 50 μl assay buffer 
was added (Gluc substrate; New England Biolabs, Ipswich, USA). Light units indicative 
of the Gaussia Luciferase-mediated enzymatic transition of coelenterazine into coel-
enteramide were measured according to the manufacturer’s instructions (Mediators, 
Vienna, Austria) and expressed (in RLU) relative to wt TCR luciferase activities (100% for 
each concentration).
CD107a mobilization assay
TCR-transduced human PBMC (1x106) were resuspended in 0,15 ml T cell medium, 0,5 μl 
Golgistop (BD biosciences), and 100 μl anti-CD107a-PE (BD biosciences). Mel2A and APD 
target cells (1x106) were resuspended in 0,25 ml T cell medium (± 10-5 M M1 peptide). 
Next, 50 μl target cells and 50 μl T cells were mixed in a tissue culture treated 96-well 
plate (Greiner bio-one) and incubated for 2 h at 37°C and 5% CO2. After the cells were 
washed, they were stained with anti-Vα19-FITC and anti-CD3ε-APC for 30 minutes at 
4°C in the dark. Next, cells were washed and fixed with 1% PFA and measured on a FACS 
Calibur dual-laser flow cytometer. T cells gated for viability (FSC and SSC) and positive 
for CD3ε and TCR-Vα19, were assessed for surface expression of CD107a.
Statistical analyses
Differences among TCRs in various assays were tested with Student’s t-tests (unpaired; 
two-tailed) using Graphpad Prism 4 software. Differences with p-values <0.05 were 
considered significant.
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RESULTS
CD3ζ transmembrane domain is required for surface expression of TCR:ζ
Jurkat T cells containing MelA/A2 TCR were used as recipient cells for a panel of 6 M1/
A1 minimal TCR:ζ’s, each incorporating a different but minimal of ec, tm and/or ic CD3ζ 
domains (see figure 3.1 for details). These dual-TCR Jurkat T cells were assessed for surface 
expression of transgenic TCR by flow-cytometry. Minimal TCR:ζ ∆ec, ∆ic, ∆ec+ic, all con-
taining the CD3ζ tm domain, revealed a surface expression pattern like that of parental 
TCR:ζ with a typical diagonal, high mean fluorescence intensity (MFI) and absence of 
single TCR-chain positive cells (see fig. 3.2A; (63)). TCR:ζ ∆ic and ∆ec+ic revealed lower 
levels of surface expression than TCR:ζ ∆ec or TCR:ζ. In contrast, TCR:ζ ∆tm, ∆tm+ic and 
∆ec+tm transduced Jurkat T cells showed no surface expression of either or both TCRα:ζ 
and TCRβ:ζ chains (fig. 3.2A). Further analysis of these latter TCRs revealed that mRNA, but 
not intracellular protein were consistently present, suggesting that not gene transcrip-
tion but more likely protein translation and/or transportation to the cell surface were 
hampered (supplementary fig. 3.1). Notably, the TCR:mu+cys, a murinized and cysteine-
modified TCR used as a control TCR, shows an extended diagonal surface expression 
pattern and no or less single TCR-chain positive T cells than wt TCR, similar to TCR:ζ or its 
CD3ζ tm-containing variants (fig. 3.2A) and suggestive for high preferential TCR pairing.
CD3ζ transmembrane domain critically determines the inability of TCR:ζ to 
associate with endogenous CD3 and TCR chains
The minimal TCR:ζ variants were assessed for their inability to associate with endogenous 
CD3, considered a unique characteristic of TCR:ζ, using conventional flow cytometry 
and flow cytometric Fluorescence Resonance Energy Transfer (FRET). Flow cytometry 
analyses after double-staining for TCRβ and CD3ε revealed diagonal dotplots in Jurkat T 
cells expressing wt TCR and TCR:mu+cys, but not TCR:ζ or any of its minimal TCR variants 
(fig. 3.3A). These data suggest on the one hand a CD3-independence of minimal TCR:ζ 
variants that contain CD3ζ tm, similar to the reported CD3-independence of TCR:ζ, and 
confirm on the other hand a CD3-dependence of wt TCR and TCR:mu+cys (see chapter 
2) . The lack of competition for CD3-proteins by TCR:ζ ∆ec, ∆ic, ∆ec+ic was also reflected 
in the expression of endogenous TCR. TCR:ζ or these variants did not alter the MFI of 
endogenous TCRβ, whereas wt TCR or TCR:mu+cys approximately halved the MFI of 
endogenous TCRβ (data not shown). Subsequent studies focused only on the three 
minimal TCR:ζ variants that were expressed on the cell surface. Flow cytometric FRET 
confirmed lack of association between TCR:ζ or its minimal variants, but not wt TCR or 
TCR:mu+cys, and CD3ε (fig. 3.3B). Flow cytometric FRET was also applied to address the 
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extent TCRs were prone to TCR mis-pairing. Using antibodies specific for endogenous 
TCR-Vβ27 (PE-fluorochrome, donor) and the TCR-Vα19-transgene (Cy5-fluorochrome, 
acceptor), we observed no FRET signals above background for TCR:ζ ∆ec, ∆ic, or ∆ec+ic 
variants, similar to parental TCR:ζ, indicating that these variants preserve TCR:ζ’s abil-
ity to successfully address TCR mis-pairing (fig. 3.3C). Notably, when using a sensitive 
methodology such as FRET, TCR:mu+cys TCRα mis-paired with endogenous TCRβ to the 
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Figure 3.2. Minimal TCR:ζ ∆ec, ∆ic and ∆ec+ic express at T cell surface. Jurkat T cells expressing MelA/
A2 TCR (Jurkat cl. 19) were transduced with one of the following M1/A1 TCRs: minimal TCR:ζ ∆ec, ∆tm, ∆ic, 
∆ec+ic, ∆tm+ic, ∆ec+tm, TCR tmζ 1, tmζ 2, TCR:ζ, wt TCR, TCR:mu+cys, or no TCR transgene. (A) Surface ex-
pression levels of transgenic MA1/A1 TCRs were measured via flow cytometry using anti-TCR-Vα19FITC and 
anti-TCR-Vβ9PE mAbs. Representative dotplots out of 5 individual measurements are displayed. See supple-
mentary figure 3.1 for extended analysis of intracellular protein and mRNA expression of those minimal 
TCR:ζ variants that did not show surface expression of both TCR-Vα19 and TCR-Vβ9, i.e., minimal TCR:ζ ∆tm, 
∆ec+tm, ∆tm+ic, TCR:tmζ 1 and tmζ 2. (B) TCR surface expression of Jurkat T cell lines transduced with mini-
mal TCR:ζ ∆ec, ∆ic and ∆ec+ic or controls wt TCR, TCR:ζ and TCR:mu+cys after FACSort with anti-TCR-Vα19FITC 
and anti-TCR-Vβ9PE mAbs. Representative dotplots out of 5 individual measurements are displayed and 
percentages of stained T cells in upper left and upper right quadrants are indicated. (C) Mean Fluorescence 
Intensities or percentages (both + SEM) of TCRαβ in upper right quadrants in (B), n=6-11 independent 
measurements (statistically significant differences in comparison to wt TCR are calculated with Student’s 
t-tests; p-values indicated in figure).
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same extent as wt TCRα. Additional proof for the absence or presence of TCR mis-pairing 
came from single TCR chain transductions of Jurkat T cells. Supplementary figure 3.2 
demonstrates significant cell surface expression of a TCRαβ heterodimer (indicative of 
TCR mis-pairing) upon transduction with single chains (either TCRα or -β) of wt TCR or 
TCR:mu+cys, but not minimal TCR:ζ variants or TCR:ζ.
Next, we attempted to identify a limited number of CD3ζ tm amino acids important 
for TCR:ζ’s surface expression and inability to mis-pair. A 3D-modeling strategy was 
applied to define a set of CD3ζ transmembranal amino acids that was subsequently 
transplanted onto favorable positions in the transmembrane domain of TCR chains. This 
resulted in TCR:ζ variants TCR:tmζ1 and -2 which were retrovirally introduced in Jurkat T 
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Figure 3.3. Minimal TCR:ζ ∆ec, ∆ic and ∆ec+ic show neither CD3 association nor TCR mis-pairing. (A) 
Jurkat T cells expressing minimal TCR:ζ ∆ec, ∆ic and ∆ec+ic, TCR:ζ, wt TCR, TCR:mu+cys transgenes were 
tested for surface expression of transgenic TCR and CD3ε via flow cytometry using anti-TCR-Vβ1PE and anti-
CD3εAPC antibodies. Representative examples out of 5 individual measurements are displayed. (B) CD3ε 
association and (C) TCR mis-pairing were determined of minimal TCR:ζ ∆ec, ∆ic and ∆ec+ic and control TCRs 
using Fluorescence Resonance Energy Transfer (FRET) between anti-Vβ9PE->anti-CD3ε-RαMCy5 and anti-
Vβ27PE->anti-Vα19-RαMCy5 mAbs, respectively. Please note that FRET was measured using TCR-transduced 
but non-sorted Jurkat T cells after gating on M1/A1-specific TCR expressing cells. Dotted line represents the 
level of background signal (5%) and bars represent mean FRET values + SEM, n=4 independent measure-
ments (statistically significant differences in comparison to wt TCR are calculated with Student’s t-tests: * = 
p<0.05; ** = p<0.005).
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cells. Flow cytometry revealed no cell surface expression of minimal TCR:tmζ1 or -2 het-
erodimers on these dual-TCR Jurkat T cells (fig. 3.2A). TCRα:tmζ1 and -2 chains were not 
able to complex with TCRβ:tmζ or endogenous TCRβ. Also, TCRβ:tmζ showed moderate 
levels of surface expression through mis-pairing with the endogenous TCRα. Analysis of 
mRNA and intracellular protein suggested difficulties in protein transportation to the 
cell surface of particularly both TCRα-chains (supplementary fig. 3.1). Thus, we were un-
able to attribute strong CD3-independent cell surface expression and prevention of TCR 
mis-pairing to a subset of CD3ζ transmembranal amino acids.
Minimal TCR:ζ ∆ec performs best at preserving the ability of TCR:ζ to bind 
pMHC and activate NFAT
To study TCR-mediated functions, we have FACSorted Jurkat TCR-transductants with 
TCRα and -β mAbs to enhance and equalize surface expression levels of the different TCR 
formats (fig. 3.2B). Enrichment resulted in similar surface expression levels of TCRs (range 
between 74 - 92%), except for TCR:ζ ∆ec+ic which fell behind (48%) (fig. 3.2C). MFIs were 
within the same range for TCR:ζ ∆ec, ∆ic and parental TCR:ζ (TCR:ζ ∆ec: 163 and 1145; 
TCR:ζ ∆ic: 133 and 998; and TCR:ζ: 242 and 1646 for TCRα and -β chains, respectively), 
and were lowered for TCR:ζ ∆ec+ic (76 and 578) (fig. 3.2C). In fact, MFIs of TCR:ζ ∆ec+ic 
were within the same range as those for wt TCR and TCR:mu+cys (wt TCR: 64 and 633; 
TCR:mu+cys: 66 and 540). Please note that levels of surface expression of TCR:ζ and its 
variants do not take into account TCR stainings in upper left quadrants of flow cytometry 
dot plots. Since these stainings extend the diagonal of flow cytometry dotplots and are 
not due to TCR mis-pairing (fig. 3.3C), levels of surface expression, as put in figure 3.2C, 
may underestimate total surface expression levels of TCR:ζ and its variants.
Subsequently, transgenic TCRs were standardized for average cell surface expression 
levels (with % surface expression of wt TCR, see figure 3.2C, set to 1.0) and compared for 
their ability to recognize and bind pMHC. The TCR:ζ ∆ec transgene revealed a slightly 
lower percentage of pMHC binding compared to the TCR:ζ transgene, detected at all 
measured concentrations, although differences reached no statistical significance (fig. 
3.4A). Wild-type TCR, TCR:mu+cys, and TCR:ζ transduced Jurkat T cells showed the highest 
percentages of pMHC positive populations (fig. 3.4A). Again, when analyzing the MFIs of 
pMHC binding, we noted that Jurkat T cells expressing TCR:ζ ∆ec or parental TCR:ζ were 
the two T cell lines with the highest TCR expression levels (figs. 3.4B and 3.2C). Although 
TCR:ζ ∆ec shows a pMHC binding approximately half of that of parental TCR:ζ, both 
show a significantly increased MFI compared to wt TCR (TCR:ζ vs wt TCR: p<0.05 at all 
concentrations; and TCR:ζ ∆ec vs wt TCR: p<0.05 at 4 out of 6 concentrations). TCR:ζ ∆ic 
and ∆ec+ic variants showed a negligible pMHC binding, whereas TCR:mu+cys showed a 
pMHC binding that was slightly lower than wt TCR.
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Next, we measured antigen-specific T cell activation by employing a Gaussia Lucif-
erase reporter assay based on six response elements of Nuclear Factor of Activated 
T cells (NFAT), a transcription factor that is a key step in T cell activation. With trans-
genic TCRs being standardized for average cell surface expression levels (fig. 3.2C), we 
observed that TCR:ζ ∆ec and parental TCR:ζ proved to be most potent in activating 
Jurkat T cells by inducing the highest level of luminescence, which was significantly 
higher when compared to wt TCR (fig. 3.5). TCR:ζ ∆ic and ∆ec+ic variants, however, 
did not mediate T cell activation, even though these TCRs were able to bind pMHC. To 
further investigate the potency of TCR:ζ ∆ic and ∆ec+ic to induce intracellular T cell 
signaling, we stimulated Jurkat T cells with anti-TCR-Vβ9 mAbs and demonstrated that 
these two TCRs, both lacking the intracellular CD3ζ immunoreceptor tyrosine-based 
activation motifs (ITAMs), were not able to mediate T cell activation (supplementary 
fig. 3.3). Stimulations of the endogenous TCRβ with anti-TCR-Vβ27 mAb did not show 
reduced NFAT activation upon transduction with TCR:ζ ∆ec, ∆ic or ∆ec+ic, in line with 
parental TCR:ζ ((63) and data not shown). In contrast, stimulation with anti-TCR-Vβ27 
mAb did show significantly reduced NFAT activation upon transduction with wt TCR 
or TCR:mu+cys, a result of down-regulated surface expression of CD3-dependent TCRs 
in dual TCR T cells.
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Figure 3.4. T cells transduced with minimal TCR:ζ ∆ec, ∆ic or ∆ec+ic show decreased ability to bind 
pMHC, which is least compromised for TCR:ζ ∆ec. Jurkat T cells expressing minimal TCR:ζ ∆ec, ∆ic and 
∆ec+ic, TCR:ζ, wt TCR, TCR:mu+cys transgenes or no TCR transgene were tested for their ability to bind 
M1/A1-tetramer-PE complexes. The amount of M1/A1-tetramer used to stain 0.5 x 106 cells (30 min, RT) 
was titrated from 112 nM down to 3.5 nM. Percentages (A) and MFIs (B) of pMHC binding by T cells were 
measured via flow cytometry. Percentages of pMHC binding were standardized for average cell surface 
expression levels (with % surface expression of wt TCR, see figure 3.2C, set to 1.0). Curves represent mean 
percentages of MFI or pMHC binding + SEM, n=4 independent measurements (statistically significant dif-
ferences in comparison to wt TCR are calculated with Student’s t-tests: * = p<0.05; ** = p<0.005).
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Minimal TCR:ζ ∆ec shows a compromised surface expression and function in 
primary human T cells
The next step was to test the minimal TCR:ζ variant that performed best in Jurkat T cells 
with respect to surface expression, absence of TCR mis-pairing, pMHC binding and 
activation of NFAT, i.e., TCR:ζ ∆ec, in primary human T cells. Anti-CD3 mAb-activated hu-
man PBMC were retrovirally transduced with TCR:ζ ∆ec, TCR:ζ, wt TCR and TCR:mu+cys. 
To enhance the functional expression of TCR:ζ ∆ec, we codon optimized CD3ζ ∆ec and 
aligned the two chains in a TCRβ-2A-TCRα configuration in a pMP71 retroviral vector (93, 
95, 96, 151). Surface expression of TCR transgenes and pMHC binding was assessed by 
flow-cytometry in cultures of TCR-engineered T cells (> 90 % CD8-positive T cells). Please 
note that, for reasons explained above, percentages of surface expression displayed in 
the upper right quadrants of flow cytometry dotplots may provide an underestimation 
of the actual levels of surface expression of TCR:ζ and TCR:ζ ∆ec (with and without co-
don optimization) (fig. 3.6A). TCR:ζ ∆ec revealed a weak surface expression and pMHC 
binding, which was, unexpectedly, not improved when using TCR:opt.ζ ∆ec in a β-2A-α 
configuration in pMP71 (figs 3.6A and B). Notably, the surface expression levels of TCR:ζ 
and TCR:mu+cys were higher when compared to wt TCR (fig. 3.6A). However, when 
looking at the pMHC binding, only TCR:ζ, but not TCR:mu+cys, demonstrated enhanced 
performance when compared to wt TCR (fig. 3.6B).
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Figure 3.5. T cells transduced with minimal TCR:ζ ∆ec show a potent antigen-specific NFAT response. 
Jurkat T cells expressing minimal TCR:ζ ∆ec, ∆ic and ∆ec+ic, TCR:ζ, wt TCR, TCR:mu+cys transgenes or no TCR 
transgene were tested for their ability to mediate activation of Nuclear Factor of Activated T cells (NFAT). 
TCR-transduced Jurkat T cells were nucleofected with a Gaussia Luciferase reporter construct under control 
of 6 NFAT response elements, and stimulated for 6h with pMHC monomers. The concentration of mono-
mers was titrated from 126 nM down to 4 nM. Luciferase activities of wt TCR T cells for 4, 8, 16, 32, 63, 
and 126 nM pMHC were: 588926, 670147, 656821, 444174, 181790, and 37084 relative luminescence units 
(RLU), respectively, and were all set at 100% (dotted line). Luciferase activities of TCR-transduced T cells 
were standardized for average cell surface expression levels (as explained in legend to figure 3.4A). Curves 
represent mean luminescence units + SEM, n=6-14 independent measurements (statistically significant dif-
ferences in comparison to wt TCR are calculated with Student’s t-tests: * = p<0.05, *** = p<0.0005).
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Figure 3.6. Minimal TCR:ζ ∆ec demonstrates compromised surface expression and antigen-specific 
function in primary human T cells. Primary human T cells were transduced with one of the following M1/
A1 TCRs: TCR:ζ ∆ec, pMP71 β-2A-α TCR:opt.ζ ∆ec, TCR:ζ, wt TCR, TCR:mu+cys, or no TCR. (A) Surface expres-
sion of transgenic TCR was measured via flow cytometry. Anti-TCR-Vα19FITC and anti-TCR-Vβ9PE antibodies 
were used to stain TCR-transduced T cells. Representative examples out of 5 individual measurements of 
two healthy donors are displayed and percentages of stained T cells in upper left and upper right quad-
rants are indicated. Percentages indicated in italics are either percentages of upper right quadrants (wt 
TCR, TCR:mu+cys) or the sum of percentages of upper left and upper right quadrants (TCR:ζ, TCR:ζ ∆ec, 
TCR:opt.ζ ∆ec), corrected for the corresponding percentage(s) of Mock T cells. These percentages (in italics) 
may better represent the actual levels of surface expression of TCR:ζ and its variants (see Result section for 
details). (B) pMHC binding by transgenic TCR was measured via flow cytometry. M1/A1-tetramer-PE com-
plexes (15 nM) were used to stain TCR-transduced T cells, and percentages of positive cells in histograms 
are indicated. Representative examples out of 5 individual measurements of two healthy donors are dis-
played and percentages of stained T cells in selected histogram region are indicated (in italics: corrected for 
pMHC binding observed by Mock T cells). (C) CD107a-mobilization to cell surface of TCR-transduced T cells. 
TCR-transduced T cells were stimulation for 2h with medium, Mel2A or APD (both M1 negative, HLA-A1 
positive), or Mel2A and APD loaded with 10-5 M M1 peptide, after which T cells were analyzed for CD107a 
expression by flow cytometry (see materials and methods section for details). Bars represent mean CD107a 
values + SEM, 2 independent measurements of two healthy donors (statistically significant differences are 
calculated with Student’s t-tests: ** = p<0.005). Please note that at the time of flow cytometry analyses, 
TCR-engineered primary human T cells contained > 90 % CD8-positive T cells.
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Finally, primary human T cells expressing TCR transgenes were stimulated with 
antigen-positive and negative target cells, after which CD107a mobilization on the cell 
surface was measured within the TCR-Vα19 positive T cell population as a measure for 
cytotoxicity. TCR:ζ ∆ec, whether or not with codon optimized CD3ζ and in an optimal 
vector cassette, mediated negligible antigen-specific responses in contrast to TCR:ζ 
(p<0.005; fig. 3.6C). Both TCR:ζ and TCR:mu+cys show a higher percentage of CD107a 
positive cells than T cells with wt TCR transgenes.
DISCUSSION
In this study, we generated novel MAGE-A1-specific TCRs fused to partial rather than 
complete human CD3ζ in an effort to identify a minimal TCR:ζ that preserved the TCR 
pairing and functional properties of TCR:ζ. To this end, a panel of 8 minimal TCR:ζ’s (see 
figure 3.1 for details) were tested for surface expression, association with endogenous 
CD3 and TCR chains, pMHC binding and TCR transgene-mediated functions in Jurkat T 
cells and primary human T cells. Our observations revealed that for TCR:ζ and its variants: 
(I) intact CD3ζ transmembrane (tm) domain critically determines surface expression and 
inability to associate with endogenous CD3 and TCR chains in Jurkat T cells; (II) both 
CD3ζ extracellular (ec) and intracellular (ic) domains are dispensable for pMHC binding, 
whereas only CD3ζ ec domain is dispensable for T cell mediated signaling in Jurkat T 
cells; and (III) the combination of CD3ζ ec, tm and ic domains is required for surface 
expression and T cell function in primary human T cells.
In a first series of experiments, we have analyzed 6 minimal TCR:ζ variants, in which 
the ec, tm and/or ic domain(s) of CD3ζ were omitted (and replaced by corresponding 
TCR domain(s)). Cell surface expression analysis revealed that not all minimal TCR:ζ vari-
ants resulted in detection of a M1/A1 TCR heterodimer. In case the CD3ζ tm domain was 
absent (i.e., TCR:ζ ∆tm, ∆tm+ic, ∆ec+tm), TCRα:ζ and -β:ζ transgenes were not properly 
expressed as a TCR heterodimer (fig. 3.2A). In fact, TCR chains of these minimal TCR:ζ 
variants showed aberrant protein expression or transport to the cell surface (supple-
mentary figs. 3.1B and C). TCR:ζ and its variants that were expressed (i.e., TCR:ζ ∆ec, 
∆ic, and ∆ec+ic,), show similarly strong levels of cell surface expression (TCR:ζ ∆ec+ic 
to a lesser extent; fig. 3.2) and an inability to associate with CD3ε (figs. 3.3A and B). 
Functional assays, however, identified two groups of TCRs: (I) TCR:ζ and TCR:ζ ∆ec; and 
(II) TCR:ζ ∆ic and TCR:ζ ∆ec+ic. The latter group of TCRs, in contrast to the first group, 
revealed lowered to negligible binding of pMHC (figs. 3.4A and B) and an inability to 
induce NFAT activity upon stimulation with either pMHC (fig. 3.5) or anti-TCR-Vβ9 mAb 
(supplementary fig. 3.3). Our finding that TCR:ζ variants that lack the CD3ζ ic domain 
showed compromised pMHC binding is unexpected. Studies with other antigen-spe-
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cific receptors argue that lack of, or not having access to, ITAM-bearing CD3ζ ic domain 
results in enhanced surface expression and pMHC binding. In example, inhibition of 
protein tyrosine kinases demonstrated that early TCR-mediated signaling normally 
provides a negative feedback loop that facilitates pMHC-induced TCR down-regulation 
and T cell apoptosis (184, 185). Moreover, studies with Chimeric Antibody Receptors 
coupled to CD3ζ (i.e., CAR:ζ) showed that CD3ζ ITAMs directly contribute to loss of 
transgene expression and enhanced sensitivity to apoptosis (186). In contrast, TCR:ζ 
is different from other receptors since it does not dimerize with endogenous TCR/CD3 
complexes (63) and may signal differently (187). Moreover, recent studies into immune 
synapses suggested that TCR:ζ has a distinct conformation (177), and we propose that 
conformational changes due to extensive deletions, such as ∆ic and ∆ec+ic, cause the 
observed decrease in pMHC binding. The observation that TCR:ζ ∆ic and ∆ec+ic cannot 
mediate activation of NFAT, even upon stimulation with anti-TCR mAb, points out that 
TCR-mediated signaling either requires a modified TCR that contains ITAMs (i.e., TCR:ζ 
or minimal TCR:ζ ∆ec) or a (modified or wt) TCR that is able to recruit endogenous and 
ITAM-containing CD3 molecules.
In addition to the shared inability to associate with CD3ε, minimal TCR:ζ ∆ec, ∆ic, and 
∆ec+ic and the parental TCR:ζ, all containing an intact CD3ζ tm domain, showed no as-
sociation with endogenous TCR chains (fig. 3.3C and supplementary fig. 3.2). Notably, flow 
cytometry of TCR:ζ ∆tm+ic and TCR:ζ ∆ec+tm showed cells that were single positive for 
either TCR-Vα19 or -Vβ9, respectively (fig. 3.2A), indicating that CD3ζ ec or ic domains do 
not completely prevent these TCRs from mis-pairing. Our finding that prevention of TCR 
mis-pairing, and consequently enhanced pairing between TCRα:ζ and -β:ζ, is governed 
by the CD3ζ tm domain is consistent with a report by Rutledge and colleagues (188), in 
which the CD3ζ tm domain was used to induce dimerization of monomeric proteins, 
such as the IL-2Rα chain.
In a next series of experiments, we have transplanted a limited set of CD3ζ tm amino 
acids onto TCRα and TCRβ with the intent to preserve surface expression and inability to 
TCR mis-pair and, at the same time, retain structural and spatial requirements to associate 
with endogenous CD3 chains (i.e., TCR:tmζ1 and -2; see figure 3.1). This ‘transplantation 
set’ of amino acids were identified through 3D modeling and included the ones defined 
by Call and colleagues to be critically involved in CD3ζ homodimerization (i.e., C2, D6, 
L9, Y12, T17 and F20) (189). We observed that TCR:tmζ heterodimers did not express at 
the cell surface (fig. 3.2A). In fact, TCRα:tmζ1 and -2 chains were not able to complex 
with TCRβ:tmζ nor endogenous TCRβ, and TCRβ:tmζ showed moderate levels of surface 
expression through mis-pairing with the endogenous TCRα. These data suggest that 
TCR:ζ properties related to the presence of an intact CD3ζ tm domain, such as enhanced 
cell surface expression and inability to associate with endogenous CD3 and TCR chains, 
cannot be attributed to a limited number of individual CD3ζ tm amino acids.
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TCR:ζ’s pairing and functional properties were best preserved in minimal TCR:ζ ∆ec. 
This TCR variant retains high surface expression levels (fig. 3.2), prevents pairing with 
endogenous CD3 and TCR chains (fig. 3.3), binds pMHC (although binding is somewhat 
reduced when compared to TCR:ζ; fig. 3.4), and potently activates NFAT (fig. 3.5). Interest-
ingly, recent confocal microscopy studies demonstrated that minimal TCR:ζ ∆ec is able to 
form immunological synapses with similar sizes as those formed by parental TCR:ζ (177). 
In minimal TCR:ζ ∆ec there is only a single artificial boundary, i.e., the one between TCR 
ec and CD3ζ tm sequences, potentially preventing or diminishing humoral and/or cel-
lular immunogenicity. Collectively, our observations warranted testing of minimal TCR:ζ 
∆ec in primary human T cells. In bulk populations of human PBMC (non-sorted for either 
TCR or CD8 expression), we observed that the difference in surface expression between 
minimal TCR:ζ ∆ec and parental TCR:ζ was more pronounced when compared to Jurkat 
T cells (fig. 3.6A). Also, minimal TCR:ζ ∆ec showed lower pMHC binding and induced 
negligible CD107a mobilization to the cell surface when compared to TCR:ζ (figs. 3.6B 
and C), which most likely was accounted for by the low level of surface expression. These 
observations, perhaps unexpectedly, were not different when using minimal TCR:ζ ∆ec 
in an optimal vector, an optimal TCR cassette and with codon optimized CD3ζ tm+ic 
domains. Apparently, the absence of the membrane-proximal CD3ζ ec domain in mini-
mal TCR:ζ ∆ec results in a stringent decrease in functional TCR expression. Interestingly, 
single chain (sc) Fv (190) and scTCR ((64) and data not shown) that do contain CD3ζ ec 
coupled to either CD3ζ tm+ic, CD4 tm + Fc(ε)RIγ ic, or Fc(ε)RIγ tm+ic, have indeed dem-
onstrated significant surface expression in human T cells. In minimal TCR:ζ ∆ec, six CD3ζ 
ec amino acids (GDLDPK) were replaced by either TCRα (DVKLVEKSFETDTNLNFQNLS) 
or TCRβ (GFTSESYQQGVLSATILYE) ec amino acids (that cover the connecting-peptide 
motifs CPMα and CPMβ, respectively). The CPMα and CPMβ are reported to interact 
with tetracysteine motifs in the membrane-proximal stalk regions of CD3δε and CD3γε 
dimers, and as such contribute to TCR/CD3 complex formation and T cell activation 
(115, 116). In addition, a defective or mutated CPMα is compromised with respect to its 
association with CD8, translation of antigen-specific stimulation into phosphorylation 
of LCK, FYN, and ZAP70, and production of IL-2 (115, 191, 192). We observed that the 
presence of CPMα and -β in minimal TCR:ζ ∆ec appears not sufficient to induce TCR/CD3 
complex formation (figs. 3.3A and B), suggesting a more critical role for intact TCR tm for 
association with CD3 chains (114). The extent to which the presence of CPMα and -β in 
minimal TCR:ζ ∆ec improved pMHC binding in T cells is difficult to assess due to poor ex-
pression levels in primary human T cells (fig. 3.6A) and non-specificity of pMHC binding 
in CD8α-transduced Jurkat T cells (data not shown). Nevertheless, earlier findings proved 
that M1/A1-specific TCR:ζ, not containing CPMα or –β, were able to associate with and 
depend on CD8α for ligand binding (177, 193), and may suggest a non-dominant role of 
CPM with respect to TCR:CD8α association.
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An alternative TCR format that is designed to address TCR mis-pairing, in addition 
to TCR:ζ, is TCR:mu+cys (see also chapter 2). In TCR:mu+cys two separate strategies 
have been combined: murinization of the TCR-C domain and introduction of cysteine 
amino acids at structurally favorable positions to allow formation of an additional 
disulfide bridge, which together result in enhanced functional expression (125, 128). 
Our studies with M1/A1-specific TCR:mu+cys, taken along as a control TCR in the pres-
ent paper, confirmed this notion to some extent. In Jurkat T cells, TCR:mu+cys, when 
compared to wt TCR, showed similar levels of surface expression and pMHC binding, 
and somewhat enhanced levels of antigen-specific NFAT activation (figs. 3.2A, 3.4 and 
3.5), whereas in primary human T cells TCR:mu+cys showed enhanced levels of surface 
expression and similar levels of pMHC binding and antigen-specific CD107a mobiliza-
tion to the cell surface (fig. 3.6). However, we did observe that TCR:mu+cys mediates a 
significantly enhanced antigen-specific IFNγ response (data not shown). These findings, 
although not fully in accordance with previous reports and potentially unique to the 
TCR-V regions of the M1/A1 TCR (125, 128), generally argue that TCR:mu+cys improved 
functional TCR expression. Expectedly, enhanced functional TCR expression was related 
to enhanced preferential pairing between the two modified TCR:mu+cys chains, which 
was suggested by the flow cytometric absence of single TCRα or TCRβ positive cells 
(fig. 3.2A). Unexpectedly, however, flow cytometric FRET (fig. 3.3B) and single TCR chain 
transductions (supplementary fig. 3.2) clearly demonstrated that TCR:mu+cys mis-paired 
with endogenous TCR chains to the same extent as wt TCR. Also in vivo, murine TCRs with 
a cysteine modification did not fully prevent the pathology related to TCR mis-pairing, 
i.e., TCR transfer-induced Graft versus Host disease (65). We therefore propose that from 
a safety point of view, TCR:ζ but not TCR:mu+cys provides a better alternative to wt TCR.
In conclusion, our studies showed that CD3ζ domains separate various properties of 
TCR:ζ, i.e., the CD3ζ tm domain determines surface expression and lack of association 
with endogenous CD3 and TCR chains, whereas CD3ζ ic domain contributes to T cell 
signaling. Functional expression of TCR:ζ in primary human T cells, however, required 
the complete rather than minimized content of CD3ζ.
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SUPPLEMENTARY METHODS
Cloning of minimal TCR:ζ variants
TCR:ζ variants generated by a domain exchange strategy or 3D-modeling strategy were 
acquired through cloning or gene synthesis. Exact amino acid constitutions of PCR, 
digestion, or gene synthesis products are indicated below. Primer sequences will be 
provided upon request.
TCR:ζ ∆ec: TCR chains (TCRα: nucleotide (nt) 1-702; TCRβ: nt 1-789) were fused together 
with CD3ζ tm+ic domains (CD3ζ: nt 91-489) (started from 1st methionine). PCR products 
were digested with NcoI-XhoI (TCRα:ζ) and XhoI- XhoI (TCRβ:ζ) and ligated in digested wt 
TCR pBullet vectors. For experiments in primary human T cells, the TCR:ζ ∆ec chains were 
put in a pMP71 vector in a TCRβ-2A-TCRα configuration. Overlap PCR fused together 
both TCR ec domains to codon optimized CD3ζ tm+ic domains (the latter domains from 
Geneart, Regensburg, Germany), after which PCR products were digested with NotI-MluI 
(TCRβ) and MfeI-EcoRI (TCRα) and sequentially ligated in digested pMP71 vector.
TCR:ζ ∆tm: TCR chains were partially constructed by hybridized oligomers (oligomers 
ordered via Eurogentec, Maastricht, Netherlands), digested with BamHI-SacI, that cov-
ered nt: CD3ζ: 76-90; TCRα: 766-825; CD3ζ: 154-220 or CD3ζ: 76-90; TCRβ: 847-912; CD3ζ: 
154-220. The additional CD3ζ sequence (nt 221-489) was acquired through a SacI-XhoI 
digestion of TCRα:ζ, after which both fragments were ligated in BamHI-XhoI digested 
TCRα:ζ pBullet vector. To generate TCRβ:ζ ∆tm, an additional NcoI-BamHI fragment of 
TCRβ:ζ was required (to circumvent digestion of an internal XhoI site) and all fragments 
were ligated into a NcoI-XhoI digested pBullet vector.
TCR:ζ ∆ic: TCR chains were obtained via NcoI-BamHI digests of parental TCR:ζ (covering 
nt TCRα: 1-702; CD3ζ: 73-75 or TCRβ: 1-789; CD3ζ: 73-75) and hybridized oligomers (Euro-
gentec), the latter digested with BamHI-XhoI (CD3ζ: 76-153; TCRα: 826-840 or CD3ζ: 76-153; 
TCRβ: 913-933). Variants were finalized by ligation in NcoI-XhoI digested pBullet vectors.
TCR:ζ ∆ec+ic: TCR chains were obtained via hybridized primers (Eurogentec) (cover-
ing nt TCRα: 724-765; CD3ζ: 91-153; TCRα: 276-280 or CD3ζ: 108-153; TCRβ: 913-933), 
digested with HinDIII-XhoI (TCRα) or BfuA1-XhoI (TCRβ). For TCRβ a NcoI-BfuA1 digestion 
fragment from TCRβ:ζ was acquired to circumvent an internal XhoI site, and fragments 
were ligated in digested wt TCR pBullet vectors.
TCR:ζ ∆tm+ic: TCRα was generated via gene synthesis (Geneart) (nt TCRα: 1-702; CD3ζ: 
73-90; TCRα: 826-840) and ligated via NcoI-XhoI in a pBullet vector. TCRβ was obtained 
via a NcoI-BamHI digestion of TCRβ:ζ ∆ic (nt TCRβ: 1-789; CD3ζ: 73-75), a BamHI-XhoI 
fragment from hybridized primers (Eurogentec) (CD3ζ: 76-90; TCRβ: 847-933), and liga-
tion of these fragments in a pBullet vector.
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TCR:ζ ∆ec+tm: TCRα was obtained via BspI-XhoI digestion of TCRα:ζ ∆tm and ligation 
of this fragment in a pBullet vector already containing wt TCRα. TCRβ was generated by 
NcoI digestion of wt TCRβ and ligation of this fragment in a pBullet containing TCRβ:ζ ∆tm.
TCR:tmζ1 and -2: YASARA (www.yasara.org (194)) was used to build a model of the 
interacting transmembranal amino acids in the TCR/CD3 complex. The structure of 
the CD3ζζ transmembrane domain has been resolved by NMR and was introduced as 
such in our model (PDB file 2hac (189)). The other CD3 transmembrane helices were 
modeled based on the large CD3ζ helix. Predicted CD3 helices were used to identify 
transmembrane amino acids of CD3ζ important for interaction with the other helices 
in the complex. These amino acids were transplanted onto TCRα and TCRβ chains, pref-
erentially replacing amino acids defined to mediate TCRα-TCRβ but not TCRα-CD3δε or 
TCRβ-CD3γε associations. This 3D-modelling exercise revealed two modified TCRα and 
one TCRβ tm domain(s) (see figure 3.1B). For both TCRα chains the tm domain with small 
flanking regions was generated through gene synthesis (Geneart), digested with HinDIII 
and XhoI, and ligated in pBullet vector with wt TCR. CD3ζ amino acids substitute TCRα 
amino acids at positions 256, 260, 266, 270, 271, and 274 for variant tmζ1, and positions 
255, 256, 259, 266, 269, 270, 273, and 274 for variant tmζ2. The TCRβ chain (combined 
with either TCRα chain) was generated through gene synthesis (Geneart) and ligated in 
a pBullet vector (64) using SalI and NotI. CD3ζ amino acids substitute TCRβ amino acids 
at positions 282, 256, 289, 292, 296, 297, and 300.
Intracellular flow cytometry
TCR-transduced T cells (1x104 cells) were monitored by flow cytometry for intracellular 
expression of transgenic TCR using FITC-conjugated anti-TCR-Vα19 and PE-conjugated 
anti-TCR-Vβ9 mAbs. After T cells were washed, they were permeabilized with the per-
meabilization kit (BD Biosciences) for 10 minutes at room temperature (RT) and washed 
again. T cells were stained with TCR-Vα19 and TCR-Vβ9 mAbs for 20 minutes on ice. Next, 
T cells were washed and measured on a FACSCalibur dual-laser flow cytometer.
mRNA isolation and RT-PCR
mRNA was isolated by means of TRIzol (Invitrogen). 1x106 cells were lyzed in 1 ml TRIzol 
and incubated for 5 minutes at RT. The lysate was mixed with 0,2 ml Chloroform (Sigma-
Aldrich), incubated for 2 minutes at RT, and subsequently centrifuged for 15 minutes at 
12,000g and 4°C. The aqueous phase was acquired, supplemented with 0,5 ml isopropanol 
(Sigma-Aldrich) and 1 μl glycogen (Roche, Woerden, the Netherlands), and centrifuged 
for 10 minutes at 12,000g and 4°C. The pellet was resuspended in 1 ml ethanol (Merck, 
New Jersey, USA), mixed, and centrifuged for 5 minutes at 7,500g and 4°C. The pellet was 
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reconstituted in RNase-free water. For cDNA synthesis 5 μg mRNA was mixed with 0.5 ng 
oligo-dT primers (Invitrogen), 0.05 ng random hexamer primers (Promega) and water 
to 12 μl. The mixture was heated to 70°C for 10 minutes and quickly cooled on ice. 1st 
strand buffer (Invitrogen), 0.5 mM dNTPs (Promega), 0.005 M DTT (Invitrogen), and RNasin 
(Promega) was added to the mixture before incubation at 42°C for 2 minutes. Superscript 
III RTase (Invitrogen) was added to the mixture and placed at 42°C for 50 minutes, followed 
by 10 minutes at 70°C. The subsequent PCR was performed with transgene and GAPDH 
specific primers, sequences of which will be provided upon request.
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Supplementary figure 3.1. Minimal TCR:ζ variants without a complete CD3ζ transmembrane domain 
show aberrant protein production or transportation to cell surface. Jurkat T cells expressing MelA/A2 
TCR were transduced with one of the following M1/A1 TCRs (those that were not surface-expressed, see 
figure 3.2A): minimal TCR:ζ ∆tm, ∆tm+ic, ∆ec+tm, TCR tmζ 1 or tmζ 2. Surface (A) and intracellular (B) ex-
pressions of transgenic TCR were measured via flow cytometry using anti-TCR-Vα19FITC and anti-TCR-Vβ9PE 
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mAbs. Representative dotplots out of 5 individual measurements are displayed. T cells were permeabilized 
with the permeabilization 2 kit before mAb staining for intracellular transgenic TCR expression measure-
ments. (C) mRNA expression of TCR transgenes (TCRα = α; TCRβ = β) and GAPDH (+; positive control). mRNA 
was isolated by means of TRIzol after which cDNA synthesis was performed with superscript III reverse tran-
scriptase. PCR was performed with TCR transgene and GAPDH specific primers, and products were loaded 
on an agarose gel. TCRα and TCRβ transgenes vary in size between 795 nt – 1164 nt and 891 nt – 1248 nt, 
respectively, due to altering TCR and CD3 domain compositions. GAPDH primers amplify a sequence of 
319 nt. Data of one out of two independent experiments with similar results are shown. See supplementary 
methods for details.
TCRα:ζ ∆ec+ic
anti-TCR-Vα19-PE
wt TCRα TCRα:mu+cys TCRα:ζ  TCRα:ζ ∆ic
A
TCRβ:ζ ∆ec+ic
anti-TCR-Vβ9-PE
wt TCRβ TCRβ:mu+cys TCRβ:ζ  TCRβ:ζ ∆icB
Supplementary figure 3.2. Single TCRα or TCRβ chains of wt TCR and TCR:mu+cys, but not TCR:ζ ∆ec, 
∆ic, ∆ec+ic or parental TCR:ζ, express at the surface of T cells. Jurkat T cells expressing MelA/A2 TCR 
were transduced with either the TCRα-chain (A) or the TCRβ-chain (B) of minimal TCR:ζ ∆ec, ∆ic, ∆ec+ic, 
parental TCR:ζ, wt TCR , TCR:mu+cys or no TCR transgene. Surface expression of transgenic TCR was de-
tected via flow cytometry using anti-TCR-Vα19FITC or anti-TCR-Vβ9PE mAbs and presented as histograms. 
Percentages of TCRα or TCRβ expression are indicated. Representative examples out of 2 individual mea-
surements are displayed.
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Supplementary figure 3.3. TCR:ζ ∆ic and ∆ec+ic show no NFAT activation upon stimulation with anti-
TCR mAb. Jurkat T cells expressing minimal TCR:ζ ∆ec, ∆ic, ∆ec+ic, parental TCR:ζ, wt TCR, TCR:mu+cys or 
no TCR transgene were tested for their ability to mediate activation of Nuclear Factor of Activated T cells 
(NFAT). TCR-transduced Jurkat T cells were nucleofected with a Gaussia Luciferase reporter construct un-
der control of 6 NFAT response elements, and stimulated for 6 hours by anti-TCR-Vβ9 mAb or control mIg. 
Luciferase activities of wt TCR for TCR-Vβ9 mAb stimulation was 1069540 relative luminescence units, which 
was set to 100% (dotted line). Bars represent mean luminescence units + SEM of 15 to 27 independent 
measurements. Statistical significance is based on Student’s t-tests: *** = p<0.0005.
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ABSTRACT
Adoptive transfer of T cells that are gene-engineered to express a defined T cell receptor 
(TCR gene therapy) represents a feasible and promising therapy for patients with tumors. 
TCR gene therapy, however, is challenged by a transient presence and effectiveness of 
transferred T cells, which is anticipated to be improved by adequate T cell co-stimulation. 
Here, we report the identification and characterization of novel TCR transgenes that 
genetically incorporate signaling cassettes which consist of the accessory molecules 
Fc(ε)RIγ, CD3ε or CD3ζ with or without the co-stimulatory molecule CD28. Two-chain 
TCR transgenes linked to CD28 and CD3ε, i.e., TCR:28ε, demonstrated enhanced binding 
of peptide-MHC and mediated enhanced CD107a mobilization and cytokine production 
following stimulation with antigen when compared to wild type (wt) TCR. TCR:28ε does 
neither mis-pair with endogenous TCR nor associate with endogenous CD3. In addition, 
this co-stimulatory TCR does not show off-target recognition as evidenced by preserved 
specificity towards a panel of altered peptide ligands as well as antigen-positive and 
negative melanoma cells. Notably, TCR:28ε induces the formation of immune synapses 
with significantly enhanced accumulation of TCR transgenes and markers of early TCR 
signaling. Taken together, our data show that TCR transgenes that harbor a signaling 
cassette consisting of CD28 and CD3ε confer T cells with correctly paired TCR dimers and 
enhanced and antigen-specific T cell activation.
Coen BW1.indd   74 15-Aug-13   11:37:04 AM
TCR:28ε shows antigen-specific responses but no mis-pairing 75
4
INTRODUCTION
Metastatic melanoma is a highly lethal disease with an incidence that continues to rise 
and for which currently no standard curative treatments are available. Adoptive transfer 
of tumor infiltrating lymphocytes (TILs) as well as T cell receptor (TCR)-engineered T 
cells has shown clinical successes in the treatment of metastatic melanoma (97, 195). 
In example, T cells expressing TCR transgenes that were directed against the human 
leukocyte antigen (HLA)-A2-restricted antigens MART-1, gp100 or NY-ESO-1 mediated 
objective clinical responses in patients with metastatic melanoma that ranged between 
12 and 45% (32, 46). Despite these potent anti-tumor responses, clinical responses are 
currently challenged by both toxicities and a transient nature of tumor regression in the 
majority of patients.
T cell therapy-mediated toxicities became evident from studies with TCRs, in particular 
those of high-affinity, directed against antigens that are over-expressed on melanoma 
but also expressed on healthy cells, albeit a minute number. Toxicities included severe 
inflammation of skin, eyes, and ears (for MART-1, gp100) and neurological toxicities, with 
the latter resulting in comas and death in two patients (a MAGE-A3 derived-epitope that 
is shared with MAGE-12) (45, 62). The observed toxicities can be addressed by using TCRs 
directed against antigens that are highly selectively expressed by tumor but not healthy 
tissues, such as neo-antigens and potentially some defined and non-shared Cancer 
Testis Antigens (CTA). Besides the above-mentioned on-target toxicities, TCR-gene 
engineering may result in recognition of off-target (i.e., unknown) self-peptides as a 
consequence of new TCR dimers that are formed between introduced and endogenous 
TCR chains (i.e., TCR mis-pairing). Although there has been no formal proof of TCR mis-
pairing-mediated toxicity in patient studies, preclinical studies clearly demonstrated the 
destructive ability of T cells that express mixed TCR dimers towards healthy cells (65, 66). 
These findings warrant for measures to prevent or limit TCR mis-pairing, such as genetic 
modification of TCR transgenes (see chapter 2) or disruption of endogenous TCR chains 
via zinc-finger nucleases (69).
The transient nature of tumor regression following T cell therapy became clear 
from observations that anti-tumor responses are most often incomplete in 80 to 90% 
of patients (27, 111). The compromised anti-tumor responses coincided with a limited 
persistence of transferred T cells (25). T cell persistence and anti-tumor activity appear 
sensitive to T cell co-stimulation as evident from a recent clinical study in which T cells 
engineered with a CD19-specific CAR that incorporated CD137 and CD3ζ were used to 
treat patients with B cell lymphoma. In this study, T cell persistence was significant (de-
tectable up to 6 months) and complete clinical responses were observed in two out of 
three patients (77). Similarly, clinical studies using CD19-targeted T cells with CARs that 
incorporated CD28 and CD3ζ showed beneficial effects on long-term T cell persistence 
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and clinical responses (76, 78). In addition to genetic engineering, MART-1-specific T 
cells stimulated with artificial antigen presenting cells that expressed the CD28 ligands 
and used to treat patients with metastatic melanoma also revealed enhanced T cell 
persistence and clinical responses (85). Importantly, inclusion of T cell co-stimulation 
in these clinical protocols relieved the requirement for patient preconditioning with 
chemotherapy and/or in vivo IL-2 administration (77, 85).
Here, we designed and generated TCRs directed against MAGE-1/HLA-A1 and gp100/
HLA-A2 that incorporated signaling cassettes to simultaneously address TCR mis-pairing 
and enhance T cell co-stimulation. The modular design of signaling cassettes allowed us 
to compare and test combinations of the accessory molecules Fc(ε)RIγ, CD3ε or CD3ζ 
with or without the co-stimulatory molecule CD28. Our results showed that TCRs bear-
ing a cassette consisting of CD28 and CD3ε (i.e., TCR:28ε) resulted in maximum ability to 
bind peptide-MHC, no TCR mis-pairing, and no loss of antigen and peptide-fine specific-
ity. Moreover, T cells expressing TCR:28ε mediated enhanced T cell responses, and highly 
active immune synapses and early T cell signaling.
MATERIALS AND METHODS
Cells and reagents
T lymphocytes derived from healthy donors were isolated and expanded using a feeder 
system as described elsewhere (179) and cultured in HEPES-buffered RPMI 1640 me-
dium (BioWhittaker, Verviers, Belgium) supplemented with 10% human serum (Sanquin, 
Amsterdam, The Netherlands), 2 mM L-glutamine, 100 μg/ml streptomycin and 100 U/
ml penicillin. Jurkat T cells expressing a single MelanA/HLA-A2 specific TCR (clone J.19 
(63)), J.19 transduced with CD8α (J.19-CD8 (177)), the B cell lines APD and BSM, and 
the TAP-deficient TxB hybrid T2 cells were cultured in RPMI 1640 medium (BioWhittaker) 
containing 10% Fetal Bovine Serum (FBS, Stonehouse, Gloucestershire, UK) and antibiot-
ics. The packaging cell lines 293T and Phoenix-A, the C1R B cell lines expressing either 
wild type HLA-A2 or the D227K/T228A mutant of HLA-A2 (196), and the melanoma 
cell lines G43, MZ2-MEL43, GE-F-, FM3 and MEL2A were cultured in DMEM medium 
(BioWhittaker) containing 10% FBS, 2 mM L-glutamine, non-essential amino acids and 
antibiotics. Antibodies used in this study were: PE-conjugated TCR-Vβ9 (clone BL37.2 for 
flow cytometry and clone IM2355 for microscopy, Beckman-Coulter, Marseille, France); 
non and FITC-conjugated TCR-Vα19 (clone 6D6.6; Pierce Biotechnology, Inc., Rockford, 
IL); PE-conjugated TCR-Vβ27 (clone CAS1.1.3; Beckman-Coulter); non-conjugated CD3ε 
(clone OKT3; Beckman-Coulter); PerCP-conjugated CD3ε (clone SP34-2; BD Biosciences, 
San Jose, CA); non-conjugated CD8α (clone UCHT4; Adipogen, San Diego, CA); PE-con-
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jugated CD107a (clone H4A3; BD Biosciences); AlexaFluor647-conjugated pCD3ζ (SC-
9975; Santa Cruz Biotechnology, Heidelberg, Germany); pLCK (clone SC-28445-R; Santa 
Cruz Biotechnology); pERK (clone SC-7976; Santa Cruz Biotechnology); pZAP70 (clone 
SC-33526; Santa Cruz Biotechnology); Cy5-conjugated RαM (Jackson immunoresearch, 
West Grove, PA); and AlexaFluor647-conjugated GαM (Life technologies-Invitrogen, 
Paisley, UK). AlexaFluor647-conjugated CD3ε, CD8α, and CD45 antibodies were acquired 
and conjugated as described previously (177). MAGE-A1161-169/HLA-A*0101 (M1/A1) 
and gp100280-288/HLA-A*0201 (gp100/A2) tetramers were generated from biotinylated 
monomers (Sanquin, Amsterdam, Netherlands) and Streptavidin-PE (BD Biosciences) as 
described in chapter 6. Other reagents used in this study include: Retronectin (human 
fibronectin fragments CH-296, Takara Shuzo Co. Ltd., Otsu, Japan); PMA (Sigma-Aldrich, 
St. Louis, MO); PHA (Remel Europe, Dartford, England); golgistop (BD Biosciences); 
Influenza (INF) peptide (CTELKLSDY), M1 peptide (EADPTGHSY) and gp100 peptide 
(YLEPGPVTA) (Proimmune). Altered peptide ligands of gp100 peptide (A1 to A8, and G9) 
were synthesized as described previously (132).
TCR gene constructs
The M1/A1 TCR has been derived from CTL clone MZ2-82/30 (64, 135) and is composed 
of TRAV19/J39/C and TRBV9/D2/J2-3/C2, and the gp100/A2 TCR has been derived from 
CTL clone 296 and is composed of TRAV13-1/J52/C and TRBV27/J2-7/D2/C2 ((132) with 
TCR-V(D)J gene nomenclature according to http://imgt.org). A single-chain M1/A1 TCR 
platform (64) was used to incorporate various human signaling cassettes that consisted 
of Fc(ε)RIγ (γ), CD3ε (ε) or CD3ζ (ζ) without or with CD28 (28γ, 28ε, 28ζ). See figure 4.1A 
for a schematic overview of all 8 scTCR constructs and table 4.1 for the amino acid 
boundaries of fused molecules. The γ cassette comprised of extracellular amino acids of 
the immunoglobulin κ light chain (Cκ) constant domain, the transmembrane domain of 
CD4 and the intracellular domain of Fc(ε)RIγ (190), whereas the ε and ζ cassettes (the lat-
ter described in (64)) comprised the complete CD3ε or CD3ζ, which were amplified from 
human PBMC cDNA. In CD28-containing cassettes, the transmembrane and intracellular 
domains of CD28 preceded the intracellular domains of γ, ε or ζ. The cassettes compris-
ing Fc(ε)RIγ or CD3ζ coupled to CD28 were derived from cassettes incorporated into 
Chimeric Antigen Receptors (CARs) (10) and TCRs (131), respectively. The 28ε cassette 
was derived via overlap PCR using template DNAs containing either molecule. In case of 
ε and 28ε an additional extracellular cysteine residue was introduced at the 5’ end of the 
signaling cassette yielding cys-ε and cys-28ε. The resulting scTCRs were introduced in 
the retroviral vector pBullet via NotI or BamHI cloning sites. In addition, the 28ε cassettes 
were cloned into both pBullet-TCRα (amino acids ending at SPESS) and TCRβ (amino ac-
ids ending at WGRAD) via NotI and BamHI. See figure 4.2A for a schematic representation 
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of the two-chain TCR:28ε. Primer sequences used for cloning TCR and signaling cassettes 
can be provided upon request. All TCR constructs were sequence verified (Service XS, 
Leiden, Netherlands).
Retroviral gene transfer into T cells
Moloney Murine Leukemia retroviruses were produced by co-cultures of 293T and 
Phoenix-A cells. Cells were calcium phosphate-transfected with TCR transgenes, the 
Table 4.1. Composition and functional responses of signaling cassettes in a scTCR formata
Signaling 
cassette
Linker with 
cloning siteb
Boundaries within signaling 
cassettec
TCR surface 
expressiond
pMHC 
bindinge
Cyto-
toxicityf
IFNγ 
releaseg
γ GGR (NotI)
RADAA…LLDRS (ec Cκ)
QPMAL...LGIFF (tm CD4)
RLKIQ...EKPPQ (ic Fc(ε)RIγ)
+ + - -
28γ AAAK (NotI)
FWVLV…AAYRS (tm+ic CD28)
RLKIQ…EKPPQ (ic Fc(ε)RIγ)
++ + - -
ε GS (BamHI)
DGNEE...NQRRI 
(ec+tm+ic CD3ε)
++ + - -
28ε GSPK (BamHI)
FWVLV…AAYRS (tm+ic CD28)
KNRKA…NQRRI (ic CD3ε)
++ + +++ +++
cys-ε CGDGS (BamHI)
DGNEE...NQRRI 
(ec+tm+ic CD3ε)
++ + + -
cys-28ε
CGDGSPK 
(BamHI)
FWVLV…AAYRS (tm+ic CD28)
KNRKA…NQRRI (ic CD3ε)
++ ++ ++ +++
ζ
CGDLDPK 
(BamHI+ec CD3ζ)
LCYLL...ALPPR (tm+ic CD3ζ) + - + +
28ζ
CGDLDPK 
(BamHI)
FWVLV…AAYRS (tm+ic CD28)
LRVKF…ALPPR (ic CD3ζ)
++ + + -
a Signaling cassettes consisting of extracellular (ec) Ck + transmembrane (tm) CD4 + intracellular (ic) Fc(e)
RIg (g); tm+ic CD28 + ic Fc(e)RIg (28g); ec+tm+ic CD3e (e); tm+ic CD28 + ic CD3e (28e); ec+tm+ic CD3e with a 
N-terminal cysteine (cys-e); tm+ic CD28 + ic CD3e with a N-terminal cysteine (cys-28e); ec+tm+ic CD3z (z); 
and tm+ic CD28 + ic CD3z (28z) were fused to single-chain (sc)TCR using different cloning sites and protein 
domains as described in the legend to figure 4.1. Expression and antigen-specific functions of these scTCR 
were tested, following expression on primary human T cells, and summarised findings, that correspond to 
data shown in supplementary figure 4.1, are shown.
b The cloning sites are underlined in the linker sequences
c The first and last five amino acids of the boundaries between the various components of the signaling 
cassettes are provided
d TCR surface expression (measured by flow cytometry with M1/A1-tetramer): 0-50% = -; 51-75% = +; 76-
90% = ++; >90% = +++
e Peptide-MHC binding: 0-10% = -; 11-25% = +; 26-50% = ++; >50% = +++
f Antigen-specific cytotoxicity at E:T ratio 40:1: 0-10% = -; 11-25% = +; 26-50% = ++; >50% = +++
g antigen-specific IFNγ release: 0-100 pg/ml = -; 101-250 pg/ml = +; 251-500 pg/ml = ++; >500 pg/ml = +++. 
Abbreviations used: Cβ, TCRβ constant domain; cys, cysteine; ec, extracellular; ic, intracellular; sc, single-
chain; tm, transmembrane; Vα, TCRα variable domain; Vβ, TCRβ variable domain.
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helper vectors pHIT60 MLV GAG/POL and either pVSV-G ENV or pCOLT-GALV ENV in case 
of Jurkat T cells or primary human T cells, respectively. Transduction of human T cells was 
optimized and described previously (71).
Figure 4.1. A schematic representation of signaling cassettes tested for functional expression on pri-
mary human T cells. Single-chain (sc)TCRs were generated bearing one of the following eight signaling 
cassettes which are schematically represented: ec Cκ + tm CD4 + ic Fc(ε)RIγ (γ); tm+ic CD28 + ic Fc(ε)RIγ 
(28γ); ec+tm+ic CD3ε (ε); tm+ic CD28 + ic CD3ε (28ε); ec+tm+ic CD3ε with an N-terminal cysteine (cys-ε); 
tm+ic CD28 + ic CD3ε with an N-terminal cysteine (cys-28ε); ec+tm+ic CD3ζ (ζ); and tm+ic CD28 + ic CD3ζ 
(28ζ). These protein domains correspond to the following sequences (numbers relative to 1st Methionine): 
ec Cκ, RADAAPTVSQSFGLLDRS (GI:52119); tm CD4395-418 (GI:54696483); ic Fc(ε)RIγ45-86 (GI:4758343); ec+tm+ic 
CD3ε23-207 (GI:4502670); ic CD3ε153-207; ec+tm+ic CD3ζ27-163 (GI:4557430); ic CD3ζ51-163; and tm+ic CD28151-218 
(GI:338444). Abbreviations used: Cβ, TCRβ constant domain; cys, cysteine; ec, extracellular; ic, intracellular; 
sc, single-chain; tm, transmembrane; Vα, TCRα variable domain; Vβ, TCRβ variable domain.
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NFAT reporter gene assay
The NFAT reporter gene assay was performed as described in chapter 3. Briefly, Jurkat 
clone J.19 (5x106 cells) were nucleofected with 5 µg Firefly luciferase reporter gene 
encompassing 6 response elements of the Nuclear Factor of Activated T cells (NFAT-6-
Luc) using Amaxa’s nucleofector and program C-16 (according to the manufacturer’s 
protocol, Amaxa Biosystems, Cologne, Germany). Next, T cells were transferred to pre-
warmed medium and incubated O/N at 37°C and 5% CO2. Non-tissue culture-treated 96-
well plates were coated O/N at 4ºC with anti-TCR-Vβ9, anti-TCR-Vβ27 or non-conjugated 
control mAb. T cells (0.2x106) were incubated in pre-coated 96-well plates for 6h at 37°C 
and 5% CO2, and lysates (Cell Lysis Buffer, Promega, Madison, WI) were collected and 
used to measure photon emissions in a luminometer (Mediators, Vienna, Austria) us-
ing luminescent substrates according to the manufacturer’s instructions. Results were 
expressed as relative luminescence units (RLU) relative to non-stimulated controls 
(medium only: set at 1.0).
IFNγ release
T cell IFNγ release was determined as described previously (131). T cells were stimulated 
with B cells loaded without or with peptides, or melanoma cell lines.
Cytotoxicity assay
T cell cytolytic activity was determined with a 51Cr-release assay after 4h incubation with 
target cells (190). The percentage of specific 51Cr-release was determined as follows: 
((test counts – spontaneous counts) / (maximum counts – spontaneous counts)) x 100%.
Flow cytometry and FACSort
TCR-transduced T cells were washed and incubated with TCR mAbs or peptide-MHC 
for 30 min on ice or 15 min at RT, respectively, after which T cells were washed again 
and fixed with 1% PFA (Brunschwig, Amsterdam, the Netherlands). To detect CD107a 
expression, T cells were stimulated with target cells and analyzed as described in chap-
ter 3. T cells were gated according to forward and sideward scatter properties using a 
FACSCalibur (Beckton Dickinson, Alphen a/d Rijn, the Netherlands) equipped with Cell-
Quest software (BD Biosciences). Enrichments of T cells were performed by two-color 
Fluorescent Activated Cell Sorting (FACS) following staining with TCRα and TCRβ mAbs 
(in case of M1/A1) or peptide-MHC (in case of gp100/A2).
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Flow cytometric FRET
TCR-transduced clone J.19 T cells were stained with TCR-Vβ9-PE or TCR-Vβ27-PE mAbs 
to provide donor fluorochromes and either with non-conjugated TCR-Vα19, CD3ε or 
CD8α mAbs followed by RαM-Cy5 mAb to provide acceptor fluorochromes as described 
previously (63). Immune stainings were performed sequentially, with extensive washing 
steps in between, and using a fixed order of antibodies. First, non-conjugated mAbs 
followed by Cy5-labeled mAbs, and second, PE-labeled mAbs. Fluorescence intensities 
of donor fluorochromes (excitation at 488 nm, emission at 570 nm), acceptor fluoro-
chromes (excitation at 635, emission at 670 nm) and FRET signals (excitation 488 nm, 
emission at 670 nm) were measured and collected on a FACSCalibur. Data of viable T 
cells were analyzed with ReFLEX software on a per-cell basis (181).
Acceptor photobleaching for microscopic FRET
TCR-transduced clone J.19 T cells and primary human T cells were prepared for confocal 
microscopy as described previously (177). Briefly, target APD B cells were loaded with 
10-5 M of M1 or INF peptide and subsequently labeled with 5 µM CFSE (Life technologies-
Invitrogen). T cells and target cells were mixed and fixed with 4% formaldehyde. T cells 
were stained with TCR-Vβ9-PE mAb (donor) and either with CD3ε-AlexaFluor647, CD8α-
AlexaFluor647 or CD45-AlexaFluor647 mAbs (acceptor), covered with 50:50 glycerol:PBS, 
and analysed with a confocal microscope (Zeiss LSM 510; Carl Zeiss AG, Jena, Germany). 
Data was collected using ImageJ software (NIH, Bethesda, MD). Immune synapses 
were defined as contact regions between conjugated T and APD B cells that show an 
accumulated number of TCR molecules. Confocal laser scanning images were taken of 
4 µm thick optical sections. The FRET donor fluorochrome was excited with a 543-nm 
HeNe laser, whereas the FRET acceptor fluorochrome was excited and photobleached 
with a 633-nm HeNe laser. Confocal images were taken in the donor, acceptor and CFSE 
channels (the latter channel for target cells) prior to and post-photobleaching. FRET ef-
ficiencies per pixel were calculated using the AccPbFRET program (197).
Molecular densities in immune synapses
T cells and target cells were prepared and co-cultured as described for acceptor photo-
bleaching. T cells were stained with TCR-Vβ9-PE mAb and one of the following mAbs: 
CD3ε-AlexaFluor647, CD8α-AlexaFluor647, CD45-AlexaFluor647, pCD3ζ-AlexaFluor647, 
pLCK, pERK or pZAP70. The latter three mAbs were used in combination with Alexa-
Fluor647 GαM. Next, T cells were covered with 50:50 glycerol:PBS and imaged with a 
confocal microscope. The relative density of synaptic molecules was calculated by the 
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ratio of Mean Fluorescence Intensities (MFI) per pixel inside versus outside the synapse. 
Images were background-corrected before calculation of molecular densities as de-
scribed previously (177).
Synapse sizes
Synapses were defined as contact regions between T cells and antigen presenting cells 
where the number of introduced TCRβ molecules accumulated. Areas of single synapse 
were calculated by ImageJ software (177).
T cell counting
T cell viability was determined by tryphan blue exclusion and viable T cells were counted 
microscopically using Bürker chambers and a Leitz Laburlux 12 microscope (Leica 
Geosystems BV, Rijswijk, The Netherlands). T cell expansions are represented as fold 
increases in absolute cell numbers during a 6-day culture on feeder cells.
Statistical analysis
Statistical significant differences between TCR:28ε and wt TCR were tested by non-paired 
and two-tailed Student’s t-tests using Graphpad Prism4 software. Differences with p-
values <0.05 were considered significant.
RESULTS
Single-chain TCRs that contain CD28, in particular in combination with CD3ε, 
demonstrate enhanced functional expression in human T cells
We used single-chain (sc) TCRs to test signaling cassettes consisting of Fc(ε)RIγ (γ), CD3ε 
(ε) and CD3ζ (ζ) accessory molecules without or with the CD28 co-stimulatory molecule 
for their effect on the functional expression of TCR transgenes (fig. 4.1 and table 4.1). The 
scTCRs were specific for MAGE-A1/HLA-A1 (M1/A1) and gene-transferred into primary 
human T cells, sorted with TCR antibodies, and analyzed for surface expression, binding 
of peptide-MHC, cytotoxicity and IFNγ release. Findings are presented in supplementary 
figures 4.1A to D, and are summarized in table 4.1. The various scTCRs showed compa-
rable levels of surface expression, but differed with respect to binding of peptide-MHC. 
Single-chain TCR:γ and in particular scTCR:ζ, bound less peptide-MHC when compared 
to scTCR:ε. Notably, the ability of scTCRs to bind peptide-MHC increased in case acces-
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sory molecules were combined with a CD28 co-stimulatory molecule. When analysing 
T cell cytotoxicity and IFNγ release of scTCR T cells in response to M1 peptide-loaded 
target cells, the CD28-CD3ε (28ε) signaling cassette consistently provided T cells with 
the best functional properties. Addition of a membrane proximal cysteine residue, that 
was reported to enhance functional expression of TCRαβ (198), did not enhance the 
general properties of the 28ε signaling cassette.
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Figure 4.2. TCR:28ε shows enhanced peptide-MHC binding. Primary human T cells were transduced 
with empty virus particles (no TCR transgene) or M1/A1-specific two-chain TCR (wt TCR) or TCR:28ε. A sche-
matic representation of two-chain TCR:28ε is given in (A). See materials and methods and table 4.1 for 
details on the 28ε signaling cassette. T cells were FACSorted with TCR-Vα19 and TCR-Vβ9 mAbs and (B) 
analysed by flow cytometry following staining with mAbs directed against TCRα and TCRβ (first row) or M1/
A1 peptide-MHC (second row). Dot plots and histograms represent measurements of PBMC, n=3, from two 
healthy donors with similar results. In case of dot plots, percentages (%) correspond to the upper quadrants 
and Mean Fluorescence Intensities (MFI) (in italics) correspond to the x-axes of the upper right quadrants. 
In case of histograms, % and MFI correspond to marker-positive cells. Non-stained T cells were used to gate 
viable cells and set ordinates and markers at < 1% T cells. In (C) FACSorted T cells were stained with titrated 
amounts of M1/A1 peptide-MHC (range: 10-11 to 10-7 M) and results were expressed as % or MFI, n=3 inde-
pendent measurements. Statistically significant differences between TCR:28ε and wt TCR were calculated 
with Student’s t-test: *: p<0.05; ** : p<0.005.
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Two-chain TCRs that harbor CD28 and CD3ε mediate improved binding of 
peptide-MHC and antigen-specific T cell functions
Following the above-mentioned screen of different scTCR formats, we have translated 
the 28ε cassette to a two-chain TCR format (i.e., TCR:28ε; fig. 4.2A). Primary human T 
cells were gene-transduced with M1/A1 wt TCR or two-chain TCR:28ε, and FACSorted 
to obtain T cell populations with high and equal levels of TCR expression (> 95%) (fig. 
4.2B). Following staining with TCRα and β mAbs, flow cytometry dot plots of TCR:28ε-
positive T cells revealed a typical diagonal with enhanced MFI values and equal staining 
intensities for both TCRα and TCRβ chains. This staining pattern suggests correct pairing 
of TCRα and TCRβ transgenes and was similar to the pattern that has previously been 
reported for TCR:ζ (see chapter 3). Following staining with peptide-MHC, TCR:28ε T cells 
demonstrated a significantly enhanced percentage and MFI of peptide-MHC binding 
over a range of peptide-MHC concentrations when compared to wt TCR (fig. 4.2C).
To investigate T cell function, we have stimulated TCR-engineered T cells with anti-
TCR antibodies, peptide-loaded cells and native melanoma cells and analyzed activa-
tion of NFAT, mobilization of CD107a and production of cytokines. Using a luciferase 
reporter assay with Jurkat T cells we observed a significantly higher activation of NFAT 
upon stimulation of TCR:28ε T cells with TCR-Vβ9 antibody (against the exogenous M1/
A1 TCR) when compared to wt TCR T cells (fig. 4.3A). T cells transduced with wt TCR, but 
not TCR:28ε, demonstrated decreased NFAT activation upon stimulation with TCR-Vβ27 
antibody (against the endogenous MelanA/A2 TCR). These findings proof enhanced 
functional expression of TCR:28ε, not being at the expense of the functional expression 
of endogenous TCR. When assessing CD107a mobilization in primary human T cells, we 
observed that TCR:28ε outperformed wt TCR upon stimulation with M1 peptide, and 
that both TCR:28ε and wt TCR performed equally well upon stimulation with native, M1/
A1-positive, melanoma cells (fig. 4.3B). Using TCRs directed against a second antigen, i.e., 
gp100/A2, we confirmed enhanced peptide-MHC binding (supplementary fig. 4.2A) and 
peptide-induced mobilization of CD107a by TCR:28ε (fig. 4.3C). Enhanced responsive-
ness towards peptide-loaded targets cells of both M1/A1 and gp100/A2 specific TCRs 
was also observed upon assessing TCR:28ε T cells for their production of IFNγ and IL-2 
(fig. 4.5 and supplementary figs. 4.2B and C and 4.3).
TCR:28ε does not mis-pair with endogenous TCR chains
To assess whether TCR:28ε is prone to mis-pair with endogenous TCR chains, we gener-
ated dual TCR T cells with defined sets of TCR transgenes and performed flow cytometric 
Fluorescence Resonance Energy Transfer (FRET) to determine the molecular association 
between different TCR chains. To this end, we transduced clone J.19-CD8 T cells, already 
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Figure 4.3. TCR:28ε T cells demonstrate enhanced activation of Nuclear Factor of Activated T cells 
and antigen-specific mobilization of CD107a. Jurkat clone 19 T cells (A) and primary human T cells (B, C) 
were transduced with empty virus particles, M1/A1 or gp100/A2 wt TCR or TCR:28ε, FACSorted with TCRα 
and TCRβ mAbs (in case of M1/A1) or peptide-MHC (in case of gp100/A2), and tested for their ability to (A) 
mediate activation of Nuclear Factor of Activated T cells (NFAT) or (B, C) mobilize CD107a to the cell surface 
upon stimulation with antigen. In (A) M1/A1 TCR Jurkat T cells were nucleofected with a Firefly luciferase 
reporter construct under control of NFAT response elements, and stimulated for 6h with irrelevant, anti-
TCR-Vβ9 or anti-TCR-Vβ27 mAb coated to well plates. Bars represent mean activation of NFAT expressed in 
% RLU + SEM, n=5 independent measurements. Mock-transduced T cells showed negligible levels of NFAT 
activation (data not shown). In (B) M1/A1 TCR T cells were stimulated with the APD B cell line (A1+) loaded 
with M1 or INF (influenza) peptide (10-5 M final), and the melanoma cell lines GE-F- (M1-/A1+), G43 and MZ2-
Mel43 (both M1+/A1+). In (C) gp100/A2 TCR T cells were stimulated with the BSM B cell line (A2+) loaded with 
or without gp100 peptide (10-5 M final), and the melanoma cell lines FM3 (gp100+/A2+) and Mel2A (gp100+/
A2-). CD107a mobilization was measured by flow cytometry and expressed in % of CD107a-positive cells 
within the population of CD3-positive cells. Bars represent mean + SEM, n=2-10 independent measure-
ments. Statistically significant differences between TCR:28ε and wt TCR were calculated with Student’s t-
test: ns: non-significant; *: p<0.05; ***: p<0.0005.
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expressing the MelanA/A2 wt TCR and the CD8α co-receptor, with the M1/A1 wt TCR or 
TCR:28ε genes. Measurements of flow cytometric FRET using the MelanA/A2 TCR-Vβ27 
and the M1/A1 TCR-Vα19 specific mAbs revealed significant energy transfer in case 
of wt TCR, but not TCR:28ε where values were below the 5% background signal (fig. 
4.4). Measurements of FRET using the M1/A1 TCR-Vβ9 and either CD3ε or CD8α mAbs 
showed that TCR:CD3 associations were only observed for wt TCR but not TCR:28ε and 
TCR:CD8α associations were present for both TCR formats (fig. 4.4). These experiments 
show that TCR:28ε does not mis-pair with endogenous TCR chains nor does it associate 
with endogenous CD3 molecules, similar to observations reported for TCR:ζ in chapter 
3 and Sebestyén et. al. (63).
TCR:28ε displays a similar peptide-fine specificity as wt TCR
Next, we studied whether the 28ε cassette alters the TCRs’ peptide-fine specificity. To 
this end, we loaded T2 cells with altered gp100 peptide ligands (APL), as described 
by Schaft and colleagues (132), and measured IFNγ release following stimulations of 
TCR-transduced primary human T cells. These APLs deviate from the wt gp100 peptide 
(YLEPGPVTA) by a single amino acid mutation to alanine or, in case of the last amino 
acid, glutamic acid, indicated by an ‘A’ or ‘G’, respectively, with the number correspond-
ing to the amino acid position within the peptide. We observed that both TCR:28ε and 
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Figure 4.4. TCR:28ε does not mis-pair with TCR nor associate with CD3. Jurkat clone 19 T cells express-
ing MelanA/A2 TCR and CD8α were transduced with M1/A1 wt TCR or TCR:28ε and FACSorted with TCRα 
and TCRβ mAbs. T cells were stained with the following three sets of antibodies: (1) TCR-Vα19 + Rabbit-
anti-Mouse (RαM)-Cy5 (acceptor) + TCR-Vβ27-PE (donor); (2) CD3ε + RαM-Cy5 (acceptor) + TCR-Vβ9-PE 
(donor); and (3) CD8α + RαM-Cy5 (acceptor) + TCR-Vβ9-PE (donor). Flow cytometry was used to measure 
Fluorescence Resonance Energy Transfer (FRET) and bars represent mean % + SEM, n=3-6 independent 
measurements. Notably, FRET efficiencies <5%, with the dotted line representing a 5% background signal, 
do not imply that there is no pairing of molecules but do not allow distinction between significant and non-
significant interactions. Mock-transduced T cells (no TCR transgene) showed negligible levels of FRET (data 
not shown). Statistically significant differences between TCR:28ε and wt TCR were calculated with Student’s 
t-test: ns: non-significant; *: p<0.05; ** : p<0.005.
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wt TCR mediated IFNγ release to all APLs, except when an Alanine replaced a Glutamic 
acid at position 3 (fig. 4.5). This peptide response pattern was identical to that of the 
parental CTL-296 clone (132) and showed that incorporation of the 28ε cassette did not 
alter the peptide-fine specificity of the parental TCR.
TCR:28ε induced immune synapses with enhanced accumulation of TCR, CD3ε, 
CD8α co-receptor and phosphorylated LCk and ERk
The induction of immune synapses and their molecular profile is considered a critical 
measure of T cell activation. To study the ability to induce and the composition of im-
mune synapses, TCR-transduced Jurkat T cells were stimulated with M1 peptide-loaded 
target cells and studied by confocal microscopic FRET. We observed that TCR:28ε is able 
to induce immune synapses and, in extension to data obtained with flow cytometric 
FRET, TCR:28ε present in synapses does not associate with CD3ε nor CD45, but does 
associate with CD8α (figs. 4.6A and B). In addition, the immune synapses induced by 
either TCR:28ε or wt TCR are of similar size (fig. 6C). Notably, when repeating analyses 
with TCR-engineered primary human T cells, TCR:28ε, but not wt TCR, demonstrated 
clear antigen-induced synapse formation (fig. 4.7A and B). To investigate synaptic accu-
mulation of T cell membrane molecules in more detail, we used quantitative analysis of 
confocal microscopy data and observed that TCR:28ε mediated a 5-fold increase in the 
accumulations of TCRβ transgene, endogenous CD3ε and CD8α molecules when com-
pared to wt TCR (fig. 4.8A). When measuring markers of early T cell activation, we noted 
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Figure 4.5. TCR:28ε shows a peptide-fine specificity that is similar to that of wt TCR. Primary human 
T cells were transduced with empty virus particles, gp100/A2 wt TCRs or TCR:28ε and FACSorted with pep-
tide-MHC. T cells were O/N stimulated with T2 cells that were not loaded or loaded with gp100 wt peptide 
or altered peptide ligands (APL) (10-5 M final). APLs are coded by the letters A (Alanine) or G (Glycine) fol-
lowed by a number that corresponds to the position of the amino acid that is altered into A or G in the 
gp100 wt peptide sequence (YLEPGPVTA). IFNγ release was measured by ELISA and expressed in pg/ml, 
n=3 independent measurements. Notably, both wt TCR and TCR:28ε did not mediate a response to the 
A3 APL as indicated by ‘-‘, in contrast to other APLs as indicated by ‘+’ (enhanced response compared to 
medium). Statistically significant differences (with respect to gp100 wt peptide responses) were calculated 
with Student’s t-test: ns: non-significant; **: p<0.005.
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Figure 4.6. TCR:28ε induces formation of antigen-dependent immune-synapses in T cell line. Jurkat T 
cells were transduced with M1/A1 wt TCR or TCR:28ε, as described in the legend to figure 4.4, and analysed for 
molecular associations between the TCRβ transgene and endogenous CD3ε, CD8α, or CD45 molecules in im-
mune synapses. APD B cells (marked as target cells; Ta) were stained with CFSE, loaded with M1 peptide and 
used to stimulate TCR T cells. T cells were labeled with the donor mAb TCR-Vβ9-PE and one of the following 
acceptor mAbs: CD3ε-AlexaFluor647, CD8α-AlexaFluor647 or CD45-AlexaFluor647. Confocal microscopy was 
used to measure Fluorescence Resonance Energy Transfer (FRET). In (A) representative pictures are shown of 
immune synapses of Jurkat T cells (magnification: 200x and with a white scale bar of 5 µm), including FRET 
histograms of corresponding synapses. Vertical lines in the center of histograms denote zero FRET efficiency 
per pixel in the synapse region. TCR T cells stimulated with APD B cells loaded with irrelevant peptide showed 
low background levels of FRET (except for FRET between wt TCR and CD3ε) (data not shown). Mean % + SEM 
of microscopic FRET measured with Jurkat T cells are shown in (B), n=3 independent measurements of 15 
cells per measurement. Data of wt TCR presented in (A) were modified from Roszik and colleagues (177). In 
(C) mean μm2 + SEM of synapse sizes are shown, n=4 independent measurements. Synapses were defined 
as regions of contact between T cells and peptide-loaded target cells with an accumulation of TCR-Vβ9 mol-
ecules and their areas were calculated as described in materials and methods. Mock-transduced T cells did 
not induce the formation of immune synapses (data not shown). Statistically significant differences between 
TCR:28ε and wt TCR were calculated with Student’s t-test: ns: non-significant; *: p<0.05; ***: p<0.0005.
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that TCR:28ε mediated accumulations of phosphorylated-LCK (pLCK) (7-fold increase), 
and to a lesser extent pERK (1.6-fold increase) (fig. 4.8B). However, TCR:28ε mediated a 
significantly decreased accumulation of pCD3ζ (2.3-fold) and a non-changed accumula-
tion of pZAP70 (fig. 4.8B).
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Figure 4.7. TCR:28ε, but not wt TCR, induces formation of antigen-dependent immune-synapses in 
primary human T cells. Primary human T cells were transduced with M1/A1 wt TCR or TCR:28ε, as de-
scribed in the legend to figure 4.2, and analysed for molecular associations between the TCRβ transgene 
and endogenous CD3ε, CD8α, or CD45 molecules in immune synapses as described in the legend to figure 
4.6. In (A) representative pictures are shown of immune synapses of primary human T cells (magnification: 
200x and with a white scale bar of 5 µm), including FRET histograms of corresponding synapses. Mean % 
+ SEM of microscopic FRET measured with primary human T cells are shown in (B), n=3 independent mea-
surements of 15 cells per measurement.
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DISCUSSION
In this study, using a single-chain TCR platform, we have tested signaling cassettes that 
consisted of the accessory molecules Fc(ε)RIγ, CD3ε or CD3ζ, without or with the co-
stimulatory molecule CD28, for their effects on the functional expression of TCR chains. 
The combined use of CD28 and CD3ε proved most optimal with respect to various pa-
 












 
 





 






 








  

   



 
 


 






 



 
 



 



A

 














  

   



 
 


 






 



 
 



 



B
Figure 4.8. TCR:28ε T cells demonstrate enhanced synaptic accumulation of TCR, CD3ε, CD8α, pLCk 
and pERk. Jurkat T cells were transduced with M1/A1 TCRs, as described in legend to figure 4.4, stimulated 
with APD B cells loaded with M1 peptide, and measured for densities of (A) membrane and (B) intracellular 
proteins present in synapses. T cells were stained with TCR-Vβ9-PE mAb and one of the following mAbs: 
CD3ε-AlexaFluor647, CD8α-AlexaFluor647, CD45-AlexaFluor647, pCD3ζ-AlexaFluor647, pLCK, pERK and 
pZAP70. In case of the latter 3 non-conjugated mAbs, staining was followed by a secondary isotype-specific 
AlexaFluor647-conjugated mAb. T cells were analysed by confocal microscopy and bars represent densities 
of molecules (fold increase of signals inside versus outside synapses) + SEM, n=3 independent measure-
ments of 15 cells per measurement. TCR T cells stimulated with irrelevant peptide showed low background 
signals (data not shown). Data of wt TCR presented in (A) were modified from Roszik and colleagues (177). 
Statistically significant differences between TCR:28ε and wt TCR were calculated with Student’s t-test: ns: 
non-significant; *: p<0.05; **: p<0.005; ***: p<0.0005.
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rameters of T cell activation. When incorporating this cassette into both TCRα and TCRβ, 
we observed that a two-chain TCR:28ε provides T cells with the following beneficial 
properties for T cell therapy: (I) enhanced peptide-MHC binding; (II) more potent T cell 
responses upon stimulation with peptide and equal responses upon stimulation with 
antigen-positive melanoma cells; (III) no TCR mis-pairing; (IV) no change in peptide-fine 
specificity; and (V) antigen-dependent formation of immune synapses that are enriched 
in TCR/CD3, CD8 and markers of early T cell activation.
The enhanced potency of T cells transduced with TCR:28ε to bind peptide-MHC 
(figs. 4.2B and C, and supplementary fig. 4.2A) and respond to peptide (figs. 4.3, 4.5 and 
supplementary figs. 4.2B and C) is not related to a changed dependency for CD8α (supple-
mentary fig 4.3) but most likely a direct consequence of enhanced surface expression per 
cell (see MFI values in figure 4.2B and C, and supplementary figure 4.2A). In contrast to wt 
TCR (98), TCR:28ε does not compete for endogenous CD3 proteins to become surface-
expressed as evidenced by the lack of association between TCR:28ε and CD3ε (fig. 4.4) 
and enhanced activation of NFAT when stimulating either TCR:28ε or the endogenous 
TCR (fig. 4.3A). Unexpectedly, T cell responses towards antigen-positive tumor cells were 
equal when compared to wt TCR-transduced T cells. When testing TCR:28ε T cells in 
more detail, we observed a lowered effective dose of peptide yielding half-maximum 
response (data not shown), and a compromised response in the absence of CD8α bind-
ing (supplementary fig. 4.3). In our opinions these finding do not argue against further 
clinical development of TCR:28ε, which compared to wt TCR provides co-stimulation and 
no TCR mis-pairing. Nevertheless, we speculate that TCR:28ε enhances the potency of T 
cell responses but does so with a reduced affinity. Along this observation, earlier studies 
have reported that binding of peptide-MHC multimers may not always correlate with 
antigen sensitivity (91) and that inclusion of CD28 into a CAR or a TCR predominantly 
enhances the potency of T cell cytokine production (199).
TCR:28ε does not mis-pair with endogenous TCR as evidenced by flow cytometric 
FRET (fig. 4.4) nor does it have a changed peptide-fine specificity when compared to wt 
TCR (fig. 4.5) and is therefore most likely less prone to induce off-target toxicities (65, 66). 
In addition, our studies provide the following lines of evidence that TCR:28ε does not 
hamper safety by constitutively activating T cells. First, we did not observe activation of 
NFAT following non-specific TCR stimulation (fig. 4.3A). Second, we did neither observe 
CD107a mobilization nor release of IFNγ and IL-2 in the absence of antigen (figs. 4.3B and 
C, 4.5 and supplementary figs 4.2B and C). Thirdly, TCR:28ε T cells revealed no enhanced 
proliferation during routine culture conditions (supplementary fig. 4.4).
To study T cell activation in more depth, we analysed the formation of immune syn-
apses. TCR:28ε is able to mediate the formation of immune synapses between Jurkat T 
cells and target cells similar to wt TCR (figs. 4.6A and B). Also, the composition of immune 
synapses is similar, except for a lack of association between TCR:28ε and CD3ε. Notably, 
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TCR:28ε but not wt TCR mediated detectable synapse formation when using primary 
human T cells (figs. 4.7A and B), implying an enhanced potency of the former TCR to me-
diate the formation of immune synapses. Alternatively, we cannot exclude that TCR:28ε 
may differ from wt TCR with respect to its temporal organization of synapses. In fact, a 
reduced association with CD45 may provide TCR:28ε with a kinetic advantage (fig. 6B). 
In this respect, it is noteworthy that primary human T cells may demonstrate prolonged 
time requirements to develop molecular clusters when compared to Jurkat T cells and 
may proof better suited to perform further experiments into the kinetics and stability of 
immune synapses (200, 201). When quantifying the presence of synaptic molecules, we 
showed significant accumulation of TCR transgene, CD3ε and CD8α when comparing 
immune synapses of TCR:28ε to wt TCR T cells (fig. 4.7A). Synapses induced by wt TCR 
and TCR:28ε have identical sizes (fig. 4.6C), arguing that TCR:28ε forms highly organized 
complexes with endogenous TCR/CD3 and CD8 molecules inside synapses. Such highly 
organized TCR microclusters potentially facilitate antigen-dependent T cell activation 
(202-204). When investigating early T cell activation markers, we observed significantly 
enhanced densities of phosphorylated LCK and ERK in TCR:28ε-induced immune syn-
apses (fig. 4.8B). Enhanced densities of pLCK may be a direct consequence of enhanced 
densities of TCR:28ε and CD8 since both CD28 (contained in TCR:28ε) and CD8 harbor a 
motif for LCK recruitment. Currently, we are testing TCR:28ε and CD8α with a mutated 
LCK-binding domain (205, 206) to identify the molecular source of pLCK. Notably, pERK 
can phosphorylate LCK at Serine-59 preventing inactivation of pLCK by the phosphatase 
SHP-1 (207), thereby providing an alternative reason and possibly a positive feedback 
loop for the enhanced activation of LCK. Interestingly, the motif of CD28 that recruits 
LCK also acts as a docking site for the adaptors GRB2 and FLN3 (208), whereas a sec-
ond membrane-proximal proline-rich motif acts as a docking site for the kinase ITK 
(209). In TCR:28ε T cells, despite synaptic accumulation of pLCK, levels of pCD3ζ were 
significantly lower when compared to wt TCR (fig. 4.8B). The lack of CD3ζ phosphoryla-
tion observed in TCR:28ε T cells may be due to an inability of this receptor to associate 
with endogenous CD3z and position this molecule sufficiently close to pLCK to become 
phosphorylated. Despite the presence of fewer pCD3ζ scaffolds, the accumulated levels 
of pZAP70 in TCR:28ε T cells were similar to those in wt TCR T cells (fig. 4.8B), which may 
argue that ZAP70, even when docking to pCD3z is hampered, becomes phosphorylated 
by the enhanced presence of pLCK. Interestingly, TCR:28ε resulted in enhanced activa-
tion of two early TCR signaling pathways, namely activation of NFAT (fig. 4.3A) as well as 
pERK (fig. 4.8B). In this respect, the CD3ε molecule present in the CD28-CD3ε signaling 
cassette may serve as docking site for kinases and adaptors such as GRK2, CAST and NCK 
(210). CD3ε-bound GRK2 and CAST, together with calcium, are involved in the activation 
of NFAT and production of IL-2 (210, 211), whereas CD3ε-recruited NCK, in conjunction 
with SLP-76, leads to activation of the RAS/RAF/ERK pathway, cytoskeletal reorganization 
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and formation of immune synapses (212, 213). Taken together, the CD28-CD3ε signaling 
cassette yields a TCR that takes advantage of two critical components of T cell activation: 
CD3ε, linked to the initiation of TCR signaling, and CD28, linked to T cell co-stimulation.
So far, most studies analysing signaling cassettes were performed with CARs. Inclusion 
of CD28 into CARs, generally in combination with a CD3ζ domain, resulted in enhanced T 
cell activation and proliferation, in vivo T cell persistence and anti-tumor effects. Signal-
ing cassettes were further tested with other members of the CD28-family (186, 214-217), 
such as CD137 (4-1BB) and CD134 (OX40), which showed promising results with respect 
to cytolysis, initiation or sustainment of an effective T cell response and prevention of 
CAR-mediated proliferation of regulatory T cells (44). Importantly, clinical trials using 
CAR:CD28-CD3ζ or CAR:CD137-CD3ζ demonstrated significant objective responses in 
patients with B cell leukemia (76-78). In this manuscript, we showed that a signaling cas-
sette consisting of CD28 and CD3ε in the setting of TCRs improves the potency of T cell 
responses without compromising antigen specificity and warrants further development 
of co-stimulatory TCRs for clinical testing.
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Supplementary figure 4.1. Single-chain TCRs equipped with a CD28-CD3ε signaling cassette show 
enhanced functional expression. Primary human T cells were transduced with single chain (sc)TCRs spe-
cific for M1/A1, FACSorted with TCRα and TCRβ mAbs and analyzed for TCR surface expression (A), peptide-
MHC binding (B), cytotoxicity (C), and IFNγ release (D). In (A) and (B), flow cytometry was used either with 
TCRα and TCRβ mAbs or M1/A1 peptide-MHC. In case of dot plots, percentages (%) correspond to the upper 
quadrants, and Mean Fluorescence Intensities (MFI) (in italics) correspond to the x-axes of the upper right 
quadrants. In case of histograms, % and MFI correspond to marker-positive cells. Non-stained T cells were 
used to gate viable cells and set ordinates and markers at <1% T cells. In (C) and (D), T cells were co-cultured 
with either M1 or INF peptide-loaded APD B cells (10-5 M final) and assessed for their cytotoxic capacity and 
ability to produce IFNγ. T cell-mediated cytotoxicity was measured by 51Cr-release at E:T ratios of 1:10, 1:20, 
1:40 and 1:80 at 4h and expressed in % specific 51Cr release, whereas IFNγ release was measured by ELISA in 
supernatants collected at 24h and expressed in pg/ml. Antigen-negative target cells or Mock-transduced 
T cells (no TCR transgene) showed negligible responses (data not shown). Data presented in this figure are 
representative for three independent experiments with similar results, and are summarized in table 4.1.
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Supplementary figure 4.2. TCR:28ε T cells specific for gp100/HLA-A2 demonstrate enhanced binding 
of peptide-MHC and peptide-induced release of IFNγ and IL-2. Primary human T cells were transduced 
with empty virus particles, gp100/A2 wt TCR or TCR:28ε and FACSorted with peptide-MHC. In (A), T cells 
were stained with titrated amounts of peptide-MHC (range: 5x10-6 to 10-8 M). In (B) and (C), T cells were stim-
ulated for 24h with BSM B cells that were loaded or not loaded with gp100 wt peptide, or the melanoma cell 
lines MEL2A (gp100-/A2+) and FM3 (gp100+/A2+), and were subsequently analyzed for their release of IFNγ 
or IL-2. Representative data  of flow cytometry stainings and IFNγ and IL-2 measurements are shown (n=2).
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Supplementary figure 4.3. TCR:28ε shows an enhanced CD8 dependency. Primary human T cells were 
transduced with empty virus particles or gp100/A2 wt TCR or TCR:28ε and FACSorted with peptide-MHC. 
T cells were O/N stimulated with C1R cells expressing wt HLA-A2 or the non-CD8α binding KA mutant of 
HLA-A2 that were not loaded or loaded with gp100 wt peptide (10 M-5 final). IFNγ release was measured by 
ELISA and expressed in pg/ml, n=4 independent measurements. Fold difference (non-significant according 
to Student’s t-test) between TCR:28ε and wt TCR T cells in response to peptide-loaded C1R(wt) and C1R(KA) 
target cells are indicated.
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Supplementary figure 4.4. TCR:28ε T cells show no enhanced proliferation. Proliferation of primary 
human T cells transduced with empty virus particles or M1/A1 wt TCR or TCR:28ε was determined by count-
ing T cells following harvest from feeder cells, as described in materials and methods. Bars represent mean 
values + SEM, n=13-18 independent measurements. No significant (ns) differences were found between wt 
TCR and TCR:28ε according to Student’s t-test.
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ABSTRACT
Adoptive therapy with T cells is likely to benefit from affinity-enhancement of T cell 
receptor (TCR) transgenes. However, it is questioned whether affinity-enhanced TCRs 
selectively lead to improved T cell function without increase of self-recognition. Here, 
we used phage display to obtain affinity-enhanced TCRs specific for gp100280-288/HLA-
A*0201 (KD range: 18.5 µM to 26 nM) that harbor amino acid substitutions restricted 
to individual complementarity determining regions (CDR). Following gene transfer into 
human T cells, we demonstrated that TCRs with the highest affinity and mutations in 
CDR2β, but not CDR3β, improved peptide-HLA binding most significantly. In contrast, 
improvement of antigen-specific T cell functions was restricted to TCRs with relatively 
minor affinity enhancements (KD ≥4 µM) and mutations in CDR3α. Importantly, high-
affinity TCRs (KD <1 µM), which exclusively harbored mutations in CDR2β, lost peptide 
fine-specificity and gained reactivity towards HLA-A2. Notably, TCRs with nM affinities 
mediated target cell-independent T cell activation and differentiation when introduced 
in HLA-A2-positive donor T cells. In conclusion, perimeters of TCR affinities that deter-
mine gain of function are different from those that determine gain of self-reactivity 
and, in this study, are best distinguished by TCR-CDR3α mutations. These findings may 
facilitate the generation of functionally enhanced and therapeutically safe T cells.
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INTRODUCTION
Adoptive T cell therapy to treat viral infections or tumors is based on the ability of T 
cell receptors (TCRs) to selectively recognize antigens, i.e., peptides that are presented 
by Major Histocompatibility Complex (MHC) molecules. The contact between TCR and 
peptide-MHC is governed by loops of the three complementarity determining regions 
(CDRs) of both TCRα and TCRβ chains. CDR1 and CDR2 represent germ line-encoded 
regions that interact with MHC heavy chain alpha helices and position the highly vari-
able CDR3 region for direct interactions with the peptide (88, 89). The combined binding 
strength of CDRs determines the affinity of the TCR for peptide-MHC (see also box 1.2). 
T cell selection in the thymus and peripheral maintenance of low affinity interactions 
with self-peptide-MHC yields a functional repertoire of ~2.5 x 108 different TCRs with 
dissociation constant (KD) values for their cognate peptide-MHC typically in the range 
of 1-100 µM (88-90, 218). T cell responsiveness towards target cells, i.e. functional T cell 
avidity, is determined in large part by TCR:peptide-MHC interactions (219, 220). Studies 
with viral and tumor antigens demonstrate that high avidity T cells are able to mediate 
maximum antigen reactivity and protection from disease (219-221).
Procedures have been developed that yield high-affinity TCR variants with the inten-
tion of obtaining higher avidity, and hence therapeutically more effective T cells. One 
approach is that TCRs with moderately high affinities can be obtained from a pool of 
non-tolerant TCRs, such as in vitro systems of MHC-mismatched cytotoxic T cells (38) 
or mice that are transgenic for human MHC (Human Leukocyte Antigen, HLA) fol-
lowing immunization with human antigens (222). Gp100 and CEA-specific TCRs have 
been derived from HLA-A*0201 transgenic mice and used in clinical trials (40, 45), but 
patients developed a humoral response against these non-human TCRs (223). Mice that 
are transgenic for human TCR loci, with murine TCR loci being inactivated, provide a 
non-tolerant repertoire of completely human TCRs (39). Alternatively, TCR affinities 
can be enhanced by rationally designed mutagenesis of CDR loops (224, 225). Lastly, 
high-affinity TCR variants can be selected from a library of CDR site-directed mutants by 
phage, yeast or T cell display (226-230). Generally, T cells expressing higher than average 
affinity TCRs show enhanced functional avidity and less dependence on CD8 co-receptor 
(92, 153, 224, 228, 231). Notably, the clinical use of improved-affinity TCRs in adoptive 
transfer of TCR-engineered T cells to treat melanoma patients enhanced response 
rates (45). Although high affinity TCRs, when directed against differentiation antigens 
that are over-expressed on tumors, can result in on-target toxicities on normal tissues 
(40, 45), an improved-affinity TCR directed against a shared peptide epitope from the 
Cancer Testis Antigen (CTA) NY-ESO-1/HLA-A*0201 and LAGE-1/HLA-A*0201 has been 
successfully used in clinical TCR gene therapy without observations of either on-target 
or off-target toxicities (46). However, apart from the nature of the target antigen, studies 
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have shown that affinity-enhanced TCR bear the risk of reduced antigen-specificity and 
increased affinities for self-peptide-MHC (92, 228). One of the current challenges in the 
development of affinity-enhanced TCRs for adoptive T cell therapy is to control the risk 
of generating self-reactive TCRs.
In the present study, we questioned whether selected CDR amino acid substitutions 
are able to improve functional T cell avidity without loss of specificity. Starting from a 
TCR specific for gp100280-288/HLA-A*0201 (gp100/A2), we generated phage libraries that 
harbored amino acid substitutions either in CDR2β, CDR3α or CDR3β and selected TCR 
variants with KD values ranging from 18.5 µM to 26 nM. Following gene transfer into hu-
man T cells we demonstrated that improved peptide-HLA binding was most significant 
for TCRs with the highest affinity enhancement. Gain in TCR function, however, appeared 
restricted to a lower KD limit of ~4 µM and was only observed for TCR variants with amino 
acid substitutions in CDR3α. These CDR3α TCR variants (but not the CDR2β variants with 
KD values less than 1 µM) preserved the antigen and peptide-fine specificity of wild type 
TCR. Extending our findings to a therapeutic setting, we note that, when introduced in 
HLA-A2-positive donor T cells, TCRs with nM affinities conveyed significant T cell acti-
vation and differentiation in the absence of tumor target cells. In conclusion, affinities 
with KD values down to 4 µM, in this study best captured by amino acid substitutions in 
CDR3α, with a potential safe guard set at 1 µM, may facilitate the generation of function-
ally optimal therapeutic T cells.
MATERIALS AND METHODS
Cells and reagents
T lymphocytes were derived from healthy donors, isolated and expanded in HEPES-
buffered RPMI 1640 medium (BioWhittaker, Verviers, Belgium) supplemented with 2 mM 
L-glutamine, 10% human serum, streptomycin, penicillin and 360 IU/ml rIL-2 (Proleukin; 
Chiron, Amsterdam, The Netherlands) were stimulated every other week with a mixture 
of irradiated allogeneic feeder cells as described elsewhere (232). Both the retroviral 
packaging cell lines, 293T and Phoenix-A, and melanoma cell lines were cultured in 
DMEM medium (BioWhittaker) supplemented with 2 mM L-glutamine, non-essential 
amino acids, 10% FBS and antibiotics. Melanoma cell lines included C1R wild-type (wt) 
and C1R-227/228KA cell lines, expressing wt HLA-A2 and a mutant non-CD8α binding 
HLA-A2, respectively ((196); a kind gift of Prof.dr. Andrew Sewell, Cardiff University, UK) 
and melanoma cell lines positive for gp100 and HLA-A2: FM3, MEL624, DAJU, BLMgp100, 
453AO; positive for gp100 but negative for HLA-A2: MEL2A, MZ2-MEL43, G43; and 
negative for gp100 but positive for HLA-A2: BLM, 607B, 518A2 and Brown. Monoclonal 
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antibodies used in this study were: PE-conjugated anti-TCR-Vβ19 (TCR nomenclature 
according to http://imgt.org; clone E17.5F3.15.13; Beckman-Coulter, Marseille, France); 
FITC-conjugated anti-CD3ε (clone SK7; BD Biosciences, San Jose, CA); PerCP-conjugated 
anti-CD3ε (clone SP34-2; BD biosciences); non-conjugated anti-CD3ε (clone OKT3; 
Beckman-Coulter); PerCP-conjugated anti-CD8α (clone SK1; BD biosciences); APC-
Cy7-conjugated anti-CD27 (clone M-T271; BD biosciences); APC-conjugated anti-CD28 
(clone CD28.2; BD biosciences); PE-Cy7-conjugated anti-CD45RA (clone L48; BD biosci-
ences); PE-conjugated anti-CD107a (clone H4A3; BD Biosciences); APC-conjugated anti-
CD137 (clone 4B4-1; BD biosciences); and PE-conjugated anti-CCR7 (clone 150503; R&D 
systems, Abingdon, UK). Gp100280-288/HLA-A*0201 (gp100/A2) peptide-HLA-tetramers 
were generated from biotinylated monomers (Sanquin, Amsterdam, Netherlands) and 
PE-conjugated streptavidin (BD Biosciences) as described in chapter 6. Other reagents 
used in this study include: Retronectin (human fibronectin fragments CH-296, Takara 
Shuzo Co. Ltd., Otsu, Japan); PMA (Sigma-Aldrich, St. Louis, USA); PHA (Remel Europe, 
Dartford, UK); Golgistop (BD Biosciences); gp100280-288 wild type (wt) peptide (YLEPG-
PVTA) (Proimmune, Oxford, UK) or Altered Peptide Ligands (APL) in which single amino 
acids were substituted (A1 to A8 and G9).
Phage libraries and selections
A wildtype (wt) TCR specific for gp100/A2 with the genes: TRAV17*01/J29*01/TRAC and 
TRBV19*01/D1/J2*07/TRBC1 was used as a starting TCR to obtain affinity-enhanced TCR 
variants (a kind gift of Prof.dr. Cassian Yee, Fred Hutchinson Cancer Research Centre, 
Seattle, WA, USA). Phage libraries of TCRs with CDR amino acid substitutions were gener-
ated and TCR variants were selected from these libraries with peptide-HLA as described 
previously (153). In short, CDR2β, CDR3α and CDR3β libraries were constructed by 
splicing overlap extension PCR (SOE-PCR) using a panel of 5-NNK mutagenic oligonucle-
otides that spanned the codons encoding the CDR loop regions. M13KO7 helper phage 
was used to rescue TCR-displaying phage particles, which were subsequently subjected 
to three cycles of panning against gp100 peptide complexed to biotinylated-A2. TCR-
phage:gp100/biotinylated-A2 complexes were captured with streptavidin-labeled 
magnetic beads. Binding of selected phages to gp100/A2 was validated using ELISA 
and corresponding CDR amino acid substitutions were analyzed by DNA sequencing. A 
panel of 8 TCRs each containing 2 or 3 amino acid substitutions in either CDR3α, CDR2β 
or CDR3β regions was used for the present study (see table 5.1).
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Soluble TCRs and Surface Plasmon Resonance measurements
Soluble proteins of wt and affinity-enhanced TCR variants were produced as disulfide-
linked heterodimeric TCRs (126). Surface Plasmon Resonance (SPR) analysis of TCRs was 
performed essentially as described elsewhere (153). Briefly, binding kinetics of soluble 
TCRs were measured using biotinylated gp100280-288/HLA-A2 (233) immobilized to a 
streptavidin-coated flow cell in a BIAcore 3000 and performing 60s injections (20 µl/
min). For TCRs with half-lives (t1/2) of <9s, binding at equilibrium was recorded against 
gp100/A2 concentrations in µM. KD values were determined by non-linear curve fitting 
using Graphpad Prism, whereas Kon values were calculated using Kon=Koff/KD. For TCRs 
with t1/2>9s, Koff values were determined by dissociation fitting using BIAevaluation, and 
Kon values were fitted to the 1:1 Langmuir binding model using BIAevaluation, and KD 
values were calculated using KD=Koff/Kon. For TCRs with t1/2>50s, binding of gp100/A2 was 
fitted to a single cycle kinetics model again using BIAevaluation. Affinity enhanced TCRs 
were numbered 1 to 8 according to decreasing KD values (table 5.1).
TCR constructs
TCRs were selected from phage libraries and, in soluble format, characterized using 
surface plasmon resonance. Genes for both the α and β chains of wt TCR and affinity-
Table 5.1. CDR amino acid substitutions and peptide-HLA binding properties of affinity-enhanced 
gp100/A2 specific TCRa
TCRb Clone 
no.
CDR3α
(110-129)
CDR2β
(68-73)
CDR3β
(111-131)
kon
(M/s-1x1000)
koff
(s-1)
kD
(µM)
t1/2
(s)
wt ATDGDTPLVFGKGTRLSVIA SQIVND ASSIGGPYEQYFGPGTRLTVT 34 0.635 18.5 1.10
1 ADB97     S   M 125 0.99 7.9 0.70
2 ADB98     S  MQ 197 0.79 4.0 0.88
3 ADB217    F A 75 0.194 2.6 3.60
4 ADB243    Y A 65 0.122 1.9 5.70
5 ADB242    W A 74 0.082 1.1 8.50
6 ADB212  W TG 275 0.0683 0.402 10.2
7 ADB241  WGT 325 0.0115 0.035 60.3
8 ADB213  WG G 304 0.0078 0.026 89.2
a The wt TCR consists ofTRAV17*01/J29*01/TRAC and TRBV19*01/D1/J2*07/TRBC genes. Affinity-enhanced 
TCR protein variants were obtained from phage libraries of expressed TCR genes with CDR amino acid sub-
stitutions following selections with gp100280-288 peptide-HLA-A2. TCR genes were cloned and produced 
as soluble, disulfide-linked heterodimeric TCR proteins. Binding kinetics of soluble TCR proteins were 
measured using biotinylated peptide-HLA-A2 antigen immobilized to a streptavidin-coated flow cell in a 
BIAcore 3000 (see materials & methods section for details).
b Affinity enhanced TCRs were numbered 1 to 8 according to decreasing KD values.
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enhanced TCR variants were codon-optimized for expression in human cells (Geneart, 
Regensburg, Germany) and sub-cloned into the pMP71 retroviral vector with the TCRα 
and TCRβ joined together as a single open reading frame intervened by a 2A skipping 
sequence preceded by codons encoding a furin protease cleavage site (i.e. pMP71:TCRα-
2A-TCRβ; (234)). All constructs were confirmed by DNA sequencing.
Retroviral gene transfer into T cells
Co-cultures of the packaging cells 293T and Phoenix-A were used to produce Moloney 
Murine Leukemia retroviruses. Packaging cells were calcium phosphate-transfected with 
pMP71:TCRα-2A-TCRβ and the helper vectors: pHIT60 and pCOLT-GALV. Transduction of 
human T cells was performed as described previously (43).
Flow cytometry
TCR-engineered primary human T cells were washed with PBS and incubated with gp100/
A2 peptide-HLA-tetramers for 15 min at RT or incubated with CD3ε-FITC, CD8α-PerCP, 
CD45RA-PE-Cy7, CD27-APC-Cy7, CD28-APC, CCR7-PE, CD107a-PE, and/or CD137-APC 
mAbs (up to 6 colors simultaneously) for 30 min on ice. Next, T cells were washed and 
fixed with 1% PFA (Brunschwig, Amsterdam, the Netherlands). CD107a expression was 
detected as described in chapter 3. Briefly, 2x105 T cells were re-suspended in a mixture of 
T cell medium, Golgistop and anti-CD107a mAb. Next, tumor target cells and T cells were 
mixed in a 1:1 ratio and incubated for 2h at 37 °C and 5% CO2. T cells were analyzed by flow 
cytometry using a FACSCalibur or a FACSCanto cytometer (BD Biosciences), equipped with 
Cell Quest or FACS DIVA software (BD Biosciences), respectively. Viable lymphocytes were 
gated according to forward and side scatter properties and data were analyzed within 
CD3+ or CD3+/CD8+ dual-positive T cells. Sets of T cell differentiation markers to define 
naïve, central memory, effector memory and end-stage T cells are provided in figure 5.7.
Measurement of cytokines
T cell release of cytokines was determined as described previously (131). BLM cells loaded 
without or with titrated amounts of gp100 peptide and a panel of melanoma cell lines 
were used as target cells. T cells (6x104) were incubated overnight with target cells in a 
3:1 ratio and tested in triplicate. IFNγ, IL-2 or TNFα levels present in supernatants were 
determined using a human IFNγ (Pelikine compact, Sanquin), IL-2 (U-cytech biosciences, 
Utrecht, The Netherlands) or TNFα (Pelikine compact, Sanquin) ELISAs, respectively, and 
a Titertek plus ELISA reader (Merlin, Breda, Netherlands) according to the manufacturer’s 
instructions.
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T cell counts
T cells were counted when harvested from feeder cultures and after 4 days of culture 
in IL-2 supplemented medium. Trypan blue exclusion was applied to determine T cell 
viability and viable T cells were counted microscopically using Bürker chambers and a 
LeitzLaburlux 12 microscope (Leica Geosystems BV, Rijswijk, The Netherlands).
Statistical analyses
Differences between affinity-enhanced and wt TCR or between APL and gp100 wt 
peptide were assessed for their significance with Student’s t-tests (unpaired; two-tailed, 
unless stated otherwise) using Graphpad Prism4 software. Differences with p-values 
<0.05 were considered significant.
RESULTS
Amino acid substitutions in CDR2β and CDR3α, but not CDR3β, resulted in 
enhanced binding of peptide-HLA by TCR-engineered T cells
Affinity-enhanced TCR variants were selected for gp100 peptide:HLA-A2 complex binding 
from phage libraries displaying TCRs with amino acid substitutions either in CDR2β, 3α or 
3β. We obtained and characterized 8 TCR variants with affinities that were 2 to 712-fold 
higher when compared to the parental wt TCR. TCRs were numbered 1 to 8 according to 
their KD values (range: 7.9 to 0.026 µM), which grouped affinity-enhanced TCR variants 
according to the CDR that contained amino acid substitutions (table 5.1). TCR gene trans-
fer in primary human T cells and flow cytometric analysis of TCRβ transgene expression 
revealed similar cell surface expression levels for all introduced TCRs, except for TCR 6 and 
8 (supplementary fig. 5.1). The latter two TCRs lost the epitope recognized by anti-TCR-Vβ19 
mAb due to CDR2β amino acid substitution(s) as also observed in reports of affinity-
enhanced NY-ESO-1/HLA-A2 TCRs (92), and is probably related to an asparagine to glycine 
substitution (i.e., N72G). Analyses of binding of titrated amounts of gp100/A2 peptide-HLA 
tetramers revealed significantly higher percentages and Mean Fluorescence Intensities 
(MFI) with T cells transduced with TCRs 6 to 8 when compared to T cells transduced with wt 
TCR (fold decrease in KD: 46 to 712). It is noteworthy that the observed ability of TCR6 and 8 
to bind gp100/A2 peptide-HLA tetramers provides phenotypical evidence for the surface 
expression of these two TCRs (figs. 5.1A and B). Interestingly, TCRs 1 and 2 (fold decrease 
in KD: 2 to 5) result in significantly increased MFI values, whereas TCRs 3 to 5 (fold decrease 
in KD: 7 to 17) did not result in improved binding of gp100/A2 peptide-HLA complexes.
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TCRs with a lower kD limit of 4 μM and amino acid substitutions in CDR3α 
demonstrated improved antigen-specific T cell functions
To investigate how TCR affinity relates to T cell sensitivity, we tested T cell IFNγ release fol-
lowing stimulations with titrated amounts of gp100 wt peptide. Findings are presented 
in figure 5.2 and demonstrated that TCRs 1, 2, 6, 7 and 8 mediate enhanced IFNγ release 
when compared to wt TCR at the lower end of peptide concentrations used (10-9, 10-8 
and 10-7 M of wt peptide). Notably, TCRs 1 and 2 were the only TCRs mediating antigen-
specific IFNγ release, i.e., showing no IFNγ release in the absence of peptide. TCRs 3 to 
5 showed no benefit when compared to wt TCR. In fact, these TCRs, as well as TCRs 6 to 
8, mediated a decreased IFNγ release when compared to wt TCR at the higher end of 
peptide concentrations used (10-6, 10-5, and 10-4 M of wt peptide) (fig. 5.2A). The half-
maximal effective concentrations (EC50), used as measures for T cell sensitivity, revealed 
2.3 and 4.4-fold increases in sensitivity for TCRs 1 and 2, respectively, when compared 
to wt TCR (fig. 5.2B). Although not entirely antigen-specific, TCRs 6 and 7 revealed 2.2-
fold increases in EC50, and, most notably, TCR 8 mediated a 1.4-fold increase. Analysis of 
CD107a surface expression in response to stimulation with titrated amounts of gp100 
wt peptide revealed similar differences among the different TCRs, although CD107a sur-
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Figure 5.1. Primary human T cells showed increased binding of peptide-HLA when expressing TCRs 
with enhanced affinity. Primary human T cells were transduced with empty virus particles (no TCR trans-
gene), a gp100/A2 specific wt TCR or affinity-enhanced TCR variants (TCRs 1 to 8; see table 5.1). Gene-
engineered T cells were stained with titrated amounts of gp100/A2 peptide-HLA tetramer (range: 10-12 to 
10-10 M) and analyzed by flow cytometry. (A) Percentages (%) and (B) Mean Fluorescence Intensities (MFI) 
of peptide-HLA tetramer binding is presented as curves connecting mean values +/- SEM for each TCR, n=4 
independent measurements. In (A) and (B) data of wt TCR are presented as a bold line. Similar results were 
obtained with a second healthy donor (data not shown). Statistically significant differences relative to wt 
TCR were calculated with Student’s t-tests: * = p<0.05; ** = p<0.005.
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face expression appeared less sensitive and hence less discriminative than IFNγ release 
(supplementary fig. 5.2).
We next questioned whether the observed changes for TCR variants in T cell sensitiv-
ity were related to loss of CD8αβ dependency. To address this issue, we first analyzed the 
ability of TCR variants to bind gp100/A2 peptide-HLA in the absence of CD8αβ (using 
CD4+ T cells). Experiments demonstrated that enhanced TCR affinity did not lead to a 
proportional increase of CD4 T cells that bind peptide-HLA tetramers (fig. 5.3A). In fact, 
the proportion of CD4 T cells binding peptide-HLA is fairly constant and similar to the 
proportion of total CD4 T cells following transduction with individual TCR variants. Sec-
ond, we analyzed the ability of the TCR variants to mediate IFNγ release in the absence of 
HLA-A2:CD8αβ binding. To this end, C1R-227/228KA cells that harbor mutated HLA-A2 
and are unable to bind CD8α (196) and wt C1R cells were loaded with gp100 wt peptide 
and used in T cell stimulation assays. All TCRs, including the wt TCR, triggered IFNγ re-
leases that were independent of the presence of CD8αβ binding (fig. 5.3B). Collectively, 
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Figure 5.2. TCRs 1 and 2 with a lower kD limit of 4 µM mediate enhanced sensitivity of antigen-spe-
cific IFNγ release. Primary human T cells transduced with wt or affinity-enhanced TCRs 1 to 8, as described 
in the legend to figure 5.1, were tested for their ability to produce IFNγ following stimulation with BLM 
melanoma cells that were either unloaded (no peptide) or loaded with titrated amounts of gp100 wt pep-
tide (range: 10-11 to 10-4 M). (A) IFNγ was measured in supernatants from overnight cultures by ELISA and 
expressed as pg/ml and (B) half maximal effective concentrations of gp100 wt peptide (EC50) were calcu-
lated with 4-parametric logistics using Masterplex ReaderFit software. Bars represent mean values + SEM, 
n=2 to 6 independent measurements. Similar results were obtained with a second healthy donor (data not 
shown). Statistically significant differences relative to wt TCR were calculated with paired Student’s t-tests: 
* = p<0.05, ** = p<0.005.
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these data suggest that the wt TCR, and consequently also the affinity-enhanced TCR 
variants, are able to bind peptide-HLA and activate T cells independently of CD8αβ.
TCRs with a lower kD limit of 4 μM and amino acid substitutions in CDR3α 
retained peptide-fine specificity
Next, we studied how TCR affinity relates to T cell specificity. To this end, we tested T cell 
IFNγ release following stimulations with gp100 altered peptide ligands (APL) contain-
ing alanine or glycine substitutions, as described by Schaft and colleagues (132). Wild 
type TCR recognized, in addition to wt gp100 peptide, APLs A1, A2, A4, A7, A8 and G9 
(fig. 5.4). Although APL A2 resulted in a significant increase in IFNγ release compared to 
medium stimulation, at the same time it also resulted in a clear and significantly reduced 
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Figure 5.3. Affinity-enhanced TCRs bind peptide-HLA and mediate IFNγ production independently 
of CD8. Primary human T cells transduced with wt or affinity-enhanced TCRs were (A) stained with both 
gp100 peptide-HLA-A2 and CD4 mAb and (B) tested for IFNγ production following stimulation with gp100 
wt peptide-loaded C1R and C1R-KA cells (final concentration of peptide: 10-5 M) (IFNγ levels expressed 
in pg/ml). In (A) stacked and grey bars show mean % of total T cells and CD4 T cells that bind gp100/A2 
peptide-HLA, respectively, n=4 independent measurements. For reasons of simplicity, SEM values (in all 
cases less than 10% of mean values) have been left out of figure. The % of CD4 T cells within total popu-
lation of T cells that bind gp100/A2 peptide-HLA has been indicated above the stacked bars. In (B) bars 
represent mean values + SEM, n=3 independent measurements. Similar results as those presented in (A) 
and (B) were obtained with a second healthy donor. Statistically significant differences relative to wt TCR 
were calculated with Student’s t-tests: ns = non-significant.
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IFNγ release compared to wt peptide. The wt TCR did not recognize APLs A3, A5 and A6 
(fig. 5.4). TCRs 1 and 2 were the only TCR variants that, identical to the wt TCR, recognized 
all APLs except A3, A5 and A6, and also showed a significantly lowered A2 response. 
TCRs 6 to 8, and to a lesser extent TCRs 3 to 5, lost peptide-fine specificity and were able 
to recognize APL A3, A5 and A6, with highest IFNγ levels produced upon stimulations 
with A5 and A6.
TCRs with kD values lower than 1 µM and amino acid substitutions in CDR2β 
resulted in peptide-independent but HLA-A2-dependent reactivity towards 
melanoma cells
To follow up on our findings with respect to sensitivity and specificity, we tested T cell 
IFNγ release following co-culture with a panel of melanoma cell lines. In line with our 
findings with gp100 wt peptide and APLs, TCRs 1 and 2 significantly enhanced IFNγ 
responses in co-culture with various gp100/A2-positive melanoma cells when com-
pared to wt TCR, but did not respond to melanoma cells lacking either HLA-A2 or gp100 
expression (fig. 5.5). TCRs 3 to 5 did not result in improved IFNγ responses, but rather 
showed a trend of reduced IFNγ release when stimulated with gp100/HLA-A2-positive 
melanoma cells. In addition, TCRs 3 and 5 mediated minor, but significant, reactivity 
towards gp100-negative and HLA-A2-positive melanoma targets. TCRs 6 to 8 produced 
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Figure 5.4. TCRs 1 and 2 with a lower kD limit of 4 µM preserve peptide-fine specificity of wt TCR. 
Primary human T cells transduced with wt or affinity-enhanced TCRs were tested for IFNγ release follow-
ing stimulation with BLM melanoma cells that were loaded with altered peptide ligands (APL, final con-
centration: 10-5M). APLs are coded by the letters A (alanine) or G (glycine) followed by a number, which 
corresponds to the amino acid and position that is altered in the wt gp100 peptide (YLEPGPVTA). T cell 
stimulations with wt gp100 peptide or no peptide were included as controls. Bars represent mean values 
+ SEM, n=3 to 5 independent measurements. Statistically significant differences relative to medium were 
calculated with paired Student’s t-tests. For reasons of simplicity, significant responses towards APLs (p-
values < 0.05) are indicated by asterisks and placed below the bars. Note that APL responses for wt TCR 
are all significant, except for A3, A5 and A6. This APL response is only preserved for TCRs 1 and 2, and non-
significant responses have reached significant in case of TCRs 6 to 8. P-values < 0.005 were observed for 
responses of wt TCR to G9; TCR 1 to wt peptide, A7, A8, and G9; TCR 5 to wt peptide, A1, A2, A4, A7, A8, and 
G9; and TCR 7 to A2 and A3.
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high and significantly enhanced IFNγ responses towards gp100/HLA-A2-positive 
melanoma cells, in some cases even more pronounced when compared to TCRs 1 and 2, 
but resulted in similarly high and significant responses to gp100-negative and HLA-A2-
positive melanoma cells. Identical responses for the TCR variants were observed when 
measuring IL-2 and TNFα release (supplementary figs. 5.3A and B).
CDR2β-mutated TCRs with kD values lower than 1 µM mediate constitutive 
activation when expressed in HLA-A2-positive T cells
The observed HLA-A2-driven reactivity of high affinity TCRs may prevent the use of 
these TCRs in a therapeutic setting. To address this issue, we have transduced TCRs 1-8 in 
both HLA-A2-negative as well as HLA-A2-positive and gp100-negative peripheral blood 
T cells. In a first series of experiments, we tested (constitutive) surface expression of 
the T cell activation markers CD107a and CD137 under standard culture conditions. We 
observed only marginal expression of both CD107a and CD137 in HLA-A2-negative pri-
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Figure 5.5. TCRs 1 and 2 with a lower kD limit of 4 µM result in enhanced reactivity towards antigen-
positive but not antigen-negative tumor cells. Primary human T cells gene-engineered with wt and 
affinity-enhanced TCRs were tested for IFNγ release following stimulation with melanoma cell lines that 
were either positive or negative for the gp100 antigen and/or HLA-A2. The presence or absence of gp100 
and HLA-A2 is indicated below the x-axis. Bars represent mean values + SEM, n=4 to 11 independent mea-
surements. Statistically significant differences relative to wt TCR were calculated with Student’s t-tests: * = 
p<0.05, ** = p<0.005, *** = p<0.0005.
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mary human T cells, which appeared independent of the TCR variant used (figs. 5.6A and 
B). In contrast, we observed significantly increased expression of CD107a and CD137 
for TCR 6 to 8 in HLA-A2-positive T cells, suggesting reactivity towards HLA-A2-positive 
neighboring T cells. Next, we analyzed a panel of T cell differentiation markers, including 
CD45RA, CD27, CD28 and CCR7 (77, 235), previously used by our group to assess the dif-
ferentiation status of gp100/A2 TCR-engineered human T cells (236). CD8-positive T cell 
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Figure 5.6. HLA-A2-positive T cells expressing TCRs with kD values lower than 1 µM constitutively 
up-regulate expression of CD107 and CD137. HLA-A2-positive and negative primary human T cells were 
gene-engineered with wt and affinity-enhanced TCRs analyzed by flow cytometry for (A) CD107a expres-
sion (MFI) on CD3-positive T cells and (B) CD137 (%) on CD3-positive T cells that bound gp100/A2 peptide-
HLA. Bars represent mean values + SEM, n=3 to 5 independent measurements. Statistically significant dif-
ferences relative to wt TCR were calculated with Student’s t-tests: * = p<0.05, ** = p<0.005.
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populations showed, irrespective of HLA-A2 status, low fractions of naïve (Tn) and central 
memory T cells (Tcm) and high fractions of effector memory (Tem) and end-stage T cells 
(Tes) (figs. 5.7A and B, see inset for a definition of T cell subsets). T cells engineered with 
wt TCR, TCR 1 or 2 revealed similar fractions of Tem and Tes in both HLA-A2-positive and 
negative T cells. TCRs with nM affinities, however, mediated significant increases in the 
fractions of Tem and decreases in the fractions of Tes in HLA-A2-positive but not negative 
T cells. In addition to mediating an enhanced fraction of Tem, TCRs 6 to 8 also mediated 
decreased T cell growth in HLA-A2-positive T cells, which was only observed for TCR 6 
but not for TCRs 7 and 8 in HLA-A2-negative T cells (supplementary fig. 5.4).
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Figure 5.7. HLA-A2-positive T cells expressing TCRs with kD values lower than 1 µM show enhanced 
numbers of effector memory CD8 T cells. Primary human T cells gene-engineered with wt and affinity-
enhanced TCRs being (A) HLA-A2 positive or (B) HLA-A2 negative were stained for CD3, CD8, CD27, CD28, 
CD45RA, and CCR7 and expression levels were measured by flow cytometry. Naïve T cells (Tn), central mem-
ory T cells (Tcm), effector memory (Tem), and end-stage T cells (Tes) are defined by a combination of markers 
mentioned in inserts (see also (235, 236)). Sum of fractions of T cells defined by these markers (range: 71-
94% of CD3, CD8-positive T cells) was set to 100%. Bars represent mean values + SEM, n=4 independent 
measurements. Statistically significant differences relative to wt TCR were calculated with Student’s t-tests: 
* = p<0.05, ** = p<0.005.
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DISCUSSION
In this study, we have determined the antigen sensitivity and specificity of affinity-
enhanced TCR variants, specific for gp100280-288/HLA-A2, that harbor amino acid substitu-
tions restricted either to CDR2β, 3α or 3β (table 5.1). With this panel of TCR variants, 
we were able to demonstrate that (I) amino acid substitutions in CDR2β and 3α, and 
KD values between 18.5 and 4 µM and below 1 µM, enhanced binding of peptide-HLA 
by T cells; (II) amino acid substitutions in CDR3α, and KD values between 18.5 and 4 
µM, resulted in enhanced tumor-specific T cell functions without loss of antigen- and 
peptide-fine specificity; and (III) amino acid substitutions in CDR2β, and KD values lower 
than 1 µM, resulted in antigen-independent activation and differentiation of T cells from 
an HLA-A2-positive donor.
Not all affinity-enhanced gp100/A2 reactive TCRs demonstrated an improved bind-
ing of peptide-HLA by T cells (fig. 5.1). In fact, TCRs with KD values between 1-4 µM, in 
particular when containing a change of a proximal isoleucine to tyrosine in CDR3β (table 
5.1; TCR 4: IGG into YGA), adversely affected peptide-HLA binding and T cell function 
(figs. 5.1B and 5.2). This observation argues that affinities of soluble TCRs do not simply 
translate to avidities of TCR-transduced T cells, which is governed not only by the TCR and 
its cellular surface density but also by accessory, co-receptor and adhesion molecules. 
Moreover, we observed that optimal functional T cell avidity towards gp100/A2-positive 
target cells, as measured by IFNγ release responses towards titrated amounts of peptide 
and native melanoma cell lines (figs. 5.2 and 5.5), was conferred by TCRs that harbored 
CDR3α amino acid substitutions with affinities no lower than 4 µM. In particular TCR 2 
revealed decreased EC50 values of peptide responses and enhanced levels of IFNγ, IL-2 
and TNFα release in response to antigen-positive melanoma cells when compared to wt 
TCR (figs. 5.2B and 5.5, and supplementary figs. 5.3A and B). Enhanced antigen-specific 
T cell responses were less apparent when looking at T cell cytotoxicity (supplementary 
fig. 5.2), which may be in agreement with the notion that T cell IFNγ release is a more 
sensitive readout than T cell cytotoxicity (237). Together, these data suggest that CDR 
amino acid substitutions that improve peptide-HLA binding as measured by BIAcore do 
not necessarily provide improved T cell function, and extend previous reports showing 
a lack of correlation between peptide-HLA binding of T cells and functional avidity of T 
cells (91, 92).
A pertinent question is whether TCR 2 with a KD of 4 µM represents a functional 
threshold for affinity enhancement. It is hypothesized that affinities above a pre-set 
threshold, reflected by KD values around 6 µM, induce thymocyte selection and activa-
tion at a same rate resulting in an ‘all-or-nothing’ quality of TCR/CD8 associations and 
TCR-mediated signaling (89, 238). As for thymocytes, activation of cytotoxic T cells may 
also require an optimal dwelling time between TCR and peptide-HLA (239). Studies 
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with primary human T cells transduced with affinity-enhanced TCRs directed against 
NY-ESO-1/HLA-A2 (240) or gp100/HLA-A2 (this report) point to the existence of a KD 
threshold of around 4 to 5 µM. TCR 2 contained a triple amino acid substitution in its 
CDR3α that was centered around a leucine (table 5.1: DLV into SMQ). Notably, Sami and 
colleagues have demonstrated that leucine substitutions in CDR3α may favour interac-
tions with CDR1α and 2α residues such that the overall stability of the TCR:peptide-HLA 
complex is enhanced (241), a scenario that may account for the properties found for TCR 
2. Functional support for the existence of an affinity threshold comes from studies by 
Carreño and colleagues, who demonstrated that APLs responsible for low half-lives of 
TCR:peptide-HLA interactions, in analogy to self-peptide-HLA ligands, are able to induce 
T cell polarization but not assembly of functional synapses (242). Consequently, these 
low affinity interactions only result in partial proximal TCR signaling that is sufficient to 
deliver tonic signals essential for T cell persistence (89). Foreign peptide-HLA ligands, on 
the other hand, are of high affinity and are able to promote the assembly of functional 
synapses and result in complete proximal TCR signaling that is sufficient to evoke T cell 
effector functions (89, 242).
A second question is why T cell functions for TCRs with KD values lower than 4 µM 
become compromised (as depicted in figure 5.2). This appears to be counterintuitive as 
high-affinity TCRs are generally expected to result in a decreased requirement for CD8α 
and enhanced T cell responsiveness (92, 153, 224, 228, 231). Using our panel of TCR vari-
ants, we were neither able to show different binding of gp100 peptide-HLA nor IFNγ 
release of T cells in the absence of an interaction between CD8αβ and HLA-A2 (fig. 5.3). 
We cannot exclude, however, that titrated levels of peptide-MHC-tetramers or gp100 
wt peptide in these assays would potentially provide a window of CD8 dependency. An 
explanation for the compromised T cell functions may come from the off rate constant 
(Koff). The decrease in KD values in our panel of TCRs, with KD defined as the ratio between 
Koff and on rate constant (Kon), appears to be predominantly a consequence of decreased 
Koff values rather than increased Kon values (table 5.1). TCRs 6 to 8 show the lowest Koff 
values (on average: 0.0301/min) and may be less prone to dissociate from peptide-HLA, 
which may decrease the ability of the TCR to be serially triggered and consequently 
decrease the ability of the T cell to respond to antigen. Along this line it is noteworthy 
that lowered antigen-specific T cell functions, as mediated by TCRs 6 to 8, could not 
be compensated by higher peptide densities. In addition to our in vitro studies, in vivo 
studies have demonstrated that high-affinity TCR:peptide-HLA interactions are not a 
prerequisite for T cell activation, but rather required for sustained T cell expansion (241). 
Importantly, intermediate-affinity rather than high-affinity ligands provided optimal T 
cell responses to immunization, observed for both CD8-positive T cells (KD values for 
intermediate affinity ligands around 3 µM) (244) and CD4-positive T cells (KD values for 
intermediate affinity ligands around 44 µM) (245).
Coen BW1.indd   115 15-Aug-13   11:37:56 AM
116 Chapter 5
In addition to T cell sensitivity, we assessed the antigen and peptide-fine specific-
ity of affinity-enhanced TCRs. Using APLs derived from the gp100 wt peptide, we 
demonstrated that the wt TCR was not able to trigger a response towards APL A3, A5 
and A6, a recognition pattern that was preserved by TCRs 1 and 2. Since these TCRs 
contain CDR3α substitutions, and CDR3 amino acid substitutions have been shown to 
enhance TCR:peptide-HLA interactions specifically by improving peptide binding (241), 
we speculate that amino acid substitutions in CDR3 are more advantageous when com-
pared to those in CDR2 with regard to retaining peptide-fine specificity. Higher affinity 
TCRs, however, revealed a gradual loss of peptide-fine specificity and, in particular, TCRs 
6 to 8 displayed clear IFNγ responses upon stimulation with APLs A3, A5, and A6 (fig. 
5.4). In addition, TCRs 6 to 8 revealed IFNγ, IL-2 and TNFα responses when stimulated 
with a panel of gp100-negative and HLA-A2-positive native melanoma cells (fig. 5.5 and 
supplementary fig. 5.3). Previous reports have demonstrated that amino acid substitu-
tions in CDR2β may result in reactivity against self or allo-peptide-HLA (92, 224). Thus, 
TCRs 6 to 8 may show affinities against self-peptides that are in a more optimal affinity 
range explaining the responsiveness to HLA-A2-positive T cells. Our finding of an affinity 
perimeter related to self-reactivity, i.e., a KD less than 1 µM, is in close accordance with 
previous studies that report upper affinity limits for antigen-specificity of around 0.5-
3.0 µM (224, 231). To further assess how data on high affinity TCRs would extend to a 
therapeutic setting, we transferred our TCRs in PBMC derived from an HLA-A2-positive 
donor. TCRs 6 to 8 confer significant T cell activation and differentiation in the absence 
of target cells (figs. 5.6 and 5.7). Notably, TCRs 6 to 8 mediated minor cytotoxic T cell 
activity (about 20%) when using non-transduced HLA-A2-positive T cells as target cells 
(data not shown). Collectively, these results show that T cells that express TCRs 6 to 8 
display an inherent reactivity towards HLA-A2 that is independent of gp100 peptide and 
clearly argue against the use of very high affinity TCRs for TCR gene therapy.
Taken together, our studies with affinity-enhanced gp100/HLA-A*0201 TCR demon-
strate that perimeters of TCR affinities that determine gain of function (here KD down to 
4 µM) are different from those that determine gain of self-reactivity (here KD lower than 1 
µM), and are in this study best captured by CDR3α amino acid substitution(s), providing 
a window to generate functionally enhanced and safe therapeutic T cells.
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SUPLEMENTARY FIGURES
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Supplementary figure 5.1. Surface expression of affinity-enhanced TCRs on primary human T cells. 
Primary human T cells transduced with wt or affinity-enhanced TCRs 1 to 8, as described in the legend to 
figure 5.1, were stained with anti-TCR-Vβ19-PE mAb and analyzed for surface expression of transgenic TCRβ 
via flow cytometry. Dot plots from a representative measurement (n=12) are shown including % and MFI 
values (italic) of TCR-positive T cells that were corrected for corresponding non-stained values (marker M1 
set at ~1%). Similar results were obtained with a second healthy donor (data not shown).
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Supplementary figure 5.2. TCRs with kD values lower than 1 µM mediated enhanced yet antigen non-
specific CD107a mobilization. Primary human T cells transduced with wt or affinity-enhanced TCRs were 
tested for their ability to up-regulate surface expression of CD107a following stimulation with BLM mela-
noma cells that were either unloaded (no peptide) or loaded with titrated amounts of wt gp100 peptide 
(range: 10-5 to 10-11 M). CD107a mobilization was measured via flow cytometry and expressed as MFI of 
CD107a staining in CD3-positive cells. Bars represent mean values + SEM, n=3-4 independent measure-
ments. Similar results were obtained with a second healthy donor. Statistically significant differences rela-
tive to wt TCR were calculated with Student’s t-tests: * = p<0.05, ** = p<0.005, *** = p<0.0005.
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Supplementary figure 5.3. TCRs with a lower kD limit of 4 µM resulted in enhanced IL-2 and TNFα 
production towards antigen-positive but not antigen-negative tumor cells. Primary human T cells 
transduced with wt or affinity-enhanced TCRs were tested for (A) IL-2 and (B) TNFα production following 
stimulation with melanoma cell lines that were either positive or negative for the gp100 antigen and/or 
HLA-A2. The presence or absence of gp100 and HLA-A2 is indicated below the x-axes. Bars represent mean 
values + SEM, n=3 independent measurements.
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Supplementary figure 5.4. TCRs with kD values less than 1 µM mediated reduced T cell growth. HLA-
A2-positive and negative primary human T cells were gene-engineered with wt and affinity-enhanced TCRs 
and assessed for T cell growth. T cells were harvested from feeder cultures and numbers of viable T cells 
were counted microscopically and expressed as fold increase. Bars represent mean values + SEM, n=3-
19 independent measurements. Statistically significant differences relative to wt TCR were calculated with 
Student’s t-tests: * = p<0.05, ** = p<0.005, *** = p<0.0005.
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ABSTRACT
T cell sorting technologies with peptide-MHC multimers or antibodies against gene 
markers enable enrichment of antigen-specific T cells and are expected to enhance 
therapeutic efficacy of clinical T cell therapy. However, a direct comparison between 
sorting reagents for their ability to enrich T cells is lacking. Here, we compared the in 
vitro properties of primary human T cells gene-engineered with gp100280-288/HLA-A2 
specific TCRαβ upon Magnetic Activated Cell Sorting (MACS) with different peptide-MHC 
multimers or an antibody against truncated CD34 (tCD34). With respect to peptide-MHC 
multimers, we observed that streptamers, when compared to pentamers and tetramers, 
improved T cell yield as well as level and stability of enrichment of TCR-engineered T 
cells (> 65% of peptide-MHC-binding T cells, stable for at least 6 weeks). In agreement 
with these findings, streptamers, the only detachable reagent, revealed significant T cell 
expansion in the 1st week after MACS. Sorting TCR and tCD34 gene-engineered T cells 
with CD34 mAb resulted in the most significant T cell yield and enrichment of T cells 
(> 95% of tCD34 T cells, stable for at least 6 weeks). Notably, T cells sorted with CD34 
mAb, when compared to streptamer, bind about two to three-fold less peptide-MHC 
but show superior antigen-specific up-regulated expression of CD107a and production 
of IFNγ. Multi-parameter flow cytometry revealed that CD4 T cells, uniquely present in 
CD34 mAb-sorted T cells, contributed to enhanced IFNγ production. Taken together, we 
postulate that CD34 mAb-based sorting of gene-marked T cells has benefits towards 
applications of T cell therapy, especially those that require CD4 T cells.
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INTRODUCTION
Adoptive therapy with tumor-infiltrating T cells, preceded by lymphodepletion, shows 
significant clinical responses in melanoma patients (27, 111). In an effort to make T cell 
therapy a more universally applicable treatment, T cells have been gene-engineered 
to express virus and tumor-specific T cell receptors (TCR). T cells transduced with TCRs 
directed against the HLA-A2-restricted antigens MART-1, gp100, CEA or NY-ESO-1 have 
been tested in clinical trials and clinical responses have been observed in patients 
with metastatic melanoma, colorectal and synovial carcinoma (32, 40, 45, 46). Clinical 
responses, although variable and based on a relatively small number of patients, are 
promising but generally lag behind those observed with tumor-infiltrating T cells (27, 
111). The clinical use of high-affinity TCRs enhances response rates and may provide a 
means to improve clinical responses (32, 45). However, high-affinity TCRs, when directed 
against differentiation antigens that are over-expressed on tumors but also present, 
albeit to a small extent, on normal tissues, result in on-target toxicities (40, 45). An alter-
native strategy to enhance functional responses of T cells is to enhance the frequency of 
TCR-transduced T cells. The threshold antigen concentration for T cell activation corre-
lates inversely with the level of TCR expression in T cell populations (246, 247), providing 
a rationale for the enrichment of TCR-transduced T cells prior to their clinical use. T cell 
populations used in TCR gene therapy studies generally demonstrated a peptide-MHC 
binding of about 62%, being in some cases as low as 3% and in some cases as high as 
97%, which presents a window for further improvement (32, 45, 46).
Magnetic Activated Cell Sorting (MACS) was developed from the late seventies 
onwards (248, 249) and now represents an established technology to enrich cells that 
is compatible to conditions of Good Medical Practice and can be applied in clinical 
cellular therapy trials (250-252). When MACS is used in combination with peptide-MHC 
multimers, this technology provides a versatile and potent platform to enrich T cells with 
a defined antigen-specificity. In example, T cells specific for multiple antigens, such as 
CMV, EBV1-3, Flu1 and MART-1 antigens, can be enriched using peptide-MHC tetramers 
from a single sample (253). Also, MART-1/HLA-A2-specific T cells have been enriched up 
to a 1000-fold from Peripheral Blood Mononuclear Cells (PBMCs) and tumor infiltrating 
lymphocytes from patients with metastatic melanoma without loss of in vitro reactivity 
(254). Currently, various forms of peptide-MHC multimers exist of which tetramers (180), 
pentamers (63), and streptamers (255, 256) represent the ones most extensively charac-
terized. These peptide-MHC multimers differ in avidity and reversibility of binding to T 
cells (as detailed in table 6.1) and it is currently not known how these reagents compare 
to one another with respect to MACSort of T cells. In addition to peptide-MHC multim-
ers, a surrogate gene marker such as truncated (t)CD34 (257) can be applied to enrich T 
cells with CD34 mAb-based MACS (258). Co-transduction of tCD34 and a Herpes Simplex 
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Virus thymidine kinase (HSVtk) suicide gene in T cells, to allow ganciclovir-mediated 
elimination of alloreactive gene-modified T cells, and subsequent MACS resulted in T 
cell populations that were highly enriched for both tCD34 and HSVtk (259).
In this paper, we have compared tetramers, pentamers, streptamers and CD34 mAb 
for their ability to enrich TCR-engineered T cells (figure 6.1 provides a schematic repre-
sentation of sort reagents used in our study). To this end, we gene-transduced human T 
cells with a gp100280-288/HLA-A2 (gp100/A2) TCR and tested the different sort reagents for 
T cell output numbers, T cell yield at later time points, T cell expansion, enrichment for 
peptide-MHC binding and gp100/A2-specific functions. With respect to peptide-MHC 
multimers, streptamers significantly enhanced T cell yield, expansion and enrichment of 
peptide-MHC-binding T cells. MACS with CD34 mAb resulted in significant T cell yield, 
expansion and enrichment of tCD34-positive T cells, but not a significant enrichment 
of peptide-MHC-binding T cells. Notably, CD34 mAb-sorted T cells demonstrated en-
hanced antigen-specific T cell functions, which were related to CD4 T cells that were 
uniquely present in CD34 mAb-sorted T cells.
Table 6.1. Reagents used to MACSort TCR-engineered T cellsa
Sort reagent Label 2nd step sort 
reagent
TCR 
transgenes
Concentrationf 
(ng/107 T cells)
pMHC 
valency
Detachable 
binding
Key 
reference(s)
gp100/A2 
tetramerb
R-Phycoerythrin Anti-PE 
microbeads
TCRαβ 700 4 No (180)
gp100/A2 
pentamerc
R-Phycoerythrin Anti-PE 
microbeads
TCRαβ 500 5 No (63)
gp100/A2 
streptamerd
R-Phycoerythrin Anti-PE 
microbeads
TCRαβ 200 8-12 Yesg (255, 256)
CD34 mAb 
microbeadse
- - TCR-tCD34 N.D. None No (258)
a Overview of specific characteristics of different sort reagents to enrich TCR-engineered T cells. N.D.: Not 
Determined.
b Tetramers contain 4 biotinylated peptide-MHC monomers, which are multimerized with streptavidin-PE 
to form a tetrahedral complex. A maximum of 3 peptide-MHC molecules are available per focal plane (260).
c Pentamers contain 5 peptide-MHC-PE monomers, which are multimerized through a coiled-coil structure. 
All 5 peptide-MHC molecules are available per focal plane (260).
d Streptamers contain between 8-12 streptagged peptide-MHC monomers, which are multimerized with 
streptactin-PE.
e CD34 mAb is directly coupled to magnetic microbeads.
f Concentrations of peptide-MHC multimers are based on molecular weight provided by manufacturers
g Release of peptide-MHC monomers is established by addition of an excess of D-biotin that has an high 
affinity for streptactin (Kd value of ~10
-13 M; (256)).
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MATERIALS AND METHODS
Cells and reagents
T lymphocytes derived from healthy donors were isolated and expanded as described 
elsewhere (179) and cultured in HEPES-buffered RPMI 1640 medium (BioWhittaker, 
Verviers, Belgium) supplemented with 10% human serum, 2 mM L-glutamine, and the 
antibiotics streptomycin and penicillin. The human embryonic kidney cell line 293T, 
TCR transgenes
TCR
TCR-tCD34
Vα J Cα
Vα J Cα
Vβ JD Cβ
Vβ JD CβtCD34 2A2A
A
B
Figure 6.1. Gene-constructs and sorting reagents to MACSort TCR-engineered human T cells. (A) 
Schematic representation of TCRα, TCRβ and TCRα-2A-tCD34-2A-TCRβ transgenes used to gene-engineer 
primary human T cells. TCR specific for gp100/A2 comprised TRAV13-1*02/J52*01/CA and TRBV27*01/J2-
7*01/D2*02/CB2 (132). tCD34 represents a truncated and functionally inert variant of CD34. T cells were 
transduced either with pBullet:TCRα + pBullet:TCRβ and termed TCR T cells or pBullet:TCRα-2A-tCD34-2A-
TCRβ and termed TCR-tCD34 T cells. Abbreviations used: V: TCRαβ-variable domain; C: TCRαβ-constant 
domain; D: TCRβ-diversity domain; J: TCRαβ-joining domain; 2A: 2A sequence coding for a self-cleaving 
peptide; tCD34: truncated CD34 molecule. (B) Schematic illustration of reagents used to MACSort TCR-
engineered human T cells. From left to right: tetramer (180), pentamer (63), streptamer (255, 256); and CD34 
mAb (258). Tetramers consist of 4 gp100 peptide (YLEPGPVTA)/HLA-A2 (gp100/A2) monomers that were 
biotinylated and multimerized with streptavidin-Phycoerythrin; pentamers consist of 5 gp100/A2 mono-
mers that were linked to Phycoerythrin and multimerized by a self-assembling, coiled-coil structure; and 
streptamers consist of 8-12 gp100/A2 monomers that were streptagged and multimerized with streptac-
tin-Phycoerythrin (depicted with 5 monomers). Anti-CD34 mAbs consist of heavy and light-chains provid-
ing 2 antigen-binding sites and are directly coupled to magnetic microbeads.
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the packaging cell line Phoenix-A, and the melanoma cell lines BLM and FM3 were 
cultured in DMEM medium (BioWhittaker) supplemented with 10% fetal bovine serum 
(FBS, Stonehouse, Gloucestershire, UK), 2 mM L-glutamine, non-essential amino acids 
and antibiotics. Monoclonal Abs used in this study are: anti-CD34 microbeads (clone: 
QBEND/10, Miltenyi Biotec, Bergisch Gladbach, Germany); anti-PE microbeads (Miltenyi 
Biotec); FITC- and PE-conjugated anti-TCR-Vβ27 (Beckman Coulter, Marseille, France); 
APC- and non-conjugated anti-CD3ε (OKT3, BD Biosciences, San Jose, USA, and Beckman 
Coulter, respectively); APC-conjugated anti-CD8α (RPA-T8, BD Biosciences); FITC-conju-
gated anti-CD34 (AC136, Miltenyi Biotec, Bergisch Gladbach, Germany); PE-conjugated 
anti-CD107a (H4A3, BD Biosciences); FITC-conjugated anti-IFNγ (B27, BD Biosciences); 
FITC-conjugated anti-IL-2 (MQ1-17H12, BD Biosciences); and FITC-conjugated anti-IL2Rα 
(M-A251, BD Biosciences). Other reagents included: Retronectin (human fibronectin 
fragments CH-296, Takara Shuzo Co. Ltd., Otsu, Japan); PMA (Sigma-Aldrich, St. Louis, 
USA); PHA (Remel Europe, Dartford, England); gp100 peptide (YLEPGPVTA) (Proim-
mune); Golgistop (BD Biosciences); Golgiplug (BD Biosciences); and PFA (Brunschwig, 
Amsterdam, the Netherlands).
TCR and tCD34 transgenes
TCRαβ specific for gp100/A2 was derived from CTL clone 296 and uses the TCR-V genes 
TRAV13-1*02/J52*01/C and TRBV27*01/J2-7*01/D2*02/C2 (nomenclature according to 
http://imgt.org) (132). TCRα and TCRβ chains were cloned in pBullet vectors either as 
single TCR chains (i.e., pBullet:TCRα + pBullet:TCRβ (132)) or combined TCRα and TCRβ 
chains and linked by 2A sequences and truncated CD34 (i.e., pBullet:TCRα-2A-tCD34-2A-
TCRβ). See figure 6.1A for a schematic representation of TCR transgenes. Truncated CD34, 
a naturally occurring splice variant of human CD34 that lacks Protein Kinase C binding 
sites in its cytoplasmic tail (257), was flanked by 2A sequences (kindly provided by Dr. 
Gilham, University of Manchester, Manchester, UK), and introduced into pBullet vector 
via PCR and a NcoI ligation. Primers used to amplify 2A-tCD34-2A are: tCD34 5’ primer: 
attcggccatggcggggcgcgcccgctcgagcgagtgaaacagactttgaat; tCD34 3’ primer: acgcgtc-
caagcttggcaattgattccctggcccggggttggactc, and introduced additional restriction sites 
that allowed subsequent introduction of TCRα and TCRβ chains in pBullet:tCD34. TCRα 
and TCRβ were sub-cloned via NcoI/XhoI and MfeI/MluI into pBullet:tCD34, respectively.
Retroviral gene transfer into T cells
Moloney Murine Leukemia retroviruses, positive for TCR and TCR-tCD34, were produced 
by co-cultures of the packaging cells 293T and Phoenix-A. Packaging cells were calcium 
phosphate-transfected with pBullet:TCRα + pBullet:TCRβ or pBullet:TCRα-2A-tCD34-2A-
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TCRβ, and the helper vectors: pHIT60 MLV GAG/POL and pCOLT-GALV ENV. Transduction 
of human T cells was performed as described previously (71).
Peptide-MHC complexes
Complexes of gp100280-288/HLA-A*0201 (gp100/A2) peptide-MHC used in this study 
are tetramers, pentamers and streptamers. Tetramers were generated by multimeriza-
tion of 5 µg biotinylated monomers (Sanquin, Amsterdam, Netherlands) with 12.5 µl 
streptavidin-PE (BD Biosciences), which were mixed and incubated for 40 min at 4 ºC. 
Streptavidin-PE was added and mixed in steps of 2.5 μl that were followed by incubations 
of 8 min; Pentamers were purchased as PE-conjugated multimers (ProImmune, Oxford, 
UK); Streptamers were generated by multimerization of 1 µg of streptagged monomers 
(IBA, Göttingen, Germany) with 0.75 µg streptactin-PE (IBA) in 50 µl buffer (PBS with 
0.5% BSA, 2 mM EDTA, and pH 7.4), which were mixed and incubated for 45 min. Sort 
reagents, during preparations and once ready, were kept at 4 ºC and protected from 
light. Concentrations of tetramers, pentamers and streptamers for use in flow cytometry 
were determined per batch by serial dilutions and set at 1:100, 1:20, and undiluted, 
respectively. See figure 6.1 for a schematic representation of peptide-MHC reagents, and 
table 6.1 for properties and usage of peptide-MHC multimers in MACS.
MACS to enrich gene-engineered T cells
Human T cells were labeled either with PE-conjugated peptide-MHC multimers and 
microbead-conjugated PE mAb or microbead-conjugated CD34 mAb according to the 
manufacturer’s instructions (Miltenyi Biotec). In case of peptide-MHC multimer stain-
ings, reagents were added to cell pellets (see table 6.1 for final concentrations) and 
incubated for 45 min (all solutions were ice-cold and all incubations were performed at 
4 ºC and protected from light). T cells were washed twice with PBS-0.5% BSA (pH 7.4), re-
suspended in PBS-0.5% BSA with PE mAb microbeads (volume ratio 4:1) and incubated 
for 15 min. In case of CD34 mAb stainings, T cells were washed with PBS, re-suspended 
in PBS-0.5% BSA with CD34 mAb microbeads and FcR-blocking reagent (volume ratio 
5:1:1) and incubated for 30 min. Microbead-labeled T cells were washed, re-suspended 
in PBS-0.5% BSA, passed over a MACS pre-separation filter and separated in MACS 
separation columns that were exposed to a magnetic field. Sorted T cells were washed 
and subsequently flushed from the column with PBS-0.5% BSA. In case of streptamers, 
sorted T cells were treated twice with 1 mM biotin-D (Invitrogen, Carlsbad, USA) for 20 
min and washed repeatedly. Finally, sorted T cells were counted and cultured on feeder 
cells (1x104 T cells / 200 µl feeder medium (179)).
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T cell counts
T cells were counted directly after MACS, 1 week after MACS, and weekly up to 6 weeks 
after MACS. T cell viability was determined by trypan blue exclusion and viable T cells 
were counted microscopically using Bürker chambers and a Leitz Laburlux 12 micro-
scope (Leica Geosystems BV, Rijswijk, The Netherlands). T cell yields and expansions are 
represented as absolute numbers or fold increases in cell numbers, respectively.
Flow cytometry
All T cell stainings were performed according to standard protocols. T cells (1x104 cells) 
were incubated with peptide-MHC multimers for 15 min at RT or mAbs for 30 min on ice, 
and fixed with 1% PFA. To measure antigen-specific T cell responses, T cells were stimu-
lated with target cells and assessed for surface expression of CD107a and intracellular 
expression of IFNγ and IL-2. Target cells used were BLM (without or with 10-5 M gp100 
peptide) and FM3 cells. CD107a expression was detected as described in chapter 3. Briefly, 
T cells were re-suspended in a mixture of T cell medium, Golgistop, and CD107a mAb-PE. 
Next, target cells and T cells were mixed in a 1:1 ratio and incubated for 2h at 37 °C and 
5% CO2. T cells were subsequently stained with CD3ε mAb to allow distinction of T cells 
from target cells at the time of analysis. Intracellular cytokine levels were detected in T 
cells (2x105) that were stimulated with target cells (6x104) in the presence of Golgiplug 
for 6 h at 37 °C and 5% CO2. Next, T cells were washed and stained with CD8α mAb-APC, 
after which T cells were washed again, permeabilized (permeabilization solution 2, BD 
Biosciences) for 10 min at RT, and stained with IFNγ mAb-FITC or IL-2 mAb-FITC. Samples 
were measured on a FACSCalibur dual-laser flow cytometer (Beckton Dickinson, Alphen 
a/d Rijn, the Netherlands). Data analysis was performed on viable and in some cases 
CD3-positive T cells using Cellquest software (BD Biosciences), and data was displayed 
either as dotplots or histograms.
IFNγ production
T cells were assayed for their IFNγ production as described previously (131). BLM mela-
noma cells, without or with titrated amounts of gp100 peptide (between 10-10 and 10-5 
M) and FM3 melanoma cells were used to stimulate T cells and O/N supernatants were 
tested in triplicate. T cell IFNγ levels were determined using ELISA (Sanquin) and a Titertek 
plus reader (Merlin, Breda, Netherlands) according to the manufacturer’s instructions.
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Statistical analyses
Student’s t-tests (unpaired; two-tailed) and Graphpad Prism 4 software were used to test 
the various sort reagents with respect to in vitro properties of T cells. Differences with 
p-values <0.05 were considered significant.
RESULTS
MACS with streptamers or CD34 mAb results in enhanced T cell yield and 
expansion
Primary human T cells were transduced with gp100/A2-specific TCR and TCR-tCD34 genes 
and MACSorted with tetramers, pentamers, streptamers or CD34 mAb. Flow cytometry 
analyses showed that pre-sort TCR T cells labeled similarly with the various peptide-MHC 
multimers, which extends an earlier report by Yao and colleagues (260). In addition, TCR 
and TCR-tCD34 T cells showed comparable binding of peptide-MHC multimers (data not 
shown). MACS of TCR T cells or TCR-tCD34 T cells with peptide-MHC multimers (input 
for all labeling conditions: 10x106 T cells) resulted in comparable numbers of T cells 
directly after MACS (output: 0.07-0.41x106 T cells), whereas MACS of TCR-tCD34 T cells 
with CD34 mAb (input again: 10x106 T cells) resulted in significantly enhanced numbers 
of T cells (output: 1.0x106 T cells; fig. 6.2A). MACS of TCR-tCD34 T cells with CD34 mAb 
also resulted in the highest yield of T cells at 1 week after MACS (22.7x106 T cells), which 
was significantly higher when compared to MACS of TCR-tCD34 T cells with streptamers 
(2.5x106 T cells; fig. 6.2B). The increased yield of CD34-mAb sorted T cells was due to both 
enhanced T cell numbers directly after MACS and enhanced T cell expansion in the 1st 
week after MACS (figs. 6.2A and C). MACS of TCR T cells with streptamers resulted in a 
significantly enhanced yield of T cells at 1 week after MACS (9.7x106 T cells) when com-
pared to tetramers and pentamers (3.1 and 0.9x106 T cells, respectively; fig. 6.2B). The 
increased yield of streptamer-sorted T cells was primarily due to enhanced T cell expan-
sion in the 1st week after MACS (fig. 6.2C) rather than enhanced T cell numbers directly 
after MACS (fig. 6.2A). Notably, streptamer-sorted TCR-tCD34 T cells, when compared to 
streptamer-sorted TCR T cells, yielded lower T cell numbers, which appeared related to a 
reduced T cell expansion in the 1st week after MACS (figs. 6.2A and B). When analyzing T 
cell yields at later time points, i.e. between 3 to 6 weeks after MACS, we observed clear 
T cell expansion rates (weekly T cell expansion > 10 fold) with no differences observed 
between the sort reagents (fig. 6.2C).
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Figure 6.2. MACS with streptamer or CD34 mAb improves T cell yield. Primary human T cells were trans-
duced either with TCR or TCR-tCD34 transgenes as depicted in figure 6.1A. TCR T cells were MACSorted with 
tetramers, pentamers, and streptamers, whereas TCR-tCD34 T cells were MACSorted with streptamers and 
CD34 mAbs. Following MACSort, T cell numbers were counted microscopically and T cells were expanded 
using feeder cultures (as described in materials and methods section). Mean T cell numbers + SEM (A) 
directly after MACS or (B) 1 week after MACS are from 2-6 repeat experiments with T cells from 2-4 healthy 
donors. (C) T cell expansion at 1 week (black bars) or 3-6 week(s) (white bars) after MACS expressed as fold 
increase in T cell numbers when comparing 1 week and directly after MACS and 3-6 weeks and 1 week after 
MACS, respectively. T cell expansions are from representative T cell cultures out of 2-4 repeat experiments 
with T cells from 2-4 healthy donors with similar results. Statistically significant differences are calculated 
with Student’s t-tests: *: p<0.05, **: p<0.005.
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MACS with streptamers, but not CD34 mAb, results in T cell populations 
significantly enriched for peptide-MHC binding
MACS of TCR T cells with tetramers, pentamers or streptamers resulted in clear enrich-
ments of peptide-MHC-binding T cells (2.2, 1.8, and 3.1 fold increase, respectively; fig. 
6.3A). Streptamers, however, were the only peptide-MHC multimers that resulted in 
percentages of peptide-MHC-binding T cells (> 65%) that were significantly enhanced 
when compared to pre-sort T cells (20%). Please note that limited output of T cell 
numbers directly after MACSort with tetramers and pentamers (in some cases < 50,000 
cells) did not allow for flow cytometry with peptide-MHC multimers since the total 
number of T cells was expanded to provide a yield at 1 week after MACSort necessary for 
downstream assays. Generally, in our experience, peptide-MHC enrichment at 1 week 
after MACS or FACSort correlates well with the actual sorting efficiency. Percentages of 
streptamer-sorted T cells that bind peptide-MHC proved stable over a culture period of 
up to 6 weeks (fig. 6.3A). In contrast, percentages of pentamer-sorted T cells that bind 
peptide-MHC decreased to pre-sort values in a 6-week time period.
MACS of TCR-tCD34 T cells with either CD34 mAb or streptamers resulted in a maxi-
mal enrichment of tCD34 expressing T cells, near to 100 %, which was stable over time 
(fig. 6.3B). Unexpectedly, MACS of TCR-tCD34 T cells with CD34 mAb did not result in an 
enrichment of peptide-MHC-binding T cells (fig. 6.3A). Also, streptamer MACS of TCR-
tCD34 T cells resulted in an enrichment of peptide-MHC-binding T cells that was 2-fold 
less and not stable over time when compared to TCR T cells (fig. 6.3A).
MACS with CD34 mAb yields T cells with enhanced CD107a mobilization and 
IFNγ production in response to antigen-positive melanoma cells
To analyze T cell functions, we decided to compare streptamers, which among the 
peptide-MHC multimers tested showed the best T cell yield and enrichment for peptide-
MHC-binding T cells, with CD34 mAb as sort reagents. Following 3-6 weeks after MACS, 
TCR and TCR-tCD34 T cells were stimulated with peptide-loaded BLM or native FM3 
melanoma cells and analyzed for surface expression of CD107a and IFNγ production. 
To better compare T cell functions, values were standardized for peptide-MHC binding 
(see supplementary figure 6.1A). Streptamer-sorted TCR-tCD34 T cells, when compared 
to similarly sorted TCR T cells, revealed a higher level of CD107a expression and similar 
levels of IFNγ production in response to FM3 melanoma cells (figs. 6.4A and B). Strik-
ingly, CD34 mAb-sorted T cells showed the highest level of CD107a expression and IFNγ 
production in response to melanoma cells (figs. 6.4A and B). To assess T cell sensitiv-
ity, we have tested IFNγ responses towards titrated amounts of gp100 peptide. CD34 
mAb-sorted T cells generally produced about 2-fold more IFNγ in response to 10-9 to 
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10-5 M peptide, however equal EC50’s of approximately 0.04 µM peptide were observed 
(supplementary fig. 6.1B).
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Figure 6.3. MACS of TCR T cells with streptamers results in enhanced peptide-MHC binding that is 
stable over time. Primary human T cells were transduced and MACSorted as described in the legend to 
figure 6.2. Sorted T cells were analyzed by flow cytometry for (A) peptide-MHC binding (using gp100/A2 
pentamer) and (B) surface expression of tCD34 (using CD34 mAb) at various time points: before MACS 
(black bars), 1 week after MACS (white bars); and 3-6 weeks after MACS (gray bars). Bars represent mean 
% + SEM of 2-4 repeat experiments with T cells from 2-4 healthy donors. Binding of peptide-MHC or CD34 
mAb before MACS was 20 and 70%, respectively. Enrichment of T cells that bind peptide-MHC or CD34 
mAb is presented as fold difference between T cells at 1 week after and before MACS, and indicated above 
corresponding bars. Statistically significant differences are calculated with Student’s t-tests: *: p<0.05; **: 
p<0.005.
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Figure 6.4. Human T cells sorted with CD34 mAb demonstrate increased antigen-specific respons-
es. Primary human T cells were transduced with empty virus particles (Mock T cells), TCR (TCR T cells) or 
TCR-tCD34 transgenes (TCR-tCD34 T cells) and were either not MACSorted (Mock T cells, blocked bars) or 
MACSorted with streptamers (TCR T cells, gray bars; TCR-tCD34 T cells, white bars) or anti-CD34 mAbs (TCR-
tCD34 T cells, black bars). T cells sorted with CD34 mAb show up-regulated (A) surface expression of T 
cell CD107a and (B) IFNγ production upon stimulation with antigen-positive melanoma cells. T cells were 
stimulated with the following target cells: BLM cells (gp100-/A2+) loaded without or with 10-5 M gp100 
peptide, and FM3 cells (gp100+/A2+). CD107a expression (%) was measured by flow cytometry, gating on 
viable and CD3-positive T cells, following a 2 hrs stimulation, and IFNγ production (ng/ml) was measured 
following O/N stimulation in conditioned supernatants by ELISA. Bars represent mean values + SEM of 2 in-
dependent measurements from two healthy donors. CD107a and IFNγ data were corrected for differences 
in peptide-MHC binding, with peptide-MHC binding of CD34 mAb-sorted T cells set to 100 % (see supple-
mentary figure 6.1A for details). Statistically significant differences are calculated with Student’s t-tests: *: 
p<0.05, **: p<0.005, ***: p<0.0005.
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MACS with CD34 mAb, but not streptamers, results in CD4 and CD8 T cells that 
both contribute to antigen-specific IFNγ production
To follow up on the enhanced function of CD34 mAb-sorted T cells, we performed 
multi-parameter flow cytometry to study the contribution of CD4 and CD8 T cell subsets 
to IFNγ production. Besides intracellular IFNγ, sorted T cells were analyzed for peptide-
MHC binding, and surface expression of TCR-Vβ27, tCD34 and CD8α. Percentages of CD4 
T cells in pre-sorted T cells are 67% (fig. 6.5A; non-sorted Mock T cells), whereas CD4 
T cell percentages in TCR T cells sorted with streptamers or TCR-tCD34 T cells sorted 
with either streptamers or CD34 mAb were 5%, 1% and 38%, respectively (fig. 6.5A). 
Expectedly, MACS with streptamers yielded a T cell population that was biased for CD8 T 
cells. In contrast, MACS with CD34 mAb yielded T cells that contained significant popula-
tions of both CD4 and CD8 T cells. CD4 T cells within CD34 mAb-sorted T cells expressed 
TCR-Vβ27 and tCD34 at levels equal to those observed in CD8 T cells, yet CD4 T cells 
did not bind peptide-MHC (figs. 6.5A-C). Stimulation of T cells with peptide-loaded 
BLM cells resulted in enhanced intracellular levels of IFNγ in CD8 T cells irrespective of 
the MACS reagent used. Notably, in CD34 mAb-sorted T cells both CD4 and CD8 T cell 
subsets demonstrated antigen-specific IFNγ production (fig. 6.5D). Similarly, although 
to a smaller extent, CD4 T cells contributed to antigen-specific IL-2 production of CD34 
mAb-sorted T cells (supplementary fig. 6.2A and B). Table 6.2 provides a summary of our 
data with respect to yield, expansion, enrichment for peptide-MHC binding and tCD34, 
and antigen-specific functions of T cells MACSorted with tetramers, pentamers, strep-
tamers or CD34 mAb.
DISCUSSION
In this study, we have performed a head-to-head comparison of tetramers, pentamers, 
streptamers and CD34 mAb as sort reagents to obtain a population of MACS-enriched 
TCR-engineered T cells. First, we compared the different peptide-MHC multimers and 
noted that streptamers provided a significantly improved output of T cell numbers, 
which was primarily due to enhanced T cell expansion in the 1st week after MACS. This 
observation is in line with a previous report that showed that dissociation of streptamers 
into monomers, as we have done following MACS, reduces activation-induced cell death 
(AICD) and improves T cell proliferation when compared to non-dissociated multimers 
(256). In fact, multimeric peptide-MHC is reported to result in up-regulated expression 
of FasL, which in turn results in FasL/Fas mediated T cell death (261). In contrast, peptide-
MHC monomers do not lead to full and endured TCR-mediated T cell activation, most 
likely due to relatively low affinity interactions with TCRs and high off kinetics of mono-
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Figure 6.5. IFNγ production of CD34 mAb-sorted T cells, but not peptide-MHC-sorted T cells, de-
pends on both CD8 and CD4 T cells. Primary human T cells were transduced and MACSorted as described 
in legend to figure 6.4. T cells were analyzed by flow cytometry after staining with APC-conjugated anti-
CD8α mAb in combination with one of the following reagents: (A) PE-conjugated gp100/A2 tetramer 
(n=12); (B) PE-conjugated anti-TCR-Vβ27 mAb (n=6); (C) FITC-conjugated anti-CD34 mAb (n=14); and (D) 
FITC-conjugated anti-IFNγ mAb (n=2). In case of IFNγ stainings, T cells were stimulated for 6 hrs with BLM 
(gp100-/A2+) cells loaded with 10-5 M gp100 peptide, permeabilized and stained with anti-IFNγ mAb, as 
described in more detail in the materials and methods section. The figures show representative dotplots, 
indicating percentages (all quadrants) and MFIs (upper and lower right quadrants when % ≥ 5, in italic) of 
stained T cells.
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meric peptide-MHC (31, 262). Besides streptamers, the use of a mAb directed against 
a truncated CD34 molecule represents another means of circumventing AICD. When 
comparing peptide-MHC multimers to CD34 mAb, we observed that CD34 mAb-sort of 
gene-marked T cells provided the highest output of T cell numbers, which was due to 
both enhanced T cell numbers directly after MACS and enhanced T cell expansion in the 
1st week after MACS. T cell populations all expanded at similar rates up to 6 weeks after 
MACS, implying that T cells bound to sort reagents such as tetramers and pentamers are 
ultimately ‘diluted out’ or lost (fig. 6.2).
With respect to enrichment for peptide-MHC binding, streptamer-based MACS of 
TCR T cells resulted in the most effective enrichment, which proved stable over time. 
The reversibility of streptamer binding, which, as discussed above, potentially aids T 
cell expansion of sorted T cells, may have contributed to the observed T cell enrich-
Table 6.2. In vitro evaluation of T cells that are MACSorted with peptide-MHC multimers or CD34 mAba
TCR T cells TCR-tCD34 T cells
T P S S CD34
T cell output numbers (directly after MACS)b ± − + + ++
T cell yield (1 week after MACS)c ± − + ± ++
T cell expansion (1 week after MACS)d ± ± ++ − ++
T cell expansion (3-6 weeks after MACS)d ± + + + ++
pMHC binding (1 week after MACS)e + + ++ + −
pMHC binding (3-6 weeks after MACS)e + − ++ ± −
tCD34 expression (1 week after MACS)f N.A. N.A. N.A. + ++
tCD34 expression (3-6 weeks after MACS)f N.A. N.A. N.A. ++ ++
Antigen-specific CD107a mobilizationg N.D. N.D. ± ± ++
Antigen-specific IFNγ secretionh N.D. N.D. ± ± ++
a Primary human T cell populations were transduced with TCR or TCR-tCD34 genes, MACSorted with gp100/
A2 tetramers (T), pentamers (P) or streptamers (S), or with CD34 mAb (CD34), and evaluated for various in 
vitro parameters. See materials and methods section for details. N.A.: Not Applicable; N.D.: Not Determined.
b T cell numbers directly after MACS (counted microscopically): − = 0-0.10x106; ± = 0.11-0.25x106; + = 0.26-
0.75x106; ++ = >0.75x106.
c T cell numbers at 1 week after MACS (counted microscopically): − = 0-1x106; ± = 2-5x106; + = 6-15x106; ++ 
= >15x106.
d T cell expansion at 1 or 3-6 week(s) after MACS (fold increase in T cell numbers at 1 week versus directly 
after MACS and 3-6 weeks versus 1 week after MACS, respectively): − = 0-10; ± = 11-15; + = 16-20; ++ = >20.
e Peptide-MHC binding at 1 and 3-6 week(s) after MACS (measured by flow cytometry with gp100/A2 pen-
tamer): − = ≤ 20% (value before MACS); ± = 21-30; + = 31-50; ++ = >50%.
f tCD34 expression at 1 and 3-6 week(s) after MACS (measured by flow cytometry with CD34 mAb): − = ≤ 
70% (value before MACS); ± = 71-80; + = 81-90; ++ = >90%.
g T cell CD107a mobilization at 3-6 weeks after MACS (measured by flow cytometry with CD107a mAb upon 
peptide-specific stimulation): − = 0-20; ± = 21-40; + = 41-60; ++ = >60%.
h T cell IFNγ production at 3-6 weeks after MACS (measured by ELISA upon peptide-specific stimulation): − = 
0-5; ± = 6-10; + = 11-20; ++ = >20 ng/ml.
Coen BW1.indd   136 15-Aug-13   11:38:14 AM
MACSort of T cells: CD34 mAb versus peptide-MHC multimers 137
6
ment. MACS of TCR-tCD34 T cells with CD34 mAb resulted in a T cell population that was 
nearly completely positive for tCD34 for at least 6 weeks but did not show an improved 
binding of peptide-MHC. Similar results were obtained with streptamer MACS of TCR-
tCD34 T cells, showing enrichment of tCD34 but only a weak and transient enrichment 
for peptide-MHC-binding T cells. Findings with TCR-tCD34 T cells suggest that a CD34 
mAb sort does not result in concomitant enrichment of peptide-MHC-binding T cells, 
whereas a peptide-MHC multimer sort does result in enrichment of tCD34-positive 
T cells. This observation may be related to the fact that surface expression of TCRαβ 
chains, but not tCD34, is prone to competition for endogenous proteins and TCR mis-
pairing (see chapter 2).
When comparing TCR-tCD34 and TCR T cells with respect to peptide-MHC binding, 
we postulate that the TCRα-2A-tCD34-2A-TCRβ cassette may compromise gene expres-
sion of TCRαβ. Although we cannot exclude that the products of TCR genes intervened 
by tCD34 are more prone to mis-pair with endogenous TCR chains, TCR genes expressed 
from a single construct are generally less prone to mis-pair when compared to TCR genes 
expressed from separate constructs (65). Sizes of transgenes in pBullet retroviral vectors 
may adversely affect gene expression (TCR-tCD34: 2867 nt; TCRα or β: 827 and 923 nt) 
(data not shown). More specifically, surface expression of the TCRα gene, positioned 5’ 
of 2A sequences, may be reduced as a consequence of the 2A amino acids added to 
the 3’ end of the TCRα protein (263, 264). Addition of 2A amino acids to the intracellular 
domain of TCRα potentially decreases the stability of immunoglobulin constant region-
containing proteins. Since TCR-Vα13 mAbs are commercially not available, we cannot 
formally proof the decreased surface expression of TCRα. However, two lines of evidence 
support a decreased expression of TCRα by TCR-tCD34 T cells. First, peptide-MHC bind-
ing by TCR-tCD34 T cells is decreased compared to TCR T cells whereas TCRβ surface 
expression is not (fig. 6.3A, supplementary fig. 6.3, and figs. 6.5A and B). Second, Mean 
Fluorescence Intensities of peptide-MHC binding by streptamer-sorted TCR-tCD34 T 
cells was 1.6-fold lower when compared to similarly sorted TCR T cells (fig. 6.5A). Along 
these same lines, binding of peptide-MHC monomers (upon reversal of streptamers 
into peptide-MHC monomers) is expected to persist less long in case of TCR-tCD34 T 
cells, potentially providing a decreased T cell proliferation signal in the setting of feeder 
cultures (with T cell co-stimulation; fig. 6.2C). TCRβ expression appears generally less 
sensitive for additional 3’ amino acids (95, 234, 265), suggesting that a TCRβ-2A-tCD34-
2A-TCRα or tCD34-2A-TCRβ-2A-TCRα configuration, in particular in those vectors that 
can carry large sized transgenes may be more favorable for stable TCRα expression and 
peptide-MHC multimer binding by TCR-tCD34 T cells.
When analyzing T cell functions, CD34 mAb-sorted T cells revealed enhanced CD107a 
mobilization and IFNγ production in response to melanoma target cells. The enhanced 
functional avidity of these T cells did not correlate with the surface expression of TCRβ, 
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which is in line with the aforementioned discrepancy between TCRβ expression and 
peptide-MHC binding. Supplementary figure 6.3 demonstrates that MACSort enhanced 
the percentages of TCRβ in a manner that appeared independent of T cell population 
and sort reagent used. Within our panel of MACSorted T cells, CD34 mAb-sorted T cells 
are unique with respect to the presence of CD4 T cells (fig. 6.5A) and these CD4 T cells 
contributed to higher antigen-specific T cell IFNγ responses (fig. 6.5D). It is noteworthy 
that besides T cell function, it is not expected that CD4 T cells contributed to differences 
observed with respect to either T cell output numbers, T cell yield or enrichment for 
peptide-MHC binding (figs. 6.2 and 6.3). First, the relative presence of CD4 T cells was 
identical in pre-sort T cells from individual donors (as in non-sorted Mock T cells; fig. 
6.5A). Second, T cell expansion rates did not differ among all sorted T cell populations 
tested (fig. 6.2C) suggesting that differences in T cell yield and enrichment for peptide-
MHC binding at 1 week after MACS (figs. 6.2 and 6.3) were not due to the presence of 
CD4 T cells. Somewhat unexpected, CD4 T cells did not contribute to peptide-MHC 
binding of CD34 mAb-sorted T cells. We hypothesize that MACS procedures, in contrast 
to for instance FACS procedures, may apply additional forces to the TCR:peptide-MHC 
interactions, such as those caused by downward flows of washing buffers (249). Conse-
quently, MACS of T cells may select for T cells with the highest avidity for peptide-MHC, 
in which case CD8 T cells generally have an advantage over CD4 T cells. Downward flow 
may not affect MACS with CD34 mAb since antibodies generally have a 10,000 fold 
higher ligand-binding affinity than TCRs (262). The absence of peptide-MHC binding by 
TCR-positive CD4 T cells is an observation that seemingly contradicts a previous report, 
which showed that the same gp100/A2 TCR acts independently of the CD8α co-receptor 
(206). In fact, in the latter study we have shown that CD4 and CD8 T cells revealed com-
parable peptide-MHC binding and nearly comparable T cell cytotoxicity, but T cells were 
transduced with TCR genes and obtained via peptide-MHC/CD8α mAb-based FACSort 
(206). The lowered and unstable TCRα expression in TCR-tCD34 T cells may reduce T cell 
avidity and hamper peptide-MHC binding, resulting, as discussed, in a lowered peptide-
MHC binding MFI of CD8 T cells and potentially, in this study, in absent peptide-MHC 
binding by CD4 T cells (fig. 6.5A).
Despite the absence of peptide-MHC binding, the CD4 T cell population in CD34 
mAb-sorted TCR-tCD34 T cells contributed to antigen-specific responses as shown by 
intracellular IFNγ and, to a lesser extent, IL-2 production (fig. 6.5D and supplementary fig. 
6.2A). This observation is in agreement with the notion that T cell function only requires 
a few peptide-MHC molecules, which may be well below the detection limit of T cell 
peptide-MHC binding by standard flow cytometry methods (266). IFNγ and IL-2 produc-
tion by CD4 T cells is important for recruitment and mobilization of CD8 T cells to the 
tumor site (267, 268). In addition, CD4 T cells aid the induction of CD8 T cell-mediated 
immune responses, targeting of tumor stroma, and formation of T cell memory (269-
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276). Findings on IFNγ and IL-2 production by CD34 mAb-sorted CD4 T cells extend a 
previous study, where we observed an antigen-specific production of high levels of IFNγ 
and low levels of IL-2 in gp100/A2 TCR-positive CD4 T cells (206). In another study, CD8 
T cells transduced with a ERBB2-specific Chimeric Antigen Receptor (CAR) revealed the 
best T cell expansion and protection against metastases when co-cultured with Th1-
type rather than Th2-type T cells (277). Thus, the anti-tumor activity of CD34 mAb-sorted 
T cells may be further exploited by skewing CD4 T cells towards a Th1 phenotype.
Our study has focused on three types of peptide-MHC multimers to enrich TCR-
transduced T cells with MACS. To date, other peptide-MHC multimers have been de-
signed that contain up to 200 peptide-MHC monomers (278-282). Although the use of 
these novel peptide-MHC reagents needs to be tested for T cell sorting, the enhanced 
valencies of these peptide-MHC multimers may allow enrichment for CD4 T cells, yet the 
accompanying lower ‘off-rates’ and inability to revert binding are likely to result in AICD.
In short, MACSort of T cells with detachable streptamers improves T cell yield and en-
richment for peptide-MHC binding T cells when compared to tetramers and pentamers. 
Truncated CD34 proves a valid surrogate marker to MACSort T cells, resulting in a further 
enhancement of T cell yield and maximal CD34 enrichment, yet does not enrich T cells 
for peptide-MHC binding. CD34 mAb sort yields CD4 T cells that significantly contribute 
to antigen-specific T cell functions. Therefore, we conclude that CD34 mAb-based MAC-
Sorting of T cells has benefits towards applications of T cell therapy, especially those that 
require CD4 T cells.
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Supplementary figure 6.1. CD34 mAb-sorted T cells demonstrated an enhanced antigen-specific 
IFNγ production. Primary human T cells were transduced and MACSorted as described in legend to fig-
ure 6.4. (A) T cells were analyzed for peptide-MHC binding 3-6 weeks after MACS by flow cytometry (us-
ing gp100/A2 tetramer). Numbers represent mean % +/- SEM of 4 repeat experiments with T cells from 2 
healthy donors. (B) Sorted T cells from (A) were analyzed for IFNγ production following antigen-specific 
stimulation. T cells were stimulated with BLM cells loaded with titrated amounts of gp100 peptide and 
O/N supernatants were tested for IFNγ by ELISA. Graphs represent mean IFNγ values (in ng/ml) +/- SEM of 
2 independent measurements from 2 healthy donors. IFNγ data were corrected for differences in peptide-
MHC-binding, with peptide-MHC-binding of CD34 mAb-sorted T cells (as in A) set to 100%. EC50 values of 
streptamer and CD34 mAb-sorted T cells (0.05 and 0.03 µM peptide, respectively) were calculated using 
Masterplex ReaderFit software. Statistically significant differences are calculated with Student’s t-tests: * = 
p<0.05; ** = p<0.005; *** = p<0.0005.
A
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Supplementary figure 6.2. CD34 mAb-sorted CD4 T cells express IL-2 and IL-2Rα. Primary human T 
cells were transduced and MACSorted as described in legend to figure 6.4. T cells were stained with APC-
conjugated anti-CD8α mAb in combination with one of the following antibodies: (A) FITC-conjugated anti-
IL-2 mAb (n=2); or (B) FITC-conjugated anti-CD25 mAb (n=10). In case of IL-2 stainings, T cells were stimulat-
ed for 6h with BLM (gp100-/A2+) cells loaded with 10-5 M gp100 peptide, permeabilized, and stained with 
anti-IL-2 mAb, as described in more detail in the materials and methods section. Stainings were analyzed by 
flow cytometry and figures show representative dotplots, indicating % (all quadrants) and MFI of stained T 
cells (upper and lower right quadrants when % ≥ 5, in italic).
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Supplementary figure 6.3. MACSort with streptamer or CD34 mAb yields T cell populations with 
significantly enhanced percentages of TCRβ expression. Primary human T cells were transduced and 
MACSorted as described in legend to figure 6.4. T cells were stained with PE-conjugated anti-TCR-Vβ27 
mAb and analyzed by flow cytometry. Bars represent mean % + SEM of 2-4 repeat experiments with T 
cells from 2 healthy donors. Statistically significant differences are calculated with Student’s t-tests: *** = 
p<0.0005.
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In preceding chapters, I have presented the following three strategies to enhance the 
functional avidity of TCR-engineered T cells without compromising their target specific-
ity:
1. equipment of TCR transgenes with signaling cassettes (chapters 3 and 4);
2. enhancement of TCR affinity (chapter 5); and
3. enrichment of TCR T cells using MACS technology (chapter 6).
In chapters 7.1 to 7.3, I discuss these strategies with respect to their impact on function 
and self-reactivity of gene-engineered T cells. In chapter 7.4, I will discuss the feasibility 
of combining these strategies and how this will potentially advance clinical TCR gene 
therapy.
7.1 EqUIPMENT OF TCR TRANSGENES wITH SIGNALING CASSETTES
In chapters 3 and 4 we have extended our previous studies on the equipment of TCR 
genes with a signaling cassette consisting of the complete human accessory molecule 
CD3ζ. This signaling cassette was coupled to both TCRα and TCRβ chains (i.e., TCR:ζ), and 
resulted in enhanced surface expression of TCR:ζ that was independent of endogenous 
CD3 and prevented mis-pairing between introduced and endogenous TCR chains (see 
chapters 1 and 2 for details). In chapter 3 we attempted to minimize the incorporation 
of CD3ζ sequences with the intent to make minimal TCR:ζ variants with less or no im-
munogenicity. With the use of two techniques, we have generated 8 minimal TCR:ζ 
variants either by replacing extracellular, transmembrane and/or intracellular CD3ζ 
domains by corresponding wild-type (wt) TCR sequences (domain-exchange technique) 
or transplanting a limited number of CD3ζ transmembrane amino acids onto structur-
ally similar positions in wt TCR (3D-modeling technique). Ideally, minimal TCR:ζ variants 
needed to preserve the ability of parental TCR:ζ to prevent TCR mis-pairing and at the 
same time introduce the ability to associate with endogenous CD3 accessory molecules, 
and potentially enhance the functional T cell responses. Our findings are summarized in 
top half of box 7.1. In short, replacing the intracellular CD3ζ domain with corresponding 
intracellular wt TCR sequences resulted in a minimal TCR:ζ with non-functional surface 
expression. When replacing the CD3ζ transmembrane domain, we demonstrated that 
this domain was required for TCR:ζ’s cell surface expression, prevention of TCR mis-pair-
ing, and lack of association with endogenous CD3. The ability of CD3ζ transmembrane 
domain to induce homodimerization, as reported for monomeric IL-2Rα chains coupled 
to CD3ζ (188), is probably critical to preserve the above-mentioned properties of paren-
tal TCR:ζ. When replacing the CD3ζ extracellular domain we observed that this domain 
was dispensable for functional expression of TCR:ζ in Jurkat T cells but not primary hu-
man T cells. The lack of minimal TCR:ζ without the extracellular CD3ζ domain to become 
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expressed on primary human T cells could not be rescued by codon optimization of 
TCR genes and optimal vector configuration. Results with a minimal TCR:ζ that lacked 
the extracellular CD3ζ domain but now included TCR sequences that encompass the 
connecting peptide motifs (CPMs) were somewhat unexpected. CPM sequences nor-
mally interact with CD3γδε and CD8α (115, 116, 191, 283), and its interaction with CD8α 
stabilizes the complex between TCR and peptide-MHC, and increases the T cell’s dwell 
time and responses towards low-affinity ligands (238). However, sensitive measure-
ments with Fluorescence Resonance Energy Transfer (FRET) did not confirm enhanced 
association between this minimal TCR:ζ (without the extracellular domain of CD3ζ) and 
endogenous CD3. Our observations may be limited to a TCR:ζ specific for MAGE-A1/HLA-
A1 since a John Cunningham virus (JCV)/HLA-A2 specific TCR fused to transmembrane 
and intracellular CD3ζ did demonstrate functional expression by primary human T cells 
(133). In total, we conclude that exclusion of intracellular, transmembrane and/or extra-
cellular domains of CD3ζ results in functionally compromised TCRs and that properties 
of TCR:ζ are best preserved when incorporating a complete CD3ζ molecule. Notably, 
recent clinical trials demonstrate that anti-CAR immune responses were directed against 
murine idiotypes, but never against boundaries between genetically introduced human 
molecules (223, 284), making it unlikely that parental TCR:ζ, or TCRs with other human 
signaling cassettes such as TCR:28ε, will demonstrate enhanced immunogenicity.
Box 7.1. Key findings from chapters 3 and 4
v  CD3ζ’s intracellular domain: this domain is dispensable for TCR:ζ cell surface expression but not for 
downstream signaling and T cell activation
v  CD3ζ’s transmembrane domain: this domain
  •  is required for cell surface expression
  •  prevents TCR mis-pairing
  •  prevents association with endogenous TCR/CD3
  •  the above mentioned properties cannot be recapitulated by transplanting a limited number of 
transmembrane amino acids of CD3ζ onto TCRαβ
v  CD3ζ’s extracellular domain: this domain is dispensable for functional surface expression in Jurkat 
T cells, but not primary human T cells. Expression of TCR:ζ without the extracellular CD3ζ domain 
by primary human T cells cannot be rescued by codon-optimization and an optimal vector con-
figuration
v  TCR:28ε does not mis-pair with endogenous TCR chains nor associate with endogenous CD3 mol-
ecules
v  Compared to wild-type TCR, TCR:28ε demonstrated enhanced:
  •  cell surface expression and peptide-MHC binding
  •  antigen-specific responses
  •  accumulation of cell surface and intracellular effector molecules in immune-synapses
v  TCR:28ε does not reveal antigen-independent T cell activation
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In chapter 4 we designed and tested a co-stimulatory signaling cassette that combined 
the transmembrane and intracellular domains of CD28 with the intracellular domain of 
CD3ε (CD28-CD3ε). This co-stimulatory domain proved most optimal with respect to 
functional expression of single-chain TCRs when comparing cassettes that contained dif-
ferent accessory molecules with or without the CD28 co-stimulatory molecule. Findings 
with TCRα and TCRβ both containing this cassette (TCR:28ε) are summarized in bottom 
half of box 7.1. TCR:28ε demonstrated enhanced cell surface expression and binding of 
peptide-MHC when compared to wt TCR. Flow cytometric FRET revealed that TCR:28ε 
does neither mis-pair with endogenous TCR, does not associate with endogenous CD3 
nor affects the CD8α dependency of a tested gp100 specific TCR. T cells expressing 
TCR:28ε mediated similar CD107a mobilization as wt TCR in response to antigen-positive 
melanoma cells but significantly enhanced CD107a mobilization in response to peptide-
loaded target cells. Importantly, genetic incorporation of the CD28-CD3ε signaling 
cassette retains the TCR’s antigen specificity as evidenced by a non-changed response 
towards altered peptide ligands and lack of T cell responses in the absence of cognate 
antigen. The latter findings argue that the CD28 sequence in TCR:28ε does not inhibit, 
but perhaps even accommodates shielding of the Immunoreceptor Tyrosine-based Ac-
tivation Motif (ITAM) that is present in CD3ε to prevent unwanted T cell activity. A basic 
rich stretch (BRS), also present in the CD3ε molecule, normally enables the embedding 
of ITAM in the plasma membrane’ phospholipid bilayer (285). Other studies have sug-
gested that positioning of the BRS more distal from the plasma membrane may render 
ITAM accessible for phosphorylation and lead to antigen-independent T cell activation 
(286). In line with our hypothesis that CD28 accommodates rather than disturbs shield-
ing of ITAM is the high level of similarity between the relative number of basic residues 
in CD3 and CD28 molecules, on average 30% in CD3’s BRS and 24% in CD28. In future 
experiments we would like to test this hypothesis using a FRET system, similar to the 
one used to determine embedding of the CD3ε intracellular tail (286), with a membrane 
dye as acceptor and TCR:28ε C-terminal fluorophore as donor. In addition to effector T 
cell responses, chapter 4 studies have demonstrated that TCR:28ε initiates highly active 
synapses that contain high levels of TCR:28ε, endogenous TCR/CD3 and CD8α, as well as 
phosphorylated LCK (pLCK) and ERK (pERK). The enhanced levels of TCR:28ε and CD8α, 
both containing LCK docking sites, may well be responsible for the observed increase 
of synaptic levels of pLCK, and consequently the enhanced function of TCR:28ε T cells. 
LCK activation is an early event in antigen-induced downstream signaling as indicated 
in figure 1.1, and induces signal amplification and diversification via activation of ZAP70, 
LAT and ERK, resulting in full T cell activation.
Introduction of CD28 into Chimeric Antigen Receptors (CARs) resulted in increased 
T cell persistence, which in turn positively correlated with clinical activity (75, 76, 78, 
79, 173, 287). Current in vitro data with TCR:28ε-transduced T cells make this receptor 
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a candidate TCR for in vivo testing of T cell persistence and anti-tumor activities. Using 
CARs, CD28 co-stimulation was shown to overcome TGF-β-mediated repression of T cell 
proliferation, the latter representing an often-observed defense mechanism in tumors 
to counteract immune responses (288). Other members of the CD28 family of co-stimu-
latory molecules such as CD134 or CD137, either as single molecules or combined with 
CD28, have also been incorporated into CARs (77, 199). T cells gene-engineered with a 
CAR that incorporated CD137 and CD3ζ persisted for 6 months and provided complete 
clinical responses in two and a partial response in one out of three patients suffering 
from chronic lymphocytic leukemia (CLL) (77). Treatment of an additional 7 patients with 
CLL revealed another complete response and three partial responses (Carl June, presen-
tation at the Cellular Therapy against Cancer Symposium, London, Febr. 27th - March 2nd, 
2013). CARs containing both CD28 and CD134, mediate decreased activation-induced 
cell death of effector T cells, prolonged peripheral persistence of T cells, and selectively 
decreased production of the repressive cytokine IL-10 (199, 289). Such newly designed 
signaling cassettes, whether incorporated into CARs or TCRs, may represent interesting 
candidates to test for their clinical anti-tumor activity. Alternatively, as described in 
more detail in chapter 1, co-stimulation of T cells can be provided ex vivo by artificial 
antigen presenting cells expressing co-stimulatory molecule ligands. In one study, in 
which patients with metastatic melanoma were treated with T cells that were educated 
with such co-stimulatory cells, four out of seven evaluable patients showed a clinical 
response (85).
Conclusion:
Modifying TCRs with signaling cassettes containing CD3ζ or a combination of CD28 and 
CD3ε successfully prevents TCR mis-pairing. Functional expression of TCR:ζ depends on 
the complete CD3ζ molecule including its intracellular, transmembrane and extracel-
lular domain. TCR:28ε conveys antigen-specific responses, and does not result in a loss of 
peptide-fine specificity nor mediates antigen-independent T cell responses. We believe 
TCR:28ε is a promising receptor format and warrants further testing in pre-clinical TCR 
gene therapy settings.
7.2 ENHANCEMENT OF TCR AFFINITY
In chapter 5, we have collaborated with Adaptimmune Ltd., Abingdon, UK, to investigate 
whether affinity-enhanced TCRs selectively lead to improved T cell function without 
increase in self-recognition. In case readers are not familiar with the terms TCR affinity 
and T cell avidity, I would like to refer to a detailed description in box 1.2. In this study, 
phage-display was used to select gp100/HLA-A2-specific TCRs with amino acid substitu-
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tions that were restricted to either Complementarity Determining Region (CDR) 3α, 2β 
or 3β, and having KD values ranging from 18.5 µM to 26 nM. These TCRs were transduced 
into primary human T cells and findings with these T cells are summarized in box 7.2. We 
observed that antigen binding and T cell function did not correlate with KD values, which 
confirmed an earlier notion that affinities of soluble TCRs do not accurately represent 
the performance of TCRs when expressed on T cells (92). When looking at production of 
multiple cytokines as a measure of functionally avid T cells, we identified a hierarchy in 
the KD values of our gp100/HLA-A2-specific TCRs. In case TCRs have KD values between 4 
and 18.5 µM, which in our panel of TCRs were limited to those with amino acid substitu-
tions in CDR3α, we observed gain of antigen-specific T cell function when compared 
to wt TCR (KD=18.5 µM). In case TCRs have KD values between 1 and 4 µM, in our panel 
limited to amino acid substitutions in CDR3β, we observed reduced T cell function and 
some loss of antigen-specificity. And in case TCRs have KD values lower than 1 µM, in 
our panel limited to amino acid substitutions in CDR2β, we observed enhanced yet sig-
nificant antigen-independent T cell functions. T cell activation may require an optimal 
dwell time in order to allow serial triggering (239, 290, 291), and enhancing TCR affinity 
beyond a certain threshold, in particular with significantly lowered Koff values (see also 
table 5.1), may adversely affect T cell function. It is hypothesized that affinities above 
a pre-set threshold, reflected by KD values around 4-6 µM, induce T cell activation at 
a similar rate resulting in an ‘all-or-nothing’ quality of TCR/CD8 associations and TCR-
mediated signaling (238). Initial findings with thymocytes were confirmed with primary 
human T cells expressing affinity-enhanced TCRs directed against NY-ESO1/HLA-A2 (92, 
240) or gp100/HLA-A2 (chapter 5). In contrast, KD values in the nanomolar range may 
allow enhanced dwell times that are primarily guided by binding to HLA-A2, not bind-
ing to peptide:HLA-A2. To what extent affinity thresholds for either T cell sensitivity or 
specificity are of a universal nature needs to be confirmed with additional studies. CDR3 
regions are responsible for peptide:TCR interaction, whereas CDR1 and CDR2 are mainly 
responsible for TCR:HLA interaction (292) (see also box 1.2). Along this line, findings from 
chapter 5 suggest that amino acid substitutions in CDR3α are less prone, while those in 
CDR2β are more prone, to result in loss of peptide specificity. On the one hand, the clini-
cal use of an affinity-enhanced NY-ESO-1/HLA-A2 specific TCR with a KD value of 730 nM 
Box 7.2. Key findings from chapter 5
v  TCR specific for gp100/HLA-A2 containing CDR3α (KD >4 µM) and CDR2β (KD <1 µM), but not 
CDR3β (KD 4-1 µM), amino acid substitutions displayed enhanced peptide-MHC binding
v  Enhanced functionality without loss of peptide-fine specificity was only mediated by TCRs with KD 
values >4 µM and containing CDR3α amino acid substitutions
v  TCRs with KD values <1 µM and amino acid substitutions in CDR2β displayed HLA-A2-dependent 
reactivity against melanoma target cells, but also HLA-A2 positive donor T cells
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and harboring CDR3α mutations showed significant anti-tumor effects with no evidence 
of side-effects (46). On the other hand, we currently cannot exclude that the specificity 
of TCR:peptide-MHC interactions is restricted not only by the site of mutations but also 
by a limited window of affinity enhancement. Holler and colleagues have shown that a 
QL9-Ld specific TCR with CDR3α mutations and an enhanced KD value of 9 nM resulted in 
loss of self-reactivity (228). Moreover, a NY-ESO-1/HLA-A2 specific TCR resulted in loss of 
antigen-specificity when the TCR harbored amino acid substitutions in CDR2β and had 
a KD value of 280 nM, but not a KD value of 1.1 μM (224). To formally prove that CDR3α 
but not CDR2β may be a preferred site for mutagenesis, it would be advisable to test 
the antigen sensitivity and specificity of a panel of TCRs, preferably covering multiple 
antigen specificities, with mutations in either CDR3α or CDR2β and having KD’s that 
ranged from nM to µM.
Conclusion:
Limited affinity-enhancement of TCRs with KD values in the (sub)micromolar range, 
potentially directed by amino acid substitutions in CDR3, may result in highly functional 
TCRs that show no loss of peptide specificity. In contrast, affinity-enhancement of TCRs 
with KD values in the nanomolar range, potentially directed by amino acid substitutions 
in CDR2, may result in TCRs with enhanced self-reactivity and argues against its use to 
generate TCRs to be tested in clinical trials.
7.3 ENRICHMENT OF TCR T CELLS USING MACS TECHNOLOGY
In chapter 6 we used Magnetic-Activated Cell Sorting (MACS) to enrich TCR-engineered 
T cells and compared various peptide-MHC complexes (i.e., tetramers, pentamers, and 
streptamers) and anti-CD34 mAb as sorting reagents. Our findings are summarized in 
box 7.3. Primary human T cells were transduced with TCRα and TCRβ genes on separate 
Box 7.3. Key findings from chapter 6
v MACSorting with streptamer, when compared to tetramers and pentamers, resulted in increased:
  •  T cell yield
  •  T cell proliferation within 1 week after cell sorting
  •  enrichment of TCR-engineered T cells that remains stable in time (6 weeks)
v MACSorting with anti-CD34 mAb, when compared to streptamers, resulted in:
  •  further increased T cell yield
  •  similar T cell proliferation within 1 week after cell sorting
  •  negligible enrichment for TCR transgene-expressing T cells
  •  a T cell population that consists of both CD8 and CD4 T cells and demonstrates enhanced func-
tional responses
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vectors and when MACSorted with peptide-MHC multimers, we observed that strep-
tamers yielded the largest T cell population with most significant and stable enrichment 
of TCR transgene expression. In accordance with the design of streptamers, which 
allows release of peptide-MHC monomers from the streptamer scaffold and prevents 
activation-induced cell death, the acquired T cell population displayed the highest fold 
of T cell expansion. In subsequent experiments, T cells were transduced with TCRα and 
TCRβ genes on a single vector interspersed by 2A coupled to truncated CD34 (tCD34) 
and MACSorted with CD34 mAb. These T cells showed similar T cell proliferation rates but 
an increased T cell yield when compared to the above-mentioned streptamers. Notably, 
tCD34-enriched T cell populations showed negligible enrichment for peptide-MHC bind-
ing, but we did observe enhanced CD107a cell surface mobilization and IFNγ release in 
response to antigen-positive tumor cells when compared to streptamer-enriched T cells. 
With respect to the lack of enrichment for peptide-MHC binding of T cells, we argue that 
this binding was below the detection limit of standard flow cytometry, potentially due 
to low expression levels of TCRα as a consequence of TCRα transgene being positioned 3’ 
of the 2A gene segment, but sufficient to induce functional responses . Multi-parameter 
flow analysis suggested that the observed improvement of functional T cell responses 
were related to the unique presence of CD4 T cells in the CD34 mAb MACSorted T cell 
population. These CD4 T cells contributed to the observed IFNγ responses by producing 
IFNγ themselves and by enhancing the IFNγ production of CD8 T cells.
In addition to the applied peptide-MHC multimers, alternative complexes to enrich 
for TCR-engineered T cells have been described. For instance, a low valency complex 
consisting of soluble TCRs dimerized via IgG molecular scaffolds (280) can be used, but 
these TCR dimers generally show a less-robust staining than tetrameric peptide-MHC 
complexes (279). Several high valency complexes are also available, such as dextramers 
(valency of 24) (282), peptide-MHC loaded quantum dots and peptide-MHC presented 
by biotinylated lipids (valency between 60 and 200; 278, 281). Although usefulness of 
these novel peptide-MHC reagents needs to be tested for T cell sorting, the high valency 
may be beneficial and, in analogy to our findings with CD34 mAb, result in sorting of CD4 
T cells thereby circumventing a bias towards CD8 T cells as observed with lower valency 
streptamers. However, a downside to irreversible high valency binding is increased risk 
of activation-induced cell death.
The magnetic activated cell sorting (MACS) technology has been developed over 
the past 30 years from a technique to assist cytometric cell separations to a faster, but 
equally effective alternative for Fluorescence-Activated Cell Sorting (FACS; (248, 249)). 
FACS may represent a more flexible platform as it does allow the simultaneous detec-
tion and selection of multiple TCR specificities, which in some instances is preferred. 
In example, two-dimensional combinatorial coding with peptide-MHC multimers using 
8 fluorochromes allows simultaneous detection and isolation of 28 different tumor 
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specifi c T cell populations (37). MACS technology, however, in the format of CliniMACS 
allows rapid and high quality isolation at Good Manufacturing Practices (GMP) level. 
CD34 mAb-based CliniMACS has proven its robustness and reproducibility in multi-
center clinical trials to prevent graft-versus-host responses (293). We propose to further 
develop CD34 mAb-based MACS for clinical T cell therapy since the co-presence of CD4 
T cells may be benefi cial towards CD8 T cell function in vivo (269-271, 273-276, 294).
Conclusion:
We demonstrate that the use of truncated CD34 as a surrogate marker to enrich for TCR-
engineered T cells constitutes an attractive alternative to the more standard peptide-
MHC based sorting protocols. In fact, in a MACS setting we show that CD34 mAb-based 
enrichment results in enhanced function of the T cell population due to sorting of both 
CD4 and CD8 T cells.
 7.4 wHAT HAVE FINDINGS LEARNED US FOR FUTURE CLINICAL TRIALS?
We have set out to increase safety and effi  cacy of TCR gene therapy through gene-
engineering of TCR and vectors along the lines discussed in chapters 7.1 to 7.3. To take 
most advantage of each of these strategies, I propose to incorporate various genetic 
enhancements into a single expression vector (fi g 7.1). The combination of the CD28-
CD3ε signaling cassette and affi  nity-matured TCRs, within the earlier defi ned perimeters, 
together with enrichment of T cell populations via CD34 mAb-based MACSort, may 
further enhance the functional avidity of infused T cells without compromising their 
antigen specifi city. Below, I will discuss how such a combined eff ort may also enhance 
TCR gene therapy effi  cacy by addressing an immune-suppressive tumor environment 
and safety by addressing more general treatment related toxicities.
2A 2A tCD34 / CD20 
TCR 
Cβ 
1 2 3 1 2 3 
TCR 
Cα 
TCR-Vβ TCR-Vα 
CD28-CD3ε 
CDR CDR 
CD28-CD3ε 
Figure 7.1. Genetic content of a single vector that combines affi  nity-enhanced TCR chains, CD28-
CD3ε signaling cassettes and a tCD34 or CD20 surrogate marker. TCRα and TCRβ variable and constant 
domains are indicated by Vα, Vβ, Cα and Cβ, respectively. Amino acid substitutions in CDR3α are indicated 
by stars. Abbreviations used in this fi gure: CDR, complementarity determining region; tCD34, truncated 
CD34; TCR-C, T cell receptor constant domain; TCR-V, TCR variable domain.
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7.4.1 Immune-suppressive tumor environments
Tumors are well capable to compromise anti-tumor T cell responses by several mecha-
nisms as reviewed by Zou and colleagues (295). In example, tumor stroma, most likely 
through a lack of Toll-Like Receptor ligands and IFNγ production, may keep antigen-
presenting cells in an immature state (296, 297). In addition, intra-tumoral T cells, often 
as a consequence of antigen stimulation in the absence of T cell co-stimulation, express 
co-inhibitory molecules such as CTLA-4, PD-1 and TIM-3 (298, 299) and show a block 
in expression of effector molecules such as IFNγ. Furthermore, presence of suppressive 
immune cells such as regulatory T cells and myeloid-derived suppressor cells, deple-
tion of key amino acids such as arginine and tryptophan (300-302), and production of 
anti-inflammatory cytokines such as TGF-β, IL-4 and IL-13 (303) all contribute to the 
inhibition of effector T cells. Interestingly, immune suppressed effector T cells show a 
reduced expression of the effector molecules pLCK and pFYN and abrogated expression 
of CD3ζ (304). We propose that a combination of CD28-mediated T cell co-stimulation, 
TCR affinity-enhancement and T cell enrichment may counteract the immune sup-
pressive nature of the tumor milieu. First, inclusion of a CD28-CD3ε signaling cassette 
provides a TCR that does not rely on endogenous CD3 proteins for its surface expression 
or initiation of T cell activation, and is able to mediate accumulation of enhanced levels 
of synaptic pLCK. In addition, inclusion of a CD28-containing cassette in a CAR conveys 
resistance to TGF-β-mediated repression of T cell function (288). A potential risk of CD28-
containing receptors is enhanced proliferation of regulatory T cells due to LCK-mediated 
IL-2 production (205), which, however, can be addressed by mutating the LCK-binding 
site of CD28 or by using cassettes that harbor additional co-stimulatory molecules such 
as CD134 (205, 289). Second, affinity-matured TCRs (within defined perimeters) provide 
optimal T cell responses. Studies with CD28-containing CARs revealed that enhanced T 
cell co-stimulation does not alter the activation threshold of T cells (305), which argues 
that combined use of affinity-matured TCRs and a CD28-CD3ε signaling cassette does 
not compromise advantages of either one component. In addition, affinity-matured 
TCRs lead to enhanced production of multiple effector cytokines, such as IFNγ, TNFα 
and IL-2, which may revert an anti-inflammatory tumor environment into a more pro-
inflammatory environment. Importantly, enhanced production of pro-inflammatory T 
cell cytokines may not only contribute to T cell-mediated anti-tumor immunity, but may 
also involve innate immunity and the eradication of antigen-negative tumor cells (306). 
Third, enrichment of the frequencies of TCR-engineered T cells via MACSort, in particular 
when enriching both CD4 and CD8 T cells, will further enhance the functional avidity 
of therapeutic T cells. The enrichment of multiple pools of T cells engineered with TCRs 
directed against different target antigens may further advance T cell therapy and limit 
the risk of tumor recurrence (307, 308).
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7.4.2 Treatment related toxicities
Patients treated with T cells are generally pre-conditioned with cytotoxic drugs such 
as cyclophosphamide and fludarabine and receive high-dose IL-2 injections directly 
following T cell infusions to enhance the clinical effectiveness of T cell administra-
tion (24). However, administration of cytotoxic drugs may result in neutropenia and 
thrombocytopenia (46), and high-dose IL-2 also is reported to cause off-target toxici-
ties (309, 310). T cell co-stimulation has been demonstrated to make T cell therapy less 
dependent on patient pre-conditioning and supportive IL-2 treatments, which became 
evident from two seminal studies. First, T cells gene-engineered with a CD19-specific 
CAR:CD137 provided complete and partial clinical responses in three and four out of 
ten patients suffering from chronic B cell leukemia, respectively, all without high-dose 
IL-2 administration (77). Second, MART-1/A2-specific T cells that were stimulated with 
artificial antigen presenting cells positive for CD28 ligands mediated clinical responses 
in four out of seven evaluable patients suffering from metastatic melanoma without 
the need for chemotherapy or IL-2 support (85). Most likely, autologous IL-2 produc-
tion is enhanced following T cell co-stimulation and constitutes an important factor in 
explaining the benefits of T cell co-stimulation. Along this line, the use of CD28 signaling 
cassettes and affinity-matured TCRs may also represent strategies to make T cell therapy 
less dependent on additional patient treatments.
With respect to toxicities that are a direct consequence of administered T cells, one 
can make the distinction between on and off-target toxicities as described in detail in 
chapter 1. Ideal T cell target antigens would be neo-antigens, which are exclusively 
expressed by tumor and not healthy cells. These antigens, however, are generally ex-
pressed by only single or limited numbers of patients. With the development of second 
generation sequencing techniques, the targeting of neo-antigens may become feasible 
in the near future (50, 51). In addition, some CTA show highly restricted expression by 
tumor cells when compared to healthy cells and may constitute safe and effective target 
antigens (see chapter 1 for details). CTA expression can be up-regulated and become 
more homogeneously expressed within tumors by the use of epigenetic modulating 
compounds, such as the 5-Aza 2’deoxyazacytidine (AZA) demethylation agent and/or 
the histone deacetylase Valproate (VPA) (311-315). Phase I and II clinical studies that tar-
get acute myeloid leukemia, myelodysplasia, multiple myeloma and renal cell carcinoma 
report enhanced anti-tumor responses due to up-regulated expression of CTA antigens 
and no evidence of adverse events related to epigenetic modulation (311, 312, 316, 317). 
Notably, recent data from clinical TCR gene therapy studies have pointed to the neces-
sity to carefully screen target antigens, including MAGEs, with respect to safety. In one 
study, in which MAGE-A3/HLA-A2 (KVA epitope) was targeted in metastatic melanoma 
patients, 2 patients lapsed into coma and died, most likely because of T cell recogni-
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tion of rare neurons positive for MAGE-A12 and possibly MAGE-A9 and expressing the 
shared KVA epitope (62). In another study, in which MAGE-A3/HLA-A1 (EVD epitope) 
was targeted in metastatic melanoma and multiple myeloma patients, 2 patients suf-
fered from cardiotoxicity and died, possibly because of T cell recognition of a similar but 
not identical peptide from the muscle protein Titin (Dr. Bent Jakobsen, Cellular Therapy 
against Cancer Symposium, London, Febr. 27th - March 2nd, 2013). These studies clearly 
warrant for stringent preclinical screening to reduce the risk of toxicities in future trials. 
In addition, such unexpected toxicities can be addressed by incorporating suicide genes 
into therapeutic T cells such as the drug-induced suicide switches HSV-TK or iCasp9, or 
the tag-mediated suicide switch CD20 (see chapter 2). In this respect, truncated CD34 
cannot be used as a suicide marker because CD34 is widely expressed on hematopoi-
etic stem cells (318). CD20, however, could represent a candidate switch to combine 
antibody-based enrichment of T cells with antibody-mediated depletion of T cells (319).
Conclusion:
The combined use of affinity-matured TCRs within defined perimeters, CD28-CD3ε 
signaling cassettes, and truncated CD34 as a marker for T cell enrichment may result 
in safe and highly avid T cells for use in TCR gene therapy studies. These strategies are 
preferably combined with TCRs specific for neo-antigens or CTAs, such as MAGE-C2 or 
NY-ESO-1, to prevent on-target target toxicities. In addition, the additional inclusion of 
a suicide switch, such as CD20, may further enhance safety of clinical TCR gene therapy.
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“ I have a friend who’s an artist and has sometimes taken a view 
which I don’t agree with very well. He’ll hold up a flower and 
say “look how beautiful it is,” and I’ll agree. Then he says “I as an 
artist can see how beautiful this is but you as a scientist take 
this all apart and it becomes a dull thing,” and I think that he’s 
kind of nutty. First of all, the beauty that he sees is available to 
other people and to me too, I believe. Although I may not be 
quite as refined aesthetically as he is … I can appreciate the 
beauty of a flower. At the same time, I see much more about 
the flower than he sees. I could imagine the cells in there, the 
complicated actions inside, which also have a beauty. I mean 
it’s not just beauty at this dimension, at one centimeter; there’s 
also beauty at smaller dimensions, the inner structure, also the 
processes. The fact that the colors in the flower evolved in or-
der to attract insects to pollinate it is interesting; it means that 
insects can see the color. It adds a question: does this aesthetic 
sense also exist in the lower forms? Why is it aesthetic? All 
kinds of interesting questions which the science knowledge 
only adds to the excitement, the mystery and the awe of 
a flower. It only adds. I don’t understand how it subtracts.”
 Richard P. Feynman
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S
SUMMARY
Standard treatment options for melanoma, such as dacarbazine or high-dose IL-2, dem-
onstrate limited objective and complete response rates. Currently, new immune thera-
pies are being developed of which adoptive transfer of Tumor Infiltrating Lymphocytes 
(TILs) demonstrates most impressive clinical results. Therapy with TCR gene-engineered 
T cells entails a variant of TIL therapy that may be more flexible and applicable to mul-
tiple forms of cancer and is based on gene-manipulation of peripheral blood T cells to 
express tumor-specific TCRα and TCRβ transgenes.
Preclinical research described in this thesis focusses on modifications of TCR transgenes, 
in particular it addresses:
1. Fusing TCR with signaling cassettes
2. Enhancing TCR affinity
3. Enriching TCR-engineered T cells
Chapter 1 provides an overview of Food and Drug Administration-approved as well as 
experimental therapies for treating melanoma. Advantages of T cells include their abil-
ity to self-replicate, kill tumor cells via different mechanisms, and form immunological 
memory, which most likely have contributed to the high objective and complete re-
sponse rates observed with adoptive T cell therapy. Clinical trials with TCR-engineered 
T cells revealed objective responses rates of up to about 70%, but at the same time 
revealed treatment-related toxicities. In this chapter strategies to further increase treat-
ment efficacy and prevent or limit toxicities are described in more detail, emphasizing 
those strategies that rely on the engineering of TCR transgenes. With respect to thera-
peutic efficacy, three critical parameters have been introduced: T cell co-stimulation, TCR 
affinity and frequency of TCR-engineered T cells. In addition, I have discussed how these 
parameters can be exploited to enhance the efficacy of T cell therapy. Toxicities include 
on and off-target toxicities. The former is often a consequence of targeting an antigen 
that is expressed on tumor tissue but also, albeit it at low levels, on healthy tissues. The 
latter may be a consequence of TCR mis-pairing, i.e., unwanted combinations of endog-
enous and introduced TCR chains that yield new TCR heterodimers of unknown and 
potentially anti-self specificity. Moreover, recent trials pointed out that off-target toxici-
ties may also be a consequence of TCRs recognizing similar yet not identical peptides 
(Dr. Bent Jakobsen, Cellular Therapy of Cancer Symposium, London, Febr 27th-March 
2nd 2013). With respect to these toxicities, I have discussed different groups of antigens 
and concluded that some cancer testis antigens and neo-antigens may constitute safe 
targets for T cell therapy, but at the same time would like to recommend stringent safety 
testing and use of suicide switches for future trials.
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A review of genetic TCR modifications to prevent or reduce TCR mis-pairing is given in 
chapter 2. We divided genetically modified TCRs according to their dependency on CD3 
proteins for surface expression and downstream signaling. CD3-dependent strategies 
include TCR murinization and/or cysteine modification. CD3-independent strategies 
include single or two-chain TCRs that are coupled to signaling cassettes, typically con-
sisting of CD3ζ or Fc(ε)RIγ. Reviewing reports on differently modified TCRs suggest that 
TCR mis-pairing is best prevented by CD3-independent strategies, such as the use of a 
CD3ζ signaling cassette (i.e., TCR:ζ) which, by not depending on the limited availability 
of endogenous CD3, also enhanced T cell avidity. More recently, techniques were devel-
oped that focus on preventing the expression of endogenous TCR chains rather than 
preventing TCR mis-pairing, such as the use of zinc-finger nucleases or silencing RNA.
In chapter 3 we attempted to minimize the content of CD3ζ in TCR:ζ without compro-
mising TCR:ζ’s ability to prevent mis-pairing and be functionally expressed, thereby 
potentially also lowering this receptor’s immunogenicity.We have generated a panel of 
TCR:ζ variants in which extracellular, transmembrane, intracellular domains or combina-
tions thereof were replaced with natural TCR domains (a domain exchange strategy), 
and in which a limited number of CD3ζ transmembrane amino acids were transplanted 
onto structurally similar positions within TCRα and TCRβ (a 3D-modelling strategy). 
TCR transgenes were transduced in human T cells and our studies have demonstrated 
that the complete CD3ζ transmembrane domain, but not a limited number of CD3ζ 
transmembrane amino acids, is critical for cell surface expression and prevention of 
TCR mis-pairing. For T cell activation, both the CD3ζ transmembrane and intracellular 
domains were required. Notably, replacing the extracellular CD3ζ domain with natural 
TCR sequences compromised cell surface expression and antigen-specific functions in 
primary human T cells. We conclude that various TCR:ζ properties can be attributed to 
defined CD3ζ domains and that the complete CD3ζ content is required for functional 
expression of TCR:ζ on primary human T cells. Immunogenicity of TCR:ζ, no otherwise 
modified TCRs, is expected to be non-existent since clinical trials have indicated that 
immune responses occurring against receptor-engineered T cells are directed against 
murine variable domains but not against boundaries between human molecules.
In chapter 4 we have built on the CD3ζ signaling cassette and included various acces-
sory molecules and/or the CD28 co-stimulatory molecule, along the lines previously 
explored for Chimeric Antigen Receptors (CARs). Using a single-chain TCR platform, we 
have compared signaling cassettes consisting of Fc(ε)RIγ, CD3ε or CD3ζ with or without 
CD28 and selected a combination of CD28 and CD3ε for optimal receptor expression 
and function. When translating this signaling cassette to a two-chain TCR (i.e., TCR:28ε), 
we observed enhanced binding of peptide-MHC and no evidence for TCR mis-pairing. 
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TCR:28ε does not show off-target recognition, as evidenced by a non-changed peptide-
fine specificity when compared to wt TCR, no loss of CD8 co-receptor dependency and 
no induction of T cell responses towards antigen-negative target cells. Notably, TCR:28ε 
induces the formation of immune synapses with significantly enhanced accumulations 
of TCR transgene and evidence of early TCR signaling. In conclusion, TCR:28ε mediates 
safe and functional avid T cell responses which merits further studies to formally inves-
tigate this receptor’s potential to advance TCR gene therapy.
TCR affinity, the second focus of this thesis, has been covered in chapter 5. We analyzed 
whether perimeters of TCR affinities that determine gain of function differ from those 
that determine gain of self-reactivity. To this end, we have used phage display to obtain 
gp100/A2 specific TCRs that were affinity-enhanced (KD value parental TCR: 18.5 µM) and 
observed that improved antigen-specific T cell function was only achieved with minor 
affinity enhancements (KD values >4 μM), which in our panel of TCRs was restricted to 
amino acid substitutions in CDR3α. A further increase in TCR affinity was related to loss 
of peptide-fine specificity. In fact, TCRs of high affinity (KD values <1 μM), with amino acid 
substitutions restricted to CDR2β, displayed gp100 peptide-independent reactivity. We 
conclude that TCR affinity-enhancement to enhance functional avidity of therapeutic 
T cells without compromising their safety should be limited to the lower micromolar 
range and is potentially best achieved through amino acid substitutions in CDR3α.
Enrichment of TCR-engineered T cells, the third focus of this thesis, was addressed in 
chapter 6. We compared several sorting reagents to enhance the frequency of TCR-en-
gineered T cells. T cells were transduced with TCRs and sorted using Magnetic Activated 
Cell Sorting (MACS) on the basis of peptide-MHC multimers or an antibody against a co-
transduced truncated CD34 (tCD34). When comparing different peptide-MHC multimers 
(i.e., tetramers, pentamers and streptamers), we observed that T cell yield, expansion and 
stability of enrichment was mostly improved when using streptamers. When using MACS 
with anti-CD34 antibody, we observed an improved T cell yield (compared to MACS with 
streptamers) and a clear enrichment for tCD34-positive T cells. Unfortunately, tCD34-
directed sort did not enrich for TCR transgene, which was possibly related to the vector 
positioning of the TCRα gene 3’ of the 2A gene resulting in low levels of TCRα expression. 
Unexpectedly, tCD34-sorted T cells revealed enhanced T cell function, which we have 
attributed to the unique presence of CD4 T cells in the T cell population when compared 
to streptamer-sorted T cells. We postulate that downward flow forces applied during 
the MACS procedure may select for high affinity interactions, providing an advantage of 
CD8 over CD4 T cells in multimer but not antibody-based sorting. Consequently, the use 
of a surrogate-marker, such as tCD34, may have benefits for in vivo anti-tumor responses 
of therapeutic T cell populations following in vitro enrichment.
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Finally, in chapter 7, the results of previous chapters have been discussed in light of 
on-going developments in the field of TCR gene therapy. I have proposed to combine 
the above-described strategies and discuss how this may address challenges such as 
the immune suppressive tumor environment and treatment-related toxicities. For fu-
ture studies, I propose in this chapter to use a single vector that encompasses TCR:28ε 
transgenes, TCR-V genes that are affinity-enhanced within defined perimeters, and a 
surrogate marker that allows sorting and potentially acts as a suicide switch.
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SAMENVATTING
Op dit moment groeit het aantal mensen dat jaarlijks wordt geconfronteerd met pla-
veiselcelkanker, ook wel melanoom genoemd, in Nederland nog altijd sterk. De kans 
op deze ziekte neemt ook toe met de leeftijd. Met de huidige vergrijzing houdt dat in 
dat het aantal patiënten zal blijven stijgen. Als het melanoom uitzaait daalt de 10-jaar 
overlevingskans naar minder dan 10%. Ondanks dat de huidige en meest toegepaste 
medicijnen (goedgekeurd volgens de Amerikaanse ‘Federal Drug Administration’) in 
ongeveer de helft van de patiënten weliswaar een effect hebben (geremde groei van 
melanoom), zorgen deze medicijnen slechts in maximaal 1 tot 6% van de patiënten 
voor genezing. De meeste medicijnen gaan ook nog eens gepaard met zeer ernstige 
neveneffecten bij 30 tot 40% van de patiënten. In dit opzicht is het vermeldenswaardig 
dat er 6% minder gevallen van melanoom zouden zijn wanneer er géén gebruik meer 
gemaakt zou worden van zonnebanken. Dit zou een verbod op zonnebanken dus even 
effectief maken als de huidige medicijnen tegen melanoom.
Sinds kort zijn er twee nieuwe klassen medicijnen, waarvan de eerste resultaten bij 
patiënten met melanoom een duidelijk toegenomen effectiviteit laten zien en, onder 
de juiste condities, een verantwoorde veiligheid. Beide klassen medicijnen resulteren in 
een actief immuunsysteem. Zo zijn er antistoffen beschikbaar die ‘remmende moleculen’ 
op immuuncellen blokkeren (zie hoofdstuk 1 voor details). De tweede klasse medicij-
nen is gebaseerd op het toedienen van immuuncellen. Een voorbeeld hiervan is T-cel 
receptor gen therapie. Deze therapie liet in eerste studies bij wel 67% van behandelde 
patiënten een effect op melanoomgroei laat zien (verkleining van tumorgrootte) en bij 
wel 18% van de patiënten genezing. De immuuncellen die worden gebruikt bij T-cel re-
ceptor gen therapie zijn de zogenaamde T-cellen. Iedereen heeft ongeveer 250 miljoen 
T-cellen. Deze cellen verschillen in de samenstelling van hun T-cel receptor (TCR). Deze 
receptor bindt aan zogenaamde ‘Major Histocompatibility Complex (MHC)’-moleculen, 
die op het celoppervlak van alle cellen in ons lichaam (met slechts enkele uitzonderin-
gen) vóórkomen. MHC-moleculen presenteren fragmenten (peptiden) van willekeurige 
eiwitten uit de cel en de combinatie tussen peptiden en MHC-moleculen zijn daardoor 
een afspiegeling van wat er in een cel gebeurt, dus ook als deze cel een infectie 
doorloopt of ‘ontspoort’ in geval van een kankercel. Elke TCR heeft een peptide-MHC 
specificiteit en alleen wanneer de TCR het gehele peptide-MHC-complex herkent leidt 
dit tot T-cel activatie en kan de T-cel overgaan tot celdoding. Voor T-cel activatie, maar 
ook voor expressie op de T-cel, is de TCR afhankelijk van CD3-eiwitten (CD staat voor 
‘Cluster of Differentiation’ wat een algemene aanduiding voor oppervlakte-eiwitten is). 
Een TCR komt tot expressie in een complex met 6 CD3-eiwitten, en het geheel van TCR/
CD3 eiwitten geeft de T-cel de mogelijkheid peptide-MHC-herkenning te vertalen naar 
activatiesignalen in de T-cel.
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In geval van een tumor zijn T-cellen met de gewenste TCR vaak niet of in onvoldoende 
aantallen aanwezig in de patiënt of heeft de tumor deze T-cellen juist in ‘slaap gesust’ 
oftewel geïnactiveerd. T-cel gen therapie pakt deze problemen aan door T-cellen uit het 
lichaam van een patiënt te halen, in het laboratorium te activeren en genen in deze 
T-cellen te introduceren die coderen voor de gewenste TCR (TCR gen transfer), namelijk 
een die een peptide-MHC-combinatie herkent dat specifiek is voor de melanoom-cellen. 
Vervolgens worden deze T-cellen weer aan de patiënt terug gegeven waarna deze cel-
len, samen met de reeds in de patiënt aanwezige immuuncellen, het melanoom kunnen 
aanvallen.
In hoofdstuk 1 worden de huidige resultaten, behaald met TCR gen therapie, in meer 
detail beschreven en belangrijke verbeteringen voor deze therapie voorgesteld, zoals 
het voorkòmen van neveneffecten en het verbeteren van anti-melanoom effecten door 
de T-cellen.
Therapie-gerelateerde neveneffecten kunnen zich uiten in zogenaamde ‘on-target’ 
en ‘off-target’ toxiciteit. On-target toxiciteit kan ontstaan door het gebruik van TCRs 
die peptide-MHC herkennen die ook tot expressie komen op gezonde cellen. Dit kan 
worden voorkòmen door TCRs te kiezen die peptide-MHC herkennen die enkel en al-
leen vóórkomen op melanoom en niet op gezond weefsel, zoals (I) peptide-MHC met 
een melanoom-gerelateerde mutatie in het peptide of (II) peptide-MHC waarvan het 
peptide afkomstig is van geselecteerde en tumor-gerelateerde eiwitten die, behalve in 
melanoomcellen, niet of nauwelijks in gezonde cellen tot expressie komen. In geval van 
off-target toxiciteit herkent de T-cel andere peptide-MHC-moleculen, welke op gezond 
weefsel kunnen vóórkomen, als gevolg van zogenaamde TCR mis-paring. Een TCR be-
staat uit een alpha(α)-keten en een beta(β)-keten waarbij de combinatie de specifieke 
peptide-MHC herkenning mogelijk maakt. Ná TCR gen transfer heeft een T-cel dus 2 sets 
van TCRαβ ketens, nl. de reeds aanwezige set en de geïntroduceerde set TCR ketens, 
hetgeen kan leiden tot onwenselijke combinaties van TCRαβ ketens. Dit proces noemen 
we TCR mis-paring. Nieuw gecombineerde TCRαβ kan mogelijk op zijn beurt peptide-
MHC herkennen die op gezonde cellen tot expressie komt.
Het verbeteren van anti-melanoom effecten door de T-cellen kan op verschillende 
manieren. Ten eerste kunnen T celeffecten via T-cel-co-stimulatie, een signaal welke T-
cellen in de tumor vaak niet ontvangen, verbeterd worden omdat dit signaal zorgt voor 
overleving van de T-cel in de patiënt. Co-stimulatie signalen kunnen verzorgt worden 
door verschillenden moleculen, zoals CD28, en deze signalen kunnen er ook voor zorgen 
dat effecten langdurig behouden blijven en dat T-cellen eenmaal aanwezig in de tumor 
niet in slaap gesust worden. Ten tweede kan het versterken van de binding tussen TCR 
en peptide-MHC, ook wel affiniteit genoemd, de T-celeffecten verbeteren. TCR-affiniteit 
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voor peptide-MHC wordt bepaald door 3 belangrijke regio’s in de α- en β-ketens. Deze 
regio’s worden ‘Complementarity Determining Regions (CDR)’ genoemd en het is bekend 
dat CDR1 en CDR2 voornamelijk de binding van TCR aan het MHC molecuul verzorgen 
en CDR3 de binding van TCR aan het gepresenteerde peptide. Door het veranderen van 
sommige aminozuren in deze CDRs kan de affiniteit van de TCR voor het peptide-MHC 
worden verhoogd. Ten derde kunnen T-celeffecten in patiënten ook worden versterkt 
door meer T-cellen met de gewenste TCR aan de patiënt te geven. Door de verkregen 
T-celpopulatie ná TCR gentransfer te verrijken, wordt het percentage T-cellen dat deze 
TCR tot expressie brengt verhoogd, hetgeen resulteert in een grotere populatie T 
-cellen met de gewenste TCR.
Wat betreft de TCR gen therapie-gerelateerde toxiciteit heeft ons onderzoek zich toege-
spitst op het voorkòmen van TCR mis-paring en daardoor potentiële off-target toxiciteit. 
Er zijn verschillende methodes ontwikkeld op basis van genetische modificatie van de 
TCR om dit te doen en deze worden uitgebreid in hoofdstuk 2 beschreven. Hier delen 
we de gemodificeerde TCRs in op basis van CD3-afhankelijkheid of –onafhankelijkheid 
voor expressie. We stellen dat een genetische aanpak die leidt tot een CD3-onafhankelijk 
TCR het probleem van TCR mis-paring het best aanpakt en zorgt voor een verhoogde 
functionele TCR-expressie. Een voorbeeld van een CD3-onafhankelijke methode is de 
genetische fusie tussen TCRα en TCRβ ketens en het CD3ζ molecuul, welke we de naam 
TCR:ζ hebben gegeven. Deze TCR bevat zelf weliswaar een CD3-molecuul maar vormt 
geen complex met de andere reeds aanwezige CD3 moleculen zoals een gewone TCR. 
Eerdere studies van onze onderzoeksgroep hebben aangetoond dat TCR:ζ resulteert in 
gewenste T-celfuncties zonder het optreden van TCR mis-paring. In hoofdstuk 3 gene-
reerden we nieuwe TCR:ζ varianten om te onderzoeken welk minimaal deel van CD3ζ 
in TCR:ζ noodzakelijk is voor de genoemde eigenschappen (de gewenste T-celfuncties 
zonder het optreden van TCR mis-paring). Ons werk toont aan dat het intracellulaire 
deel van CD3ζ cruciaal is voor T-celactivatie en dat het transmembrane deel van CD3ζ 
essentieel is voor expressie en het voorkòmen van TCR mis-paring. Echter, het verwijde-
ren van het extracellulaire deel van CD3ζ in TCR:ζ verlaagt functionele expressie. Onze 
conclusie luidt daarom dat de complete TCR:ζ in alle gevallen beter is dan minimale 
varianten van TCR:ζ.
Voor het verbeteren van T-celeffecten hebben we onderzoek gedaan naar T-cel-co-sti-
mulatie (hoofdstuk 4), het verhogen van TCR-affiniteit voor peptide-MHC (hoofdstuk 5) 
en het verrijken van T-celpopulaties voor T-cellen met de gewenste TCR (hoofdstuk 6). 
Ten eerste gaan we in hoofdstuk 4 verder in op het fuseren van moleculen met een TCR 
om, behalve het voorkòmen van TCR mis-paring, de anti-tumor activiteit te verhogen. In 
dit hoofdstuk beschrijven we het fuseren van de TCR met CD28, dat normaal voor T-cel-
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co-stimulatie zorgt en daardoor een verbeterd effect geeft. Aan de TCR:CD28 voegen 
we ook domeinen van andere signaleringsmoleculen toe, waarbij uitgebreid onderzoek 
laat zien dat TCR:CD28:CD3ε (TCR:28ε) de meest geschikte kandidaat is. TCR:28ε lijkt niet 
alleen veilig wat betreft TCR mis-paring en niet-specifieke effecten, maar lijkt ook de 
potentie van T-celeffecten te verhogen.
Ten tweede hebben we onderzocht hoe aminozuurveranderingen in verschillende CDRs 
kan leiden tot verhoogde-TCR-affiniteiten voor peptide-MHC en een verbeterde T-celef-
fect. De TCR-affiniteit voor peptide-MHC wordt uitgedrukt in de dissociatieconstante ‘KD’. 
Hoe lager deze waarde, hoe hoger de affiniteit. In hoofdstuk 5 testen we verschillende 
TCRs met aminozuurveranderingen in CDRs en 2 tot 712 keer verhoogde affiniteit ten 
opzichte van de originele TCR, met een KD waarde van 18.5 μM. Experimenten toonden 
aan dat een minimale affiniteitsverhoging, met een grens van KD waardes rond de 4 
µM, een verbeterde T-cel-reactiviteit tegen melanoomcellen tot gevolg heeft. TCRs die 
hieraan voldeden hadden aminozuurveranderingen in CDR3α.
Als laatste hebben we ons gericht op het verrijken van populaties van T-cellen die de 
gewenste TCR tot expressie brengen. Een van die verrijkingsmethoden, Magnetic Acti-
vated Cell Sorting (MACS), maakt gebruik van magneten en het labelen van T-cellen met 
kleine metalen bolletjes. In hoofdstuk 6 vergelijken we verschillende types peptide-
MHC-complexen en een genetische marker wat betreft hun bruikbaarheid voor verrij-
king van T-cellen. Peptide-MHC-complexen zijn beschikbaar in verschillende formaten 
die vaak 4, 5 of 10 peptide-MHC-complexen bevatten. Het gen dat we gebruikt hebben 
voor de markering van T-cellen codeerde voor een gemuteerd, en daardoor inactief, 
celoppervlakmolecuul CD34. Van de verschillende peptide-MHC-complexen bleek dat 
met de zogenaamde streptameren (met zo’n 10 peptide-MHC-complexen) T-cellen het 
meest efficiënt werden geïsoleerd en ook het beste overleefden. De T-celpopulatie die 
werd verkregen via isolatie op basis van CD34 toont echter de sterkste functionaliteit. 
Dit komt doordat isolatie via CD34, in tegenstelling tot streptameren, niet selecteert 
voor één type T-celsubpopulatie (de CD8-T-cellen), maar ook voor een tweede T-cel-
subpopulatie (de CD4-T-cellen) die elkaar versterken in functionele experimenten.
In hoofdstuk 7 worden de resultaten van hoofdstukken 3, 4, 5 en 6 kort samengevat en 
in een breder perspectief geplaatst van recente ontwikkelingen in het veld van TCR gen 
therapie. Door het combineren van de resultaten van deze hoofdstukken worden, naar 
mijn mening, de huidige uitdagingen van TCR gen therapie in de breedte aangepakt. Ik 
stel uiteindelijk dan ook voor om:
1. TCR-genen te introduceren die gefuseerd zijn met CD28 en CD3ε (TCR:28ε) om TCR 
mis-paring te voorkòmen en T-cel co-stimulatie te versterken.
Coen BW1.indd   194 15-Aug-13   11:38:56 AM
Samenvatting 195
S
2. aminozuurveranderingen toe te passen in CDR3α-domeinen en de TCR-affiniteit 
beperkt te verhogen om herkenning van peptide-MHC en activatie van T-cellen te 
verbeteren zonder verlies van peptide-specificiteit.
3. om een markergen te introduceren naast de TCR-genen om zo via verrijking van TCR-
expressie de functionaliteit van de T-celpopulatie het sterkst te verhogen.
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DANkwOORD
Het laatste stukje schrijfwerk om mijn proefschrift af te ronden. Er leek geen eind aan te 
komen, maar 6 jaar en 1 dag na het starten van mijn promotieonderzoek is het dan ein-
delijk zo ver. Graag wil ik iedereen bedanken die mij in die tijd heeft geholpen, gesteund 
en anderzijds heeft bijgedragen aan het tot stand komen van dit proefschrift.
Om te beginnen wil ik graag mijn promotor, Prof.dr. Jaap Verweij, bedanken voor de 
mogelijkheid mijn promotie onderzoek te doen op de afdeling Interne Oncologie en 
voor je betrokkenheid en adviezen wat betreft de voortgang en afronding van mijn 
proefschrift.
Daarnaast wil ik graag Prof.dr. Stefan Sleijfer, Prof.dr. Hemmo Drexhage, Prof.dr. Rudi 
Hendriks, Prof.dr. Harry Wichers, dr. Georges Verjans, dr. Luc van der Laan en dr. Joost 
Hegmans bedanken voor het zitting nemen in mijn promotie commissie, de tijd te 
nemen om mijn proefschrift te lezen en er vandaag met mij over te willen discussiëren.
Ik moet hier ook niet vergeten om Alain van Gool en Edwin Janssen te bedanken die 
mij tijdens mijn 2de stage voor mijn universitaire opleiding ervan overtuigde dat een 
promotie bij mij paste ook al twijfelde ik daar op dat moment zelf aan. Zonder jullie 
begeleiding en motivatie was ik hier misschien nooit aan begonnen.
Dan wil ik nu graag alle collega’s uit het Daniel den Hoed Oncologisch Centrum in Rot-
terdam Zuid bedanken dankzij wie ik elke dag met veel plezier naar mijn werk ging; 
bedankt hiervoor want ik besef hoe belangrijk dit is!
Reno, jou moet ik om te beginnen bedanken dat je mijn eigenwijsheid voor lief nam 
en mij de kans gaf me te ontwikkelen binnen de tumor-immunologie wat ik ook ná 
deze promotie nog steeds een heel leuk vakgebied vind. Ik wil je ook bedanken voor 
je doorzettingsvermogen, je passie en overtuiging in wat we proberen te bereiken. Je 
toewijding om ook mijn promotie tot een goed eind te brengen en me te leren dat 
zonder kwaliteit een ‘deadline’ weinig betekenis heeft. Je hebt me altijd op een manier 
weten te sturen die bij mij paste; direct en in detail in het begin toen ik dat nodig had en 
met meer vrijheid, uitgebreide discussies en het steunen van ideeën tegen het eind toen 
dat kon. Ik had me absoluut geen betere co-promotor, begeleider en collega kunnen 
wensen en wil je dan ook enorm bedanken voor alles wat je hebt gedaan om mij op te 
leiden tot zelfstandig wetenschapper.
Coen BW1.indd   205 15-Aug-13   11:38:58 AM
206 Dankwoord
Zsolt, jij hebt samen dingen doen met collega’s en vrienden heel erg hoog in het vaan-
del staan en ik vind het knap hoe je dit altijd weet te combineren met de vele uren die 
je werkt. Ik wil je bedanken dat je mij hierin ook zoveel mogelijk wou betrekken. Ik heb 
heel veel van je geleerd de eerste jaren van mijn promotie, totdat jij je carrière in Utrecht 
een vervolg gaf, en ben blij dat jij mijn ‘labbegeleider’ was. Jouw eindeloze geduld om 
mijn vragen te beantwoorden of uit te leggen waarom iets toch echt zo was waardeer ik 
enorm en hebben mij veel geholpen in mijn wetenschappelijke ontwikkeling.
Nadine en Miriam, met jullie heb ik in het begin een kamer gedeeld en jullie hebben 
mij geholpen met het opstarten als promovendus en kennis laten maken met wat het is 
om een promotie te doen, inclusief de eerste voorbeelden hoe je die succesvol afrond. 
Marieke, met jou heb ik kort samengewerkt aan het ‘MACS’ artikel waar maar geen einde 
aan leek te komen. Uiteindelijk hebben we hier toch een goede publicatie uit weten te 
halen. Jullie hebben allen inmiddels een andere richting gekozen waarmee ik jullie heel 
veel succes wens en we komen elkaar vast nog tegen. Verder heb ik ook, hetzij kort, met 
Ralph samen gewerkt. Ralph was iemand die ‘out-of-the-box’ durfde denken, hetgeen 
mij er toe zette mijn resultaten en conclusies te heroverwegen en beter te formuleren. 
Het nieuws van zijn plotselinge overlijden in Juni kwam dan ook als een klap. Ik wens 
zijn nabestaanden heel veel sterkte toe, en wil je bedanken voor je steun richting dit 
proefschrift.
De laatste jaren van mijn promotie heb ik mijn OIO kamer mogen delen met Erik en 
Trudy, het I-Phone duo. Trudy, ik heb je altijd bewonderd om je doorzettingsvermogen 
en gedrevenheid want jouw muizenprojecten en promotie waren van de lange adem 
en resulteerden in een prachtig werk. Erik, jouw wil om vooruit te gaan en vermogen 
om tegenslagen te verwerken werkten aanstekelijk en inspirerend. Ik ben dan ook erg 
blij dat je vandaag naast me staat als paranimf! Ik wil jullie beiden bedanken voor een 
onvergetelijke tijd, mede door de combinatie van jouw humor, Erik, en jouw nuchter-
heid, Trudy, wat vaak resulteerde in hilarische momenten. Vooral vanwege dit was het 
maar goed dat onze OIO kamer wat geïsoleerd en een stuk verder van het lab af lag. Feit 
was dat we tussen het harde werken door gewoon heel veel plezier hebben gehad.
Cor, Elike en Mandy, voor mijn gevoel vormden jullie de ruggengraat en cultuurbewa-
kers van de groep en zorgde ervoor dat alles bleef draaien. Ik wil jullie graag bedanken 
voor jullie steun, geduld en adviezen als ik er op het lab even niet uit kwam. De ‘ana-
listenkamer’ was dan vaak, ongetwijfeld af en toe tot jullie ergernis, dichtbij. Mandy, 
niet alleen zijn we tegelijk begonnen met werk in onze groep, tegen het einde van mijn 
promotie heb jij me nog ontzettend veel geholpen met experimenten. Zelfs toen ik al in 
Wageningen werkte heb jij nog enorme bergen data gegenereerd die ik nodig had om 
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artikelen en mijn proefschrift af te kunnen ronden. Daarnaast steun je me vandaag weer, 
nu als paranimf. Dank hiervoor.
Anouschka, je was de eerste student die ik begeleidde waardoor ik ook heel veel van 
jou heb geleerd en ik wil je ook bedanken voor je werk aan het ‘TCR affiniteits’ artikel. 
Verder wil ik Hanka Venselaar van de Radboud universiteit Nijmegen bedanken voor 
haar expertise en hulp voor het tot stand komen van het ‘minimal zeta’ artikel.
I also would like to express my thanks to our collaborators dr. Jakobsen and colleagues, 
Andrew Gerry, Alan Bennett, Nicholas Pumphrey and Nathaniel Liddy from Adaptim-
mune, Abingdon, Oxon, UK and Prof.dr. Szöllősi and colleagues, János Roszik, Árpád 
Szöőr and György Vereb from the University of Debrecen, Debrecen, Hungary for their 
expertise, help and valuable comments resulting in the ‘TCR affinity’ and ‘TCR:28ε’ papers.
Dan wil ik graag alle andere collega’s uit Rotterdam bedanken. De collega’s van ‘bene-
den’ Pascal, Sabine, Corrien, Brigitte, Cor Lamers, dank voor jullie gezelligheid, steun en 
interesse in mijn werk tijdens koffiepauzes of wanneer ik gewoon binnen kwam vallen. 
Ook wil ik Tom, Andre, Marian en de andere collega’s van ‘boven’, Andre, Konstantina, en 
Mesha en collega’s die ik onbedoeld vergeet te noemen, bedanken voor jullie tips, hulp 
en gezelligheid.
Ook wil ik graag mijn collega’s uit Wageningen bedanken voor jullie geduld, geboden 
ruimte en steun de afgelopen 1,5 jaar. Het (afronden van het) schrijfwerk had heel wat 
meer voeten in aarde dan we op voorhand hadden ingeschat maar eindelijk is het dan 
toch zover.
Dan zijn er natuurlijk altijd ons pap en ons mam met hun partners en schoonouders ge-
weest die mij en Kim enorm hebben gesteund. Jullie hebben van dichtbij meegemaakt 
wat een impact het wonen in Sliedrecht en de promotie op ons heeft gehad en hebben 
altijd klaar gestaan om ons op te vangen. Door altijd een luisterend oor te bieden, veel 
langs te komen, helpen ons huis zo knus en eigen mogelijk te maken en ervoor te zorgen 
dat we in Heesch een volledig nieuwe start konden maken. Dit zullen we nooit vergeten 
en we zijn jullie hier enorm dankbaar voor.
En dan mijn allerliefste Kim. Jij hebt jezelf de afgelopen jaren weggecijferd om mij 
alle ruimte te geven voor mijn promotie. Ik bewonder je kracht en hoe je met de voor 
ons moeilijke periode ‘Sliedrecht’ bent omgegaan en dat je jezelf hier doorheen hebt 
geknokt. Ik kan in woorden niet uitdrukken hoeveel het voor mij heeft betekend dat jij 
ondanks alles mij altijd voor de volle 100% hebt gesteund in mijn promotie. Inmiddels 
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wonen we alweer 2 jaar in Heesch vlak bij onze ouders, familie en vrienden en zijn we 
hier gelukkiger dan ooit. Ook omdat je jeugddroom van een eigen paard in vervulling 
is gegaan en jij met je Belgisch trekpaard Floortje, of ‘wandelende tank’ zoals je haar 
zelf noemt, bewijst dat Belzen wel degelijk dressuur kunnen lopen. Voor mij is nu het 
schrijven van mijn proefschrift in de avonduren en weekenden ook afgelopen en ben ik 
blij dat we deze tijd eindelijk samen door kunnen gaan brengen. Ik hou van je.
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